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A B S T R A C T
Background
Burning mouth syndrome (BMS) is a term used for oral mucosal pain (burning pain or discomfort in the tongue, lips or entire oral
cavity) without identifiable cause. General population prevalence varies from 0.1% to 3.9%. Many BMS patients indicate anxiety,
depression, personality disorders and impaired quality of life (QoL). This review updates the previous versions published in 2000 and
2005.
Objectives
To determine the effectiveness and safety of any intervention versus placebo for symptom relief and changes in QoL, taste, and feeling
of dryness in people with BMS.
Search methods
CochraneOralHealth’s Information Specialist searched the following databases: CochraneOralHealth’s Trials Register (to 31December
2015), theCochraneCentral Register of ControlledTrials (CENTRAL; 2015, Issue 11) in theCochrane Library (searched 31December
2015), MEDLINEOvid (1946 to 31 December 2015), and EmbaseOvid (1980 to 31December 2015). We searched ClinicalTrials.gov
and the World Health Organization International Clinical Trials Registry Platform for ongoing trials. We placed no restrictions on the
language or date of publication when searching the electronic databases
Selection criteria
Randomised controlled trials (RCTs) comparing any treatment against placebo in people with BMS. The primary outcomes were
symptom relief (pain/burning) and change in QoL. Secondary outcomes included change in taste, feeling of dryness, and adverse
effects.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Outcome data were analysed as short-term (up to three months)
or long-term (three to six months).
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Main results
We included 23 RCTs (1121 analysed participants; 83% female). Interventions were categorised as: antidepressants and antipsychotics,
anticonvulsants, benzodiazepines, cholinergics, dietary supplements, electromagnetic radiation, physical barriers, psychological thera-
pies, and topical treatments.
Only one RCT was assessed at low risk of bias overall, four RCTs’ risk of bias was unclear, and 18 studies were at high risk of bias.
Overall quality of the evidence for effectiveness was very low for all interventions and all outcomes.
Twenty-one RCTs assessed short-term symptom relief. There is very low-quality evidence of benefit from electromagnetic radiation
(one RCT, 58 participants), topical benzodiazepines (two RCTs, 111 participants), physical barriers (one RCT, 50 participants), and
anticonvulsants (one RCT, 100 participants). We found insufficient/contradictory evidence regarding the effectiveness of antidepres-
sants, cholinergics, systemic benzodiazepines, dietary supplements or topical treatments. No RCT assessing psychological therapies
evaluated short-term symptom relief.
Four studies assessed long-term symptom relief. There is very low-quality evidence of a benefit from psychological therapies (one
RCT, 30 participants), capsaicin oral rinse (topical treatment) (one RCT, 18 participants), and topical benzodiazepines (one RCT,
66 participants). We found no evidence of a difference for dietary supplements or lactoperoxidase oral rinse. No studies assessing
antidepressants, anticonvulsants, cholinergics, electromagnetic radiation or physical barriers evaluated long-term symptom relief.
Short-term change in QoL was assessed by seven studies (none long-term).The quality of evidence was very low. A benefit was found
for electromagnetic radiation (one RCT, 58 participants), however findings were inconclusive for antidepressants, benzodiazepines,
dietary supplements and physical barriers.
Secondary outcomes (change in taste and feeling of dryness) were only assessed short-term, and the findings for both were also
inconclusive.
With regard to adverse effects, there is very low-quality evidence that antidepressants increase dizziness and drowsiness (one RCT, 37
participants), and that alpha lipoic acid increased headache (two RCTs, 118 participants) and gastrointestinal complaints (3 RCTs, 138
participants). We found insufficient/contradictory evidence regarding adverse events for anticonvulsants or benzodiazepines. Adverse
events were poorly reported or unreported for cholinergics, electromagnetic radiation, and psychological therapies. No adverse events
occurred from physical barriers or topical therapy use.
Authors’ conclusions
Given BMS’ potentially disabling nature, the need to identify effective modes of treatment for sufferers is vital. Due to the limited
number of clinical trials at low risk of bias, there is insufficient evidence to support or refute the use of any interventions in managing
BMS. Further clinical trials, with improved methodology and standardised outcome sets are required in order to establish which
treatments are effective. Future studies are encouraged to assess the role of treatments used in other neuropathic pain conditions and
psychological therapies in the treatment of BMS.
P L A I N L A N G U A G E S U M M A R Y
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Review question
Which treatments help to relieve symptoms for people with burning mouth syndrome (BMS)?
Background
BMS is a common painful condition. Symptoms include burning, dryness or uncomfortable sensations in the mouth and changes to
taste, with no obvious underlying medical or dental cause. BMS is usually persistent and suffered long term, and can lead to a reduced
quality of life (QoL). Currently, scientific research suggests that BMS is caused by underlying damage to the nerves. There are many
treatments available including drugs for anxiety, other psychological conditions and increasing saliva production, protective barriers
and treatments applied to the mouth surface amongst others.
Study characteristics
This review of studies was carried out through Cochrane Oral Health, and the evidence is current up to 31 December 2015.
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We found 23 studies (assessing 1121 people; 83% were women), published between 1995 and 2015 to include in this review. Twenty-
one studies assessed short-term (up to three months) symptom relief, and four studies assessed long-term (from three to six months)
symptom relief. Seventeen studies provided information about side effect occurrence, seven studies assessed a measure of QoL, and two
studies assessed changes in taste and feeling of dryness.
All of the 23 treatments included in this review were compared to a placebo (fake treatment): antidepressants and antipsychotics (two
studies), antiseizure drugs (one study), types of tranquillisers (four studies), saliva stimulants (one study), dietary supplements (12
studies), directed energy waves (one study), physical barriers (one study), psychological therapies (one study), and treatments applied
to the mouth surface (five studies).
Key results
Short-term symptom relief
We found evidence of short-term symptom relief for directed energy waves (one study, 58 participants), a type of tranquilliser used
topically (that is held in the mouth before being removed, and which also acts as an antiseizure drug) called clonazepam (two studies,
111 participants), thin plastic tongue covers (one study, 50 participants), and an antiseizure drug called gabapentin (one study, 100
participants).
There was no difference in short-term symptom relief found for antidepressants, saliva stimulants, and another type of tranquilliser
used systemically (one that is swallowed) also called clonazepam. We were unable to show whether dietary supplements or treatments
applied to the mouth surface provide symptom relief in the short term or not.
Short-term relief was not reported for the single study that assessed a psychological therapy.
Long-term symptom relief
We found evidence of long-term symptom relief for psychological therapy (one study, 30 participants), chili pepper mouthrinse (one
study, 18 participants) and the topical tranquilliser called clonazepam (one study, 66 participants).
We found there was no difference in long-term symptom relief for dietary supplements or treatments applied to the mouth surface.
Studies which assessed antidepressants, directed energy waves, saliva stimulants, antiseizure drugs, or physical barriers did not evaluate
long-term symptom relief.
Change in QoL
There was evidence of short-term improvement in QoL for directed energy waves (one study, 58 patients), although no difference was
found for antidepressants, tranquillisers, dietary supplements and physical barriers. No study assessed long-term QoL changes.
Change in taste or feeling of dryness
A few studies assessed short-term change in taste or feeling of dryness (none evaluated these outcomes long-term), but there was not
enough evidence to judge the effects of treatment on these outcomes.
Side effects
Side effects were more likely to be experienced with antidepressants (dizziness and drowsiness more likely: one study, 37 people), and
with a dietary supplement called alpha lipoic acid (also known as ALA) with or without other ingredients (headaches more likely: two
studies, 118 people; and upset stomachs more likely: three studies, 138 people).
Quality of the evidence
Overall, we found very low-quality evidence for each short- and long-term outcome we investigated (symptom relief; changes in QoL,
taste and feeling of dryness; and side effects) in all types of assessed treatment: antidepressants and antipsychotics, antiseizure drugs,
types of tranquillisers, saliva stimulants, dietary supplements, directed energy waves, physical barriers (except side effects, which was
assessed as low quality), psychological therapies, and treatments applied to the mouth surface. As we found so few studies at low risk
of bias, we are currently unable to prove or disprove the effectiveness of any treatments for managing BMS.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antidepressants compared with placebo for treating burning mouth syndrome
Patient or population: people diagnosed with burning mouth syndrome
Settings: secondary care
Intervention: ant idepressants (trazodone)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Antidepressants
Symptom relief: short-
term (≤ 3 months)
- Mean VAS pain score
(Scale 0-10: lower bet-
ter)
4.66 1.26 higher (0.24 lower
to 2.76 higher)
- 37
(1 RCT)
⊕©©©
very low1
Only trazodone was as-
sessed by a single
study
No data were available
to est imate long-term
symptom relief
No data were available
to est imate the ef fect of
other ant idepressants
Change in quality of
life (QoL): short-term
(≤ 3 months) - Mean
Beck Depression Inven-
tory score(Scale 0-63:
lower better)
This single study narrat ively reported that both intervent ion and placebo
part icipants were less depressed at trial complet ion, but there was no
evidence of a dif ference between groups
37
(1 RCT)
⊕©©©
very low2
Single study assessing
trazodone
No data were available
to est imate long-term
change in QoL
Change in taste No included studies reported change in taste
Change in feeling of
dryness
No included studies reported change in feeling of dryness
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Adverse effects There was evidence of an increase in dizziness (RR 11.61, 95% CI 1.66 to
81.04) and drowsiness (RR 4.75, 95% CI 1.18 to 19.07) in people treated
with ant idepressants
37
(1 RCT)
⊕©©©
very low3
Only trazodone was as-
sessed by a single
study
No data were avail-
able to est imate the
harms of other ant ide-
pressants
* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI)
CI: conf idence interval; OIS: opt imal information size; RCT: randomised controlled trial; RR: risk rat io; VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1Assumed placebo risk based on mean placebo group pain score at short-term (≤ 3 months) follow-up; downgraded once
due to risk of bias: unclear risk of attrit ion and report ing biases; downgraded once due to indirectness: concerns relat ing to
applicability, only 1 type of ant idepressant assessed, ef fects of other ant idepressants may dif fer; downgraded twice due
to imprecision: OIS not met, and 95% CI includes no ef fect.
2Downgraded once due to unclear risk of attrit ion and report ing biases; downgraded twice due to indirectness: use of surrogate
measure, and also concerns relat ing to applicability (only 1 type of ant idepressant assessed, ef fects of other ant idepressants
may dif fer); downgraded once due to imprecision: OIS not met.
3Downgraded once due to risk of bias: unclear risk of attrit ion and report ing biases; downgraded once due to indirectness:
concerns relat ing to applicability, only 1 type of ant idepressant assessed, ef fects of other ant idepressants may dif fer;
downgraded twice due to imprecision: OIS not met, and narrat ive report did not permit est imation of ef fect or 95% CI.
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B A C K G R O U N D
Description of the condition
Burning mouth syndrome (BMS) is defined as burning or painful
sensations from an oral mucosa with no clinical signs of pathology
or identifiable medical or dental causes (IHS 2013). In addition to
pain, many BMS patients also report subjective xerostomia (dry-
ness), oral paraesthesia and/or altered taste (Bergdahl 1999; Woda
1999).
There is confusion in the literature as a wide variety of differ-
ent terms have been used to describe the sensation of a burning
mouth (Buchanan 2010; Fortuna 2013). These include glosso-
dynia, glossopyrosis, stomatodynia, stomatopyrosis, sore tongue,
burning mouth and oral dysaesthesia. A sensation of oral burning
can be associated with systemic or local causes such as hyposali-
vation, oral candidiasis, oral parafunction, some deficiency states
or side effects of drug treatments (Buchanan 2010; Scala 2003).
In these instances the treatment of the underlying cause results
in resolution of the burning mouth symptom, and a diagnosis of
BMS cannot be made. The diagnosis of primary BMS is thus a
diagnosis of exclusion.
The International Association for the Study of Pain (IASP) classi-
fication of chronic pain defines BMS as a “distinctive nosological
entity characterized by unremitting oral burning or similar pain in
the absence of detectable oral mucosal changes” (Merksey 1994);
however, it does not draw the distinction between burning as a
symptom and primary BMS. The International Headache Society
(IHS) describes BMS as “an intraoral burning or dysaesthetic sen-
sation, recurring daily for more than 2 hours per day over more
than 3 months, without clinically evident causative lesions” (IHS
2013).
The epidemiological data on BMS are generally poor, due in part
to lack of strict adherence to diagnostic criteria (Zakrzewska 1999).
Reported prevalence rates of burning mouth symptoms in general
populations vary from 0.1% to 3.9% (Bergdahl 1999; Kohorst
2015). A recent epidemiological study using strict diagnostic cri-
teria (albeit reporting from a predominantly Caucasian popula-
tion) estimated a BMS incidence rate of 11.4 cases per 100,000
person-years (18.8 cases per 100,000 person-years for women, and
3.7 cases per 100,000 person-years for men) (Kohorst 2014). The
incidence of BMS sharply increases after the age of 50 in both
women andmen, with the highest incidence in women (70.3 cases
per 100,000 person-years) aged 70 to 79 years (Kohorst 2014).
The natural history of BMS has not been clearly defined and there
are no reports of longitudinal cohort studies (Zakrzewska 1999).
There is anecdotal evidence of at least partial spontaneous remis-
sion in approximately half of these patients within six to seven
years (Grushka 1987a). In another study, only two out of 53 pa-
tients reported complete spontaneous remission of their symptoms
within five years after onset (Sardella 2006).
The prominent feature of BMS is the symptom of burning pain
or discomfort, which can be localised just to the tongue or lips
or both but can be more widespread and involve the whole of
the oral cavity (Grushka 1987b; Scala 2003). In most patients the
symptoms are bilateral. Often words such as ’pricking’, ’tingling’,
’numbness’ or ’itching’ instead of ’burning’ are used to describe the
pain (Braud 2013). Inmost cases the symptomshave continued for
many months and the intensity of pain tends to increase towards
the end of the day (Forssell 2012). Altered taste sensation and a
symptom of oral dryness (in patients with no alteration of the
salivary flux) are frequently reported (Bergdahl 1999; Grushka
1987b; Scala 2003), and recent studies indicate that 67% to 80%
of BMS patients suffer from sleep disturbance (Almoznino 2016;
López-Jornet 2015).
Recent neurophysiologic, psychophysical, neuropathological
functional imaging studies have elucidated that several neuro-
pathic, mainly subclinical mechanisms, act at different levels of the
nervous system and contribute to the pathophysiology of primary
BMS (Jääskeläinen 2012). Thermal quantitative sensory thresh-
old (QST) studies have demonstrated signs of small-fibre medi-
ated neuropathy (Forssell 2002; Granot 2005; Svensson 1993),
sometimes together with extrasegmental sensory alterations; sug-
gesting possibly more generalised somatosensory dysfunction in
BMS (Grémeau-Richard 2010; Puhakka 2016; Svensson 1993).
Furthermore, blink reflex studies have demonstrated subclinical
trigeminal nerve lesions in approximately 20% of BMS patients
(Forssell 2002; Jääskeläinen 1997). The frequent report of taste
dysfunction in patients with BMS has prompted the hypothesis
that there could be hyperactivity of the somatosensory fibres of the
trigeminal nerve, following loss of central inhibition due to taste
fibre damage (Kolkka-Palomaa 2016). Supporting this, three elec-
trogustatometric studies have reported evidence for chorda tym-
pani hypofunction in BMS (Eliav 2007; Grémeau-Richard 2010;
Just 2010). In line with the thermal QST and electrogustatomet-
ric evidence for focal small fibre hypofunction in BMS, several
studies have demonstrated loss of epithelial nerve fibres in tongue
mucosal biopsies from BMS patients (Lauria 2005; Penza 2010;
Puhakka 2016; Yilmaz 2007).
Central nervous system pathology seems also to be involved in
the generation of BMS pain symptoms. Giving further evidence
for the neuropathic nature of BMS, the characteristics in func-
tional magnetic resonance imaging (fMRI) activation patterns to
painful stimuli have been shown to be similar in BMS patients
andpatientswith other neuropathic pain conditions (Albuquerque
2006). A recent study on cerebral reorganisation demonstrated al-
tered grey and white matter volumes in the hippocampus and me-
dial prefrontal cortex in BMS patients, as well as altered functional
connectivity patterns of these regions (Khan 2014). Two positron
emission tomography (PET) studies have demonstrated a decline
in endogenous dopamine levels in BMS, suggesting deficiencies
in central pain modulation (Hagelberg 2003; Jääskeläinen 2001).
The question concerning the relative involvement of peripheral
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versus central mechanisms in BMS pain has important impli-
cations, especially concerning different treatment approaches. A
study investigating the effects of peripheral lingual nerve block on
spontaneous burning pain in BMS showed that in half of the pa-
tients the lingual nerve block relieved the pain, suggesting predom-
inantly peripheral mechanisms acting in this subgroup. In some
cases, lingual nerve anaesthesia had no effect or even increased the
pain intensity, indicating that central mechanisms may be more
important in the pathophysiology of pain in some BMS patients
(Grémeau-Richard 2010).
Most studies on the pathophysiology of BMS have explored the
neuropathic background of these pains, but many other fac-
tors may be involved. A hypothesis linking BMS with dysreg-
ulation of adrenal, gonadal and neuroactive steroids has been
presented (Woda 2009). Autonomic nervous system impairment
(Heckmann 2001; Koszewicz 2012) or immune function suppres-
sion (Koike 2014) have also been suggested to have a role in BMS
pathophysiology. It has also been speculated that salivary dysfunc-
tion plays a role in BMS because more than half of BMS patients
complain of dry mouth (i.e. xerostomia) (Bergdahl 1999). How-
ever, while some investigators have demonstrated decreased sali-
vary gland output in BMS (Lee 2015), some studies have indi-
cated that the salivary flow rate in BMS patients is the same as in
controls (De Moura 2009). Methodological and patient popula-
tion differences may explain the contradictory results; according
to the current definition, patients with hyposalivation should not
receive the primary BMS diagnosis. Moreover, studies concerning
the composition of saliva in BMS have yielded conflicting results
(Scala 2003).
BMS is well studied from the psychological perspective, show-
ing convincing evidence for close relationship between psycho-
logical factors and the pain experience (Galli 2016). Many BMS
patients show evidence of anxiety, depression or personality disor-
ders. One study demonstrated that when compared with a control
group, BMS patients had a significantly lower scores in socialisa-
tion, significantly higher scores in somatic anxiety and more neg-
ative thoughts (Bergdahl 1995b). It has been demonstrated that
patients with BMS show an increased tendency for somatisation,
as well as several other psychiatric features when measured on the
SCL-90 (Symptom Checklist-90) questionnaire (Eli 1994). Psy-
chological disorders could theoretically be associated with BMS by
several mechanisms. While one such mechanism, dopaminergic
hypofunction has been shown to be related to BMS pain, it has
been suggested that the high psychological or psychiatric comor-
bidity in BMS can be understood in terms of shared vulnerability
to both chronic pain and psychiatric disorders, mediated by dys-
functional brain dopamine activity (Taiminen 2011).
Description of the intervention
These recent findings from BMS research suggest both central and
peripheral neuropathological changes are present in the condition.
Consequently, it could be proposed that BMS may respond to
those treatments offered for other neuropathic conditions, such as
antidepressants, anticonvulsants, dietary/nutritional supplements
and topical anaesthetic or analgesic agents (Finnerup 2015; Foster
2007; NICE 2013). Moreover, the increasing evidence associat-
ing BMS with psychological comorbidities such as anxiety and
depression, would suggest anxiolytics, antidepressants, and psy-
chological therapies may be helpful in the management of BMS.
The application of a physical barrier may also work to reduce the
impact of parafunctional habits which may induce or sustain BMS
(López-Jornet 2009a).
How the intervention might work
Topical anaesthetic treatments would reduce BMS pain by block-
ing peripheral pain pathways, while topical capsaicin therapy aims
to desensitise peripheral nerves. Antidepressant drugs produce
blockade of various central nervous system (CNS) receptors, such
as serotonin and norepinephrine, thereby increasing the activity of
the descending inhibitory pain pathways. Some older antidepres-
sants used commonly in pain management, such as the tricyclic
antidepressants (TCAs), have complex pharmacodynamics and act
by inhibiting multiple CNS receptors. This lack of specificity may
in part be why the TCAs are clinically effective in managing pain,
but also why they tend to produce adverse effects. More modern
antidepressants such as the selective serotonin reuptake inhibitors
(SSRIs), aremore selective in their effects onCNS receptors, hence
tend to produce less side effects than the TCAs. The roles of SSRIs
in pain management have yet to be fully explored.
Anticonvulsantmedications achieve their analgesic effects through
a variety of mechanisms which include blockade of voltage-de-
pendent sodium and calcium channels in peripheral neurones
and actions on neuropeptides such as glutamate and substance
P. The benzodiazepine class of drugs possesses anxiolytic and
anticonvulsant properties, achieved through enhancing the ef-
fect of the neurotransmitter gamma-Aminobutyric acid (GABA)
(Lopez-D’alessandro 2011).
Clinical psychology is known to help patients with chronic pain
conditions improve their quality of life, despite having a back-
ground of persistent pain (Bergdahl 1995a). Recently, electromag-
netic radiation (by low-level laser and transcranial magnetic stim-
ulation) has been used as a non-invasive analgesic intervention for
chronic pain, and its application in treating drug-resistant BMS is
now being explored (Spanemberg 2015; Umezaki 2016).
Several topical agents are used in the management of BMS, with
varying degrees of biological plausibility in how they exert their
effects: benzydamine hydrochloride is known to have topical anal-
gesic properties (Sardella 1999); lactoperoxidase oral rinse is con-
sidered because of its previous role in the management of xerosto-
mia symptoms (Marino 2010); topical urea is thought to exert a
hydrating effect on the oral mucosa in a similar way to its potential
effects on the skin (Alvarenga da Silva 2014); and, capsaicin has
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been found to act as a topical desensitising agent in other neuro-
pathic pain conditions (Marino 2010).
Themechanisms of many treatments used in BMS are unclear and
not well described: bethanecol is a parasympathomimetic which
is reported to alleviate dry mouth symptoms; alpha lipoic acid is
reported to exert “a neuro-regenerative action” (Cavalcanti 2009;
Palacios-Sánchez 2015); hypericumperforatum extract is used due
to its previous role in the management of depression (Sardella
2008); ’Catuama’ is reported to have analgesic and antidepressant
properties (Spanemberg 2012); lycopene and olive oil compound
are used due to their antioxidant properties (Cano-Carrillo 2014);
and lastly, ’tongue protectors’ have been studied alone and also in
conjunction with topical aloe vera - they are reported to control
’parafunctional habits’ that may cause mucosal trauma, coupled
with the potential mucosal healing benefits of aloe vera (López-
Jornet 2013).
It is likely that there is substantial diversity amongst neuropathic
pain patients with respect to clinical presentation, sensory ex-
amination features and possibly the underlying pain mechanisms
(Chaparro 2012). This diversity in pain mechanisms may be one
reason for the limited analgesic efficacy of monotherapy phar-
macological agents. Moreover, dose-related drug side effects (e.g.
drowsiness, dizziness)may limit the tolerability of higher andmore
effective dosages. Therefore, combining medications with differ-
ent pharmacological mechanisms may result in greater effective-
ness and relatively less side effects (Chaparro 2012).
Why it is important to do this review
Burning mouth syndrome is a common, often chronic, condition
that appears to have a negative impact on quality of life. Several
investigators have found reduced quality of life in BMS patients
compared to controls when using SF-36 (36-Item Short Form
Health Survey) and OHIP-49 (Oral Health Impact Profile-49)
outcome measures (López-Jornet 2008; Souza 2011), although we
highlight that neither measure’s use is specific to BMS.
This is an update of the Cochrane review first published in 2000
and previously updated in 2005 (Zakrzewska 2000; Zakrzewska
2005).
O B J E C T I V E S
Todetermine the effectiveness and safety of any intervention versus
placebo for symptom relief and changes in quality of life, taste,
and feeling of dryness in people with burning mouth syndrome.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) comparing any treatment
against placebo.
Types of participants
People with primary burningmouth syndrome (BMS), that is, oral
mucosal pain with no dental or medical cause for such symptoms.
Trials recruiting participants with other types of pain were only to
be included if data on BMS participants could be separated out.
Types of interventions
All treatments that were evaluated in placebo-controlled RCTs.
Types of outcome measures
Primary outcomes
• Relief of burning or discomfort (symptom relief ).
• Change in quality of life (e.g. depression, anxiety).
Secondary outcomes
• Change in taste.
• Change in feeling of dryness.
• Adverse effects. We assessed treatment safety from reported
adverse events.
Search methods for identification of studies
Electronic searches
Cochrane Oral Health’s Information Specialist conducted system-
atic searches in the following databases for randomised controlled
trials and controlled clinical trials. There were no language, pub-
lication year or publication status restrictions:
• Cochrane Oral Health’s Trials Register (searched 31
December 2015) (Appendix 2);
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 11) in the Cochrane Library (searched
31 December 2015) (Appendix 1);
• MEDLINE Ovid (1946 to 31 December 2015) (Appendix
3);
• Embase Ovid (1980 to 31 December 2015) (Appendix 4).
Subject strategiesweremodelled on the search strategy designed for
MEDLINE Ovid. Where appropriate, they were combined with
subject strategy adaptations of the highly sensitive search strategy
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designed by Cochrane for identifying randomised controlled trials
and controlled clinical trials as described in theCochraneHandbook
for Systematic Reviews of Interventions,Chapter 6 (Lefebvre 2011).
Searching other resources
We searched the following trial registries for ongoing studies:
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (clinicaltrials.gov; searched 31 December
2015) (Appendix 5);
• World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch; searched 31
December 2015) (Appendix 6).
The review authors handsearched the following conference pro-
ceedings from January 2005 to December 2015:
• British Society for Oral Medicine (BSOM);
• British Society for Dental Research (BSDR);
• International Association for Dental Research (IADR).
We also scrutinised bibliographies of identified publications and
reviews for potentially relevant references, and attempted to con-
tact authors of relevant studies to identify missing data from un-
reported trials.
We did not perform a separate search for adverse effects of inter-
ventions used, we considered adverse effects described in included
studies only.
Data collection and analysis
Selection of studies
Teams of two review authors independently screened the titles
and abstracts retrieved from the initial electronic searches. Reports
from the studies that fulfilled the inclusion criteria were obtained.
When there was insufficient information available to determine
whether a study fulfilled the inclusion criteria, the full report was
obtained and assessed independently by the same review authors.
Disagreements were resolved by discussion. The review authors
were not blinded to the studies’ authorship.
Data extraction and management
At least two review authors independently extracted data from
each study included using a tool developed for the review. All stud-
ies meeting the inclusion criteria underwent data extraction and
an assessment of risk of bias using a standardised data extraction
form. Studies rejected at this and subsequent stages were recorded
in the Characteristics of excluded studies table. Differences were
resolved by discussion. For each study with more than one con-
trol or comparison group for the intervention, the results were
extracted for each intervention arm. The review authors were not
blinded to the studies’ authorship.
We extracted the following data.
• Year of publication, country of origin, number of centres,
source of study funding and any conflicts of interest.
• Details of the participants including demographic
characteristics and criteria for inclusion/exclusion.
• Details on the type of intervention and comparisons.
• Details on the study design.
• Details on the outcomes reported which included method
and timings of assessments and adverse outcomes.
We contacted authors of the relevant studies, to supply missing
information or data where necessary. We contacted trial authors
for missing data if the study was published from the year 2000
onwards. We considered it unfeasible to obtain data for trials pub-
lished prior to this cut-off date.
Assessment of risk of bias in included studies
Teams of two review authors independently assessed the risk of
bias for each included study. The ’Risk of bias’ assessment was
conducted using Cochrane’s tool for assessing risk of bias (Higgins
2011a) and in accordance with guidance included in Chapter 8
of the Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1.0 (updated March 2011) (Higgins 2011b). For each
included study we assessed the following seven key domains.
• Sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Completeness of outcome data (attrition bias).
• Selective outcome reporting (reporting bias).
• Risk of other potential sources of bias (other bias).
For each study, we determined the overall risk of bias according to
the following criteria:
• low risk of bias - when there was a low risk of bias across all
seven key domains;
• unclear risk of bias - when there was an unclear risk of bias
in one or more of the seven key domains (no domains judged to
be at high risk of bias);
• high risk of bias - when there was a high risk of bias in one
or more of the seven key domains.
For consistent rating application, one author (Anne-Marie
Glenny) arbitrated all assessments. We completed a ’Risk of bias’
table for each included study, a ’Risk of bias’ summary and ’Risk
of bias’ graph.
Measures of treatment effect
We analysed outcome data as short-term (≤ 3 months from base-
line) or long-term (> 3 to≤ 6 months from baseline) as a manage-
able cut-off threshold. For continuous outcomes (e.g. pain/burn-
ing on a visual analogue scale (VAS)), we used mean differences
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(MDs) and 95% confidence intervals (CIs) to summarise the data;
in the event that different studies measured outcomes using dif-
ferent scales, we would have expressed the estimate of effect of an
intervention as standardised mean differences (SMDs) and 95%
CIs. Dichotomous outcomes (e.g. greater or less than 50% reduc-
tion in pain intensity as measured by a VAS, or improvement from
baseline versus no change/worsened score), we expressed the esti-
mate of effect of an intervention as risk ratios (RRs) together with
95% CIs.
Unit of analysis issues
If cluster-randomised trials had been included, we would have
undertaken data analysis, whenever feasible, at the same level as
the randomisation, or at the individual level accounting for the
clustering. Analysis of cross-over studies took into account the
two-period nature of the data using for example, a paired t-test (
Elbourne 2002).We enteredMDs and standard errors intoReview
Manager (RevMan) software (Review Manager 2014), using the
generic inverse variance method (Higgins 2011b).
Dealing with missing data
When required we contacted trial authors for missing data if the
study had been published in the year 2000 or after. The review
authors considered it unfeasible to request data for trials published
prior to this date. We used methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011) to estimate missing standard deviations
(Higgins 2011b).
Assessment of heterogeneity
We assessed clinical andmethodological heterogeneity.We further
assessed the significance of any discrepancies in the estimates of the
treatment effects from the different trials, by means of Cochran’s
test for heterogeneity - heterogeneity would have been considered
significant if P value < 0.1 (Higgins 2011b). We also utilised the
I2 statistic, which describes the percentage total variation across
studies due to heterogeneity rather than chance, to quantify het-
erogeneity with I2 over 50% being considered substantial hetero-
geneity (Higgins 2011b).
Assessment of reporting biases
If there had been a sufficient number of trials (more than 10)
included in any meta-analysis, we would have assessed publication
bias in accordance with the recommendations on testing for funnel
plot asymmetry, described by theCochraneHandbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March 2011) (
Higgins 2011b).
Data synthesis
Where data allowed, we performed meta-analysis of studies which
assessed the same comparisons and outcomes. We combined RRs
for dichotomous outcomes, and MDs (we would have produced
SMDs if different scales had been used) for continuous outcomes,
using a random-effects model where there were four or more stud-
ies, or a fixed-effect model for less than four studies.
We included data from cross-over studies (provided they incorpo-
rated a washout period) in meta-analyses using the generic inverse
variance method described in the Cochrane Handbook for System-
atic Reviews of Interventions Version 5.1.0 (updated March 2011)
(Higgins 2011b), combining them with parallel studies using the
methods described in Elbourne 2002. For cross-over studies not
incorporating a washout period, we utilised the first period data
only, in accordance with Section 16.4.5 of the Cochrane Hand-
book for Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011) (Higgins 2011b).
Where single studies compared more than one active intervention
with a placebowithin the same analysis, the number of participants
in the study’s control group was halved before combining study
data to avoid double-counting control participants within a single
meta-analysis.
Subgroup analysis and investigation of heterogeneity
If there were sufficient studies, we would have used sensitivity
analyses and meta-analysis regression (using Stata software (Stata
2015)) to explore, quantify, and control for sources of heterogene-
ity between studies for type of therapy.
Sensitivity analysis
If the number (and quality) of studies had allowed, we would
have undertaken a sensitivity analysis for each intervention and
outcome limiting the analysis to studies at low overall risk of bias.
Presentation of main results
Weproduced a ’Summary of findings’ table for themain outcomes.
We assessed the quality of the body of evidence, taking into account
the overall risk of bias of the included studies, the directness of
the evidence, the inconsistency of the results, the precision of the
estimates, the risk of publication bias and the magnitude of the
effect. We categorised the quality of the body of evidence of each
of the main outcomes as high, moderate, low or very low.
R E S U L T S
Description of studies
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Details of the trial participants, interventions and outcomes mea-
sured can be seen in the Characteristics of included studies table.
Results of the search
The literature search for this review identified 377 records after
the duplicates were removed. These 377 records were screened
independently and in duplicate. After screening, we retained 64
records for further assessment and categorised 313 records as not
relevant.
We obtained published papers for 60 records. Following our as-
sessment of the 60 full-text articles, we excluded a total of 37 stud-
ies (37 articles) with reasons provided (Characteristics of excluded
studies table).
We included 23 studies (a total of 25 articles, including eight
already included studies from the previous version of the review),
of which 21 studies (all except Bogetto 1999 and Silvestre 2012)
provided useable data. Figure 1 shows the study selection process.
Figure 1. Study flow diagram.
Included studies
Previously, this review included nine trials (Bergdahl 1995a;
Bogetto 1999; Femiano 2000; Femiano 2002a; Femiano 2002b;
Grémeau-Richard 2004; Pisanty 1975; Sardella 1999; Tammiala-
Salonen 1999). This update excludes a previously included trial
(Pisanty 1975), due to insufficiently indicating whether its pa-
tients had burning mouth syndrome and also not being a ran-
domised controlled trial (RCT), and includes an additional 15
RCTs (Alvarenga da Silva 2014; Cano-Carrillo 2014; Carbone
2009; Cavalcanti 2009; Heckmann 2012; Lopez-D’alessandro
2011; López-Jornet 2009b; López-Jornet 2011; Marino 2010;
Palacios-Sánchez 2015; Rodríguez de Rivera-Campillo 2010;
Sardella 2008; Silvestre 2012; Spanemberg 2012; Spanemberg
2015).
A total of 23 RCTs (1285 patients included; 1121 patients as-
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sessed) were included in this latest update of the review (Alvarenga
da Silva 2014; Bergdahl 1995a; Bogetto 1999; Cano-Carrillo
2014; Carbone 2009; Cavalcanti 2009; Femiano 2000; Femiano
2002a; Femiano 2002b; Grémeau-Richard 2004; Heckmann
2012; Lopez-D’alessandro 2011; López-Jornet 2009b; López-
Jornet 2011; Marino 2010; Palacios-Sánchez 2015; Rodríguez
de Rivera-Campillo 2010; Sardella 1999; Sardella 2008; Silvestre
2012; Spanemberg 2012; Spanemberg 2015; Tammiala-Salonen
1999).
Characteristics of studies
Included studies were undertaken in several countries.
• Eight trials (35%) were conducted in Italy (Bogetto 1999;
Carbone 2009; Femiano 2000; Femiano 2002a; Femiano 2002b;
Marino 2010; Sardella 1999; Sardella 2008).
• Six trials (26%) in Spain (Cano-Carrillo 2014;
López-Jornet 2009b; López-Jornet 2011; Palacios-Sánchez 2015;
Rodríguez de Rivera-Campillo 2010; Silvestre 2012).
• Four trials (17%) in Brazil (Alvarenga da Silva 2014;
Cavalcanti 2009; Spanemberg 2012; Spanemberg 2015).
• The remaining five single studies (4% each, totalling 22%
of included studies) were conducted in Argentina
(Lopez-D’alessandro 2011), Finland (Tammiala-Salonen 1999),
France (Grémeau-Richard 2004), Germany (Heckmann 2012),
and Sweden (Bergdahl 1995a).
All trials were published in English, except one Italian study (
Bogetto 1999).
All studies were placebo-controlled parallel RCTs, except three
(13%) cross-over studies (Cavalcanti 2009; Femiano 2000;
Silvestre 2012). Of these three studies, only two incorporated a
washout period into the cross-over study design (Cavalcanti 2009:
20 days; Silvestre 2012: 1 week).
Grémeau-Richard 2004 was a multicentre trial, and all other
studies operated from a single centre. Sixteen trials (70%) con-
tained two arms (intervention versus placebo), one three-armed
trial (4%) contained a ’no treatment’ arm in addition to compar-
ing intervention with placebo (Sardella 1999), and the remain-
ing six trials (26%) were multi-armed to investigate several inter-
ventions (five arms: Bogetto 1999; four arms: Femiano 2002b;
Lopez-D’alessandro 2011;Marino 2010; Spanemberg 2015; three
arms: Carbone 2009).
Follow-up varied greatly between included studies, and ranged be-
tween one week (Silvestre 2012) to six months (Bergdahl 1995a;
Grémeau-Richard 2004; Rodríguez de Rivera-Campillo 2010).
Four trials (17%) followed up their patients for longer than
three months (Bergdahl 1995a; Carbone 2009; Marino 2010;
Rodríguez de Rivera-Campillo 2010).
Nine studies (39%) provided information on source of funding:
• São Paulo State Research Foundation (Alvarenga da Silva
2014; Cavalcanti 2009);
• funded by universities (Grémeau-Richard 2004; Sardella
2008);
• national dental professional body (Tammiala-Salonen
1999);
• mixed funding from a university and national government
bodies (Spanemberg 2015);
• mixed funding from a university and a national dental
professional body (Bergdahl 1995a);
• unfunded (Cano-Carrillo 2014; Heckmann 2012).
The remaining 14 studies (61%) did not report on source of fund-
ing.
Five trials (22%) reported no conflict of interests (Alvarenga da
Silva 2014; Cano-Carrillo 2014; Heckmann 2012; Marino 2010;
Palacios-Sánchez 2015), while 18 trials (78%) omitted reporting
their authors’ conflicts of interests.
Characteristics of participants
All 23 included RCTs appropriately defined their participants as
having burning mouth syndrome (BMS) - that is, persistent oral
mucosal pain with no dental or medical cause for such symptoms
(IHS 2013). Excerpted details of diagnosis and duration are pre-
sented in Additional Table 1.
In total, 1061 women (83%) and 221 men (17%) are reported to
have participated in the included studies.
The mean age of participants ranged from 45 years (Femiano
2002a) to 73 years old (Silvestre 2012); however, the aver-
age age of participants was older than 60 years in 19 trials
(83%: Alvarenga da Silva 2014; Bogetto 1999; Cano-Carrillo
2014; Carbone 2009; Cavalcanti 2009; Femiano 2000; Femiano
2002b; Grémeau-Richard 2004; Heckmann 2012; López-Jornet
2009b; López-Jornet 2011;Marino 2010; Palacios-Sánchez 2015;
Rodríguez de Rivera-Campillo 2010; Sardella 1999; Sardella
2008; Silvestre 2012; Spanemberg 2012; Spanemberg 2015).
Twenty-one studies (91%) did not report any data relating to
socioeconomic status. Of the two studies which did, Bogetto 1999
reported participants’ number of schooling years, andAlvarenga da
Silva 2014 reported data on race, occupation, and marital status.
Characteristics of interventions
A broad range of interventions were investigated by the included
studies, categorised into nine groups.
• Antidepressants and antipsychotics
◦ Paroxetine (Bogetto 1999)
◦ Amitriptyline (Bogetto 1999)
◦ Amisulpride (Bogetto 1999)
◦ Trazodone (Tammiala-Salonen 1999).
• Anticonvulsants
◦ Gabapentin (Lopez-D’alessandro 2011)
◦ Gabapentin + alpha lipoic acid (ALA)
(Lopez-D’alessandro 2011).
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• Benzodiazepines
◦ Systemic clordemetildiazepam (Bogetto 1999)
◦ Topical clonazepam (Grémeau-Richard 2004;
Rodríguez de Rivera-Campillo 2010)
◦ Systemic clonazepam (Heckmann 2012).
• Cholinergics (parasympathomimetics)
◦ Bethanechol (Femiano 2002b).
• Dietary supplements
◦ ALA without adjunctive active ingredients (Carbone
2009; Cavalcanti 2009; Lopez-D’alessandro 2011)
◦ ALA + vitamins (Tiobec) (Carbone 2009; Femiano
2000; Femiano 2002a; Femiano 2002b; Marino 2010)
◦ ALA + adjunctive lycopene + green tea extract
(Thioderm) (López-Jornet 2009b; Palacios-Sánchez 2015)
◦ Hypericum perforatum (St John’s Wort) (Sardella
2008)
◦ ’Catuama’ herbal compound (Spanemberg 2012)
◦ Lycopene (Cano-Carrillo 2014).
• Electromagnetic radiation
◦ Low-level laser therapy (Spanemberg 2015).
• Physical barriers
◦ Tongue protector + adjunctive reinforced self-control
instruction (RS-CI)) (López-Jornet 2011).
• Psychological therapies
◦ Cognitive therapy (CT) (Bergdahl 1995a).
• Topical treatments
◦ Benzydamine hydrochloride oral rinse (Sardella 1999)
◦ Lactoperoxidase oral rinse (Biotene) (Femiano 2002b;
Marino 2010)
◦ Topical urea (Alvarenga da Silva 2014)
◦ Capsaicin oral rinse (Marino 2010; Silvestre 2012).
There was heterogeneity in the administration of some treatments.
For example, alpha lipoic acid was issued in total daily dosages
ranging from 600 to 800 mg, either as single or as split doses;
and topical clonazepam was given as 1 mg three times daily or 0.5
mg up to four times daily as required (Characteristics of included
studies table).
Characteristics of outcome assessment
The outcomes used by the included studies are described in the
Characteristics of included studies table. Awide variety of outcome
measures were employed by the various studies (Additional Table
2).
Due to heterogeneity in follow-up duration between included
studies (ranging from one week (Silvestre 2012) to six months
(Bergdahl 1995a; Marino 2010; Rodríguez de Rivera-Campillo
2010)), it was agreed it would be more clinically useful to separate
outcome assessment by short term (≤ 3 months) and long term
(> 3 to ≤ 6 months).
Twenty-one studies (91%) reported short-term outcome assess-
ment (Alvarenga da Silva 2014; Bogetto 1999; Cano-Carrillo
2014; Carbone 2009; Cavalcanti 2009; Femiano 2000; Femiano
2002a; Femiano 2002b; Grémeau-Richard 2004; Heckmann
2012; Lopez-D’alessandro 2011; López-Jornet 2009b; López-
Jornet 2011;Marino 2010; Palacios-Sánchez 2015; Sardella 1999;
Sardella 2008; Silvestre 2012; Spanemberg 2012; Spanemberg
2015; Tammiala-Salonen 1999). Three studies (Carbone 2009;
Marino 2010; Rodríguez de Rivera-Campillo 2010) which re-
ported short-term outcome assessment also reported long-term
outcomes. The remaining study (Bergdahl 1995a) only reported
long-term outcome assessment.
We were unable to include data from two studies, due to excessive
attrition in the placebo arm (79%) in one study (Bogetto 1999),
and in the other study there was not only substantial attrition
(23%) during the cross-over trial’s first phase, but all patients that
developed side effects were also withdrawn (Silvestre 2012). All
other trials were included in the quantitative analysis.
Primary outcomes
Symptom relief
A broad range of scales were used to assess symptom relief (char-
acterised by included studies as change in burning/symptom in-
tensity/pain).
• Visual analogue scale (VAS), or an alternatively named
variation, of varying widths (n = 17) (Bergdahl 1995a;
Cano-Carrillo 2014 (reported separately for pain and burning);
Carbone 2009; Cavalcanti 2009; Grémeau-Richard 2004;
Heckmann 2012; López-Jornet 2009b; López-Jornet 2011;
Marino 2010; Palacios-Sánchez 2015; Rodríguez de
Rivera-Campillo 2010; Sardella 1999; Sardella 2008; Silvestre
2012; Spanemberg 2012; Spanemberg 2015; Tammiala-Salonen
1999).
• Bespoke BMS symptomology change scale (n = 3)
(Femiano 2000; Femiano 2002a; Femiano 2002b).
• Clinical Global Impression I (CGI I) scale (n = 1) (Bogetto
1999).
• Bespoke geographical burning distribution numerical scale
(0 to 4) (n = 1) (Lopez-D’alessandro 2011).
• EDOF-HC (Orofacial Pain Clinic - Hospital das Clinicas)
protocol (n = 1) (Alvarenga da Silva 2014).
Furthermore, four studies supplemented their VAS assessment of
symptom relief with:
• McGill Pain Questionnaire (MPQ) (Carbone 2009;
Tammiala-Salonen 1999);
• Faces scale (FS) (0 to 5) (Spanemberg 2012);
• visual numeric scale (VNS) (Spanemberg 2015);
• Global Perceived Effect (GPE) scale (Cavalcanti 2009).
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Change in quality of life (QoL)
Seven studies either directly assessed change in QoL or used sur-
rogate markers for its assessment.
Four studies directly assessed change in QoL.
• Two studies used a combination of assessing both general
QoL (by using the 36-Item Short Form Health Survey (SF-36))
and the impact of oral health on patients’ QoL (by using one of
two versions of the Oral Health Impact Profile (OHIP-14 or
OHIP-49)) (Cano-Carrillo 2014 (SF-36 and OHIP-14);
López-Jornet 2011 (SF-36 and OHIP-49)).
• One study singularly used OHIP-14 to assess change in
QoL (Spanemberg 2015).
• The fourth study assessed QoL by posing simple questions
to patients, rather than using a standardised or validated QoL
questionnaire (Sardella 2008).
The remaining three studies used surrogate markers to assess
change in QoL.
• Two studies assessed change in depression using the Beck
Depression Inventory (BDI) (Heckmann 2012;
Tammiala-Salonen 1999).
• The third study assessed change in anxiety using the HARS
scale, and change in depression using the Montgomery Asberg
Depression Rating Scale (MADRS) (Bogetto 1999).
Furthermore, two studies supplemented their direct assessment of
change in QoL with adjunctive use of theHAD (Hospital Anxiety
and Depression) scale to also assess anxiety and depression as sur-
rogate markers of QoL (Cano-Carrillo 2014; López-Jornet 2011).
Secondary outcomes
Change in taste
Only two studies assessed change in taste. One study used a taste
test score (Heckmann 2012), and the other assessed change in
taste by use of the gustative threshold from the Quantitative Sen-
sory Testing (QST) protocol’s combination battery of 12 tests
(Alvarenga da Silva 2014). One study contributed data to quanti-
tative synthesis (Heckmann 2012).
Change in feeling of dryness
A single study (Alvarenga da Silva 2014) assessed change in feeling
of dryness, using a xerostomia questionnaire; however no data
contributed to quantitative synthesis due to it being narratively
reported only.
Adverse effects
Side effects were included as an outcome measure in this review
update, despite not formally being included as an outcome in the
original protocol.
• Seven studies clearly reported the occurrence of adverse
effects experienced in their trials (Cavalcanti 2009;
Grémeau-Richard 2004; Marino 2010; Rodríguez de
Rivera-Campillo 2010; Silvestre 2012; Spanemberg 2012;
Tammiala-Salonen 1999).
• Six studies did not report adverse effects (Alvarenga da Silva
2014; Bergdahl 1995a; Bogetto 1999; Heckmann 2012;
Palacios-Sánchez 2015; Spanemberg 2015).
• Five studies reported that no adverse effects occurred
(Cano-Carrillo 2014; Carbone 2009; Femiano 2000;
López-Jornet 2011; Sardella 1999).
The remaining five studies provided a partial narrative report of
the occurrence of adverse effects.
• Three studies indicated potential missing adverse effects
data (“without notable adverse effects” (Femiano 2002a); “very
mild” (although data were provided by author upon request)
(Lopez-D’alessandro 2011); “minimal” (López-Jornet 2009b)).
• One multi-armed trial omitted reporting adverse effects
data for one of the arms (lactoperoxidase data missing (Femiano
2002b)).
• One trial reported the occurrence of an adverse event as
rationale for a patient withdrawal but made no further mention
of adverse effects experienced (Sardella 2008).
Nine included studies contributed adverse events data to-
wards quantitative synthesis (Cavalcanti 2009; Femiano 2002b;
Grémeau-Richard 2004; Lopez-D’alessandro 2011; López-Jornet
2009b; Rodríguez de Rivera-Campillo 2010; Silvestre 2012;
Spanemberg 2012; Tammiala-Salonen 1999).
Excluded studies
We excluded a total of 37 studies (Characteristics of excluded
studies table). The main reasons for exclusion were that the
trial did not have a placebo arm (13 studies: Bai 2010; Bessho
1998; Campisi 1997; Grechko 1996; Huang 2006; Huang 2009;
López-Jornet 2013; Lu 2002; Maina 2002; Peng 2001; Pisanty
1975; Qui 2010; Yong 2003); was not an RCT (10 studies:
Ferguson 1981; Forabosco 1992; Grushka 1998; Hirsch 2011;
Hugoson 1991; Ito 2010; Kho 2010; Petruzzi 2004; Romeo 2010;
Woda 1998); there were insufficient details to permit inclusion as
the articles were conference abstracts or letters to the editor (three
studies: Palacios-Sanchez 2010; Pellegrini 2010; Vukoja 2011); we
were unable to locate the articles (three studies: Li 2002;Ma 2006;
Mo 2003); inappropriate design (two studies: placebo group out-
come assessed after one month and intervention group assessed af-
ter three months (Miziara 2009) and intervention/placebo imme-
diately assessed, no clinical application (Grémeau-Richard 2010));
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the diagnosis of BMS was uncertain (two studies: Bogetto 1997;
Toida 2009); or data for BMS participants were combined with
other non-BMS diagnoses (four studies: Hansen 1990; Lamey
1986; Lindholm 2015; Loldrup 1989).
Risk of bias in included studies
A summary of the risk of bias for each individual study is presented
inFigure 2, andoverall across studies for each risk of bias domain in
Figure 3. One study was deemed to have a low overall risk of bias (
Sardella 2008), four studies were deemed to have an unclear overall
risk of bias (Carbone 2009; Grémeau-Richard 2004; Sardella
1999; Tammiala-Salonen 1999), and the remainder were deemed
to have a high overall risk of bias.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Nine studies were deemed to have a low risk of selection bias,
after taking into account both random sequence generation and
allocation concealment (Cano-Carrillo 2014; Cavalcanti 2009;
Grémeau-Richard 2004; Heckmann 2012; Lopez-D’alessandro
2011; López-Jornet 2009b; Sardella 2008; Spanemberg 2012;
Tammiala-Salonen 1999). Ten studies were found to have an un-
clear risk of selection bias, after taking into account both random
sequence generation and allocation concealment (Bergdahl 1995a;
Bogetto 1999; Carbone 2009; Femiano 2002a; López-Jornet
2011; Palacios-Sánchez 2015; Rodríguez de Rivera-Campillo
2010; Sardella 1999; Silvestre 2012; Spanemberg 2015). The re-
maining four studies were deemed to be at high risk of selection
bias (Alvarenga da Silva 2014; Femiano 2000; Femiano 2002b;
Marino 2010).
Blinding
Twelve studies were assessed as being at low risk of performance
bias (Alvarenga da Silva 2014; Cano-Carrillo 2014; Carbone
2009; Cavalcanti 2009; Femiano 2002a; Grémeau-Richard 2004;
López-Jornet 2009b; Palacios-Sánchez 2015; Sardella 2008;
Spanemberg 2012; Spanemberg 2015; Tammiala-Salonen 1999);
seven were assessed as being at high risk of performance bias
(Bergdahl 1995a; Bogetto 1999; Femiano 2000; Femiano 2002b;
Lopez-D’alessandro 2011; López-Jornet 2011; Silvestre 2012). All
other studies were assessed as at unclear risk of performance bias.
With regard to detection bias, 15 studies were assessed as being
at low risk of bias (Alvarenga da Silva 2014; Cano-Carrillo 2014;
Carbone 2009; Cavalcanti 2009; Femiano 2002a; Grémeau-
Richard 2004; Lopez-D’alessandro 2011; López-Jornet 2009b;
Marino 2010; Palacios-Sánchez 2015; Rodríguez de Rivera-
Campillo 2010; Sardella 2008; Spanemberg 2012; Spanemberg
2015; Tammiala-Salonen 1999); six studies were assessed as be-
ing at high risk of bias (Bergdahl 1995a; Bogetto 1999; Femiano
2000; Femiano 2002b; López-Jornet 2009b; Silvestre 2012). All
other studies were assessed as unclear risk of detection bias.
Twelve studies were assessed as being at low risk of bias for
both performance and detection bias (Alvarenga da Silva 2014;
Cano-Carrillo 2014; Carbone 2009; Cavalcanti 2009; Femiano
2002a; Grémeau-Richard 2004; López-Jornet 2009b; Palacios-
Sánchez 2015; Sardella 2008; Spanemberg 2012; Spanemberg
2015; Tammiala-Salonen 1999).
Reasons for assessing studies at unclear or high risk of bias for
performance and detection bias included vast differences in treat-
ment arm modalities, authors of studies describing them as ’open
label’, and adverse events likely to have precluded blinding of par-
ticipants.
Incomplete outcome data
Twelve studies were deemed to have a low risk of attrition
bias, after accounting for incomplete outcome data (Femiano
2000; Femiano 2002a; Femiano 2002b; Grémeau-Richard 2004;
Heckmann 2012; Lopez-D’alessandro 2011; López-Jornet 2011;
Marino 2010; Rodríguez deRivera-Campillo 2010; Sardella 1999;
Sardella 2008; Spanemberg 2015).
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Seven studies were deemed to have a high risk of attrition bias, after
accounting for incomplete outcome data (Alvarenga da Silva 2014;
Bogetto 1999; Cavalcanti 2009; López-Jornet 2009b; Palacios-
Sánchez 2015; Silvestre 2012; Spanemberg 2012). In five studies,
there was inadequate explanation as to why dropouts occurred
(Alvarenga da Silva 2014; Bogetto 1999; López-Jornet 2009b;
Palacios-Sánchez 2015; Spanemberg 2012); one study presented
data in a flow diagram (which stated two participants in each arm
were excluded from the analysis), which did not match details
provided in the text (which stated seven patients had their data
excluded from analysis) - hence the study was assessed as at high
risk of bias (Cavalcanti 2009); one study removed participants
who had experienced adverse events from the analysis (Silvestre
2012).
Four studies were deemed to have an unclear risk of attrition bias,
after accounting for incomplete outcome data (Bergdahl 1995a;
Cano-Carrillo 2014; Carbone 2009; Tammiala-Salonen 1999).
Selective reporting
Twelve studies were deemed to have a low risk of reporting bias,
after accounting for selective outcome reporting (Bergdahl 1995a;
Bogetto 1999;Cavalcanti 2009; Femiano 2000;Grémeau-Richard
2004; López-Jornet 2009b; López-Jornet 2011; Marino 2010;
Rodríguez de Rivera-Campillo 2010; Sardella 1999; Sardella
2008; Spanemberg 2012).
Eight studies were deemed to have a high risk of reporting bias,
after accounting for selective outcome reporting (Alvarenga da
Silva 2014; Cano-Carrillo 2014; Femiano 2002a; Femiano 2002b;
Heckmann 2012; Lopez-D’alessandro 2011; Palacios-Sánchez
2015; Silvestre 2012).
• Five studies failed to report on prespecified or expected
outcomes (Cano-Carrillo 2014; Femiano 2002a; Femiano
2002b; Lopez-D’alessandro 2011; Palacios-Sánchez 2015).
• Three studies did not report their prespecified outcomes
appropriately or fully (Alvarenga da Silva 2014; Heckmann
2012; Silvestre 2012).
Three studies were deemed to have an unclear risk of reporting
bias, after accounting for selective outcome reporting (Carbone
2009; Spanemberg 2015; Tammiala-Salonen 1999).
Other potential sources of bias
Seven studies were determined to have a low risk of other potential
sources of bias (Alvarenga da Silva 2014; Carbone 2009; Lopez-
D’alessandro 2011; López-Jornet 2009b; Sardella 2008; Silvestre
2012; Tammiala-Salonen 1999)
Ten studies were considered to have a high risk of other poten-
tial sources of bias (Bergdahl 1995a; Bogetto 1999; Cano-Carrillo
2014; Femiano 2000; Femiano 2002a; Femiano 2002b; Marino
2010; Palacios-Sánchez 2015; Rodríguez de Rivera-Campillo
2010; Spanemberg 2015).
• Eight studies indicated cause for concern over baseline
comparability in addition to their study’s unclearly described
randomisation process (Bergdahl 1995a; Bogetto 1999; Femiano
2000; Femiano 2002a; Femiano 2002b; Marino 2010;
Palacios-Sánchez 2015; Spanemberg 2015).
• We had lesser concerns over baseline comparability in one
study (Cano-Carrillo 2014) due to reporting appropriate
randomisation; however the distribution of anxiolytic use
amongst patients was unclear.
• One study (Rodríguez de Rivera-Campillo 2010) indicated
wide use of psychoactive medication within sample and
adjunctive non-standardised psychotherapy delivered at the
discretion of three uncalibrated clinicians; however, the
distribution of patients in receipt of psychotherapy was not
reported.
Sixwere judged to have an unclear risk of other potential sources of
bias (Cavalcanti 2009; Grémeau-Richard 2004; Heckmann 2012;
López-Jornet 2011; Sardella 1999; Spanemberg 2012).
• Three studies (Cavalcanti 2009; Grémeau-Richard 2004;
Sardella 1999) indicated concerns over baseline comparability,
although an appropriate randomisation process was undertaken.
• One study’s intervention was a systemic anxiolytic drug
(Heckmann 2012), correspondingly baseline anxiety should have
been assessed to account for confounding.
• One study (López-Jornet 2011) allowed patient use of
anxiolytics within sample although the distribution between
groups was unclear.
• The remaining study (Spanemberg 2012) presented
contradictory text within paper, raising concerns of reporting
accuracy.
Effects of interventions
See: Summary of findings for the main comparison
Antidepressants versus placebo for treating people with burning
mouth syndrome; Summary of findings 2Anticonvulsants versus
placebo for treating people with burning mouth syndrome;
Summary of findings 3 Benzodiazepines versus placebo for
treating people with burning mouth syndrome; Summary of
findings 4 Cholinergics versus placebo for treating people with
burning mouth syndrome; Summary of findings 5 Dietary
supplements versus placebo for treating people with burning
mouth syndrome; Summary of findings 6 Electromagnetic
radiation versus placebo for treating people with burning mouth
syndrome; Summary of findings 7 Physical barriers versus
placebo for treating people with burning mouth syndrome;
Summary of findings 8 Psychological therapies versus placebo
for treating people with burning mouth syndrome; Summary of
findings 9 Topical treatments versus placebo for treating people
with burning mouth syndrome
Interventions were allocated between nine groups to assess their
efficacy: antidepressants and antipsychotics, anticonvulsants, ben-
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zodiazepines, cholinergics, dietary supplements, electromagnetic
radiation, physical barriers, psychological therapies, and topical
treatments. The quality of the evidence was assessed as very low for
all outcomes (both short (up to three months from baseline) and
long term (three to six months from baseline)) in all intervention
categories (with the exception of adverse effects for physical barri-
ers, which were assessed as low-quality evidence). See Additional
Table 3 for full details of reported adverse effects, Additional Table
4 for adverse effect outcome data, and Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3; Summary of findings 4; Summary of findings 5; Summary
of findings 6; Summary of findings 7; Summary of findings 8;
Summary of findings 9.
Antidepressants and antipsychotics
Two studies (104 participants), at either high or unclear risk of
bias, provided very low-quality evidence comparing antidepres-
sants and/or antipsychotics against placebo (Bogetto 1999 (parox-
etine 20 mg daily; amitriptyline 25 mg daily; amisulpride 50 mg
daily); Tammiala-Salonen 1999 (trazodone 200 mg daily)).
Data from Bogetto 1999 are not presented due to excessive attri-
tion (19/24; 79%) in the study’s placebo arm.
Primary outcomes
Symptom relief
Short term (≤ 3 months)
One study (37 participants: Tammiala-Salonen 1999) compared
an antidepressant (trazodone 200mg daily) against placebo. There
was no evidence to demonstrate a difference in short-term symp-
tom relief (mean visual analogue scale (VAS) pain score, scale 0
to 10: lower better; mean difference (MD) 1.26, 95% confidence
interval (CI) -0.24 to 2.76; effect P = 0.10) (Analysis 1.1).
Long term (> 3 to ≤ 6 months)
No included studies, comparing antidepressants and antipsy-
chotics versus placebo, provided data on long-term symptom re-
lief.
Change in quality of life (QoL)
A single study (37 participants: Tammiala-Salonen 1999) narra-
tively reported assessment of short-term change in depression as a
surrogate measure for QoL, and indicated that both intervention
and placebo participants were less depressed at trial completion,
but there was no evidence of a difference between groups. No in-
cluded study assessed long-term change in QoL.
Secondary outcomes
No included studies, comparing antidepressants or antipsychotics
against placebo, provided data on short- or long-term change in
taste or feeling of dryness.
Adverse effects
One study (37participants: Tammiala-Salonen 1999) reported ad-
verse effect data, comparing an antidepressant (trazodone) against
placebo. There was evidence to suggest trazodone resulted in an
increase in dizziness (risk ratio (RR) 11.61, 95%CI 1.66 to 81.04;
effect P = 0.01) and drowsiness (RR 4.75, 95% CI 1.18 to 19.07;
effect P = 0.03); however, there was no evidence of a difference
between trazodone and placebo in terms of abdominal pains (RR
1.32, 95% CI 0.42 to 4.15; effect P = 0.64), headache (RR 1.58,
95%CI 0.30 to 8.40; effect P = 0.59), palpitations (RR 1.06, 95%
CI 0.17 to 6.72; effect P = 0.95), tremor (RR 2.11, 95% CI 0.21
to 21.32; effect P = 0.53), dry mouth (RR 3.17, 95% CI 0.36 to
27.72; effect P = 0.30) or urinary incontinence (RR 3.16, 95%
CI 0.14 to 72.84; effect P = 0.47).
Anticonvulsants
One multi-armed study (100 participants: Lopez-D’alessandro
2011 ), at high risk of bias, provided very low-quality evidence
comparing an anticonvulsant (gabapentin 300 mg daily ± alpha
lipoic acid (ALA) 600 mg daily) against placebo. This study did
not assess long-term outcome data.
Primary outcomes
Symptom relief
Short term (≤ 3 months)
Overall, there was evidence of short-term symptom relief in favour
of the anticonvulsant (bespoke geographical burning distribution
numerical scale 0 to 4, dichotomised; RR 4.00, 95% CI 2.09 to
7.67; effect P < 0.0001). Two subgroups were formed: gabapentin
only versus placebo and gabapentin with adjunctive ALA versus
placebo. No between-subgroup difference was shown (Analysis
2.1).
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Change in QoL
Neither short- nor long-term change inQoLdatawere available for
the comparison of anticonvulsants (with or without ALA) against
placebo.
Secondary outcomes
No short- or long-term data on change in taste or feeling of dry-
ness were available for the comparison of anticonvulsants (with or
without ALA) against placebo.
Adverse effects
The single study (Lopez-D’alessandro 2011) comparing an anti-
convulsant (gabapentin, without andwith adjunctiveALA) against
placebo, narratively reported adverse effects as being “very mild”.
Data obtained from the study author indicated that drowsiness
was more likely to be experienced when using gabapentin (with-
out adjunctive ALA) (80 participants; RR 31.95, 95% CI 1.84 to
553.64; effect P = 0.02). There was no evidence of a difference in
drowsiness (80 participants; RR 14.52, 95% CI 0.73 to 290.44;
effect P = 0.08) or mild headache (80 participants; RR 8.71, 95%
CI 0.37 to 205.80; effect P = 0.18) when using gabapentin with
ALA.
Benzodiazepines
Primary outcomes
Four studies (166 participants), at either high or unclear risk
of bias, provided very low-quality evidence comparing benzo-
diazepines against placebo (Bogetto 1999 (systemic clordemetil-
diazepam 1 mg daily); Grémeau-Richard 2004 (topical clon-
azepam 3 mg daily); Heckmann 2012 (systemic clonazepam 0.5
mg daily); Rodríguez de Rivera-Campillo 2010 (topical clon-
azepam 0.5 to 2 mg daily)).
Data from Bogetto 1999 are not presented due to excessive attri-
tion (19/24; 79%) in the study’s placebo arm.
Symptom relief
Short term (≤ 3 months)
Three studies (131 participants: Grémeau-Richard 2004;
Heckmann 2012; Rodríguez de Rivera-Campillo 2010) provided
short-term data on symptom relief for the comparison of ben-
zodiazepines versus placebo. Two studies (111 participants) eval-
uated topical benzodiazepine use and showed an improvement
in symptom relief between clonazepam and placebo, in favour
of clonazepam (mean VAS pain score, scale 0 to 10: lower bet-
ter; MD -1.89, 95% CI -2.19 to -1.59; effect P < 0.00001)
(Grémeau-Richard 2004; Rodríguez de Rivera-Campillo 2010).
Nodifference in symptom relief was shownbetween systemic clon-
azepam and placebo (mean VAS pain score, scale 0 to 10: lower
better; 20 participants; MD 0.00, 95% CI -1.86 to 1.86; effect P
= 1.00) (Heckmann 2012).
The pooled results for the topical and systemic administration of
clonazepam showed evidence of short-term symptom relief how-
ever, there was substantial statistical heterogeneity between sub-
groups.
Long term (> 3 to ≤ 6 months)
Only one study (66 participants: Rodríguez de Rivera-Campillo
2010) assessed benzodiazepines (topical clonazepam) against
placebo for long-term symptom relief. There was evidence of
symptom improvement in favour of clonazepam (mean VAS pain
score, scale 0 to 10: lower better; MD -1.39, 95% CI -1.96 to -
0.83; effect P < 0.00001) (Analysis 3.2).
Change in QoL
Heckmann 2012 (20 participants) assessed depression, as a sur-
rogate marker of QoL. No difference was shown of short-term
change in depression (mean depression score, scale 0 to 4: lower
better;MD -0.20, 95%CI -0.95 to 0.55; effect P = 0.60) (Analysis
3.3). No included studies assessed long-term change in QoL, or
its surrogate markers.
Secondary outcomes
Change in taste
One study (20 participants: Heckmann 2012) compared benzo-
diazepines (systemic clonazepam) against placebo. No difference
was shown of short-term change in taste (mean taste test score,
scale 0 to 16: higher better; MD -1.00, 95% CI -3.11 to 1.11;
effect P = 0.35) (Analysis 3.4). No included studies assessed long-
term change in taste.
Change in feeling of dryness
No included studies assessed short- or long-term change in feeling
of dryness.
Adverse effects
Two studies (114 participants: Grémeau-Richard 2004; Rodríguez
de Rivera-Campillo 2010), comparing benzodiazepines (both top-
ical clonazepam) against placebo, demonstrated no difference in
drowsiness (RR 2.71, 95% CI 0.84 to 8.74; effect P = 0.09).
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One of the two studies (48 participants: Grémeau-Richard 2004)
also showed no difference in drymouth, spasmophilia, or euphoric
behaviour (all three side effects independently: RR 3.00, 95% CI
0.13 to 70.16; effect P = 0.49).
Cholinergics
One study (40 participants: Femiano 2002b), at high risk of
bias, provided very low-quality evidence comparing a cholinergic
(bethanechol 15 mg daily) against placebo. This study did not
assess long-term outcome data.
Primary outcomes
Symptom relief
Short term (≤ 3 months)
The single study evaluating a cholinergic showed no difference
in short-term symptom relief between bethanechol and placebo
(bespoke burning mouth syndrome (BMS) symptomology change
scale, dichotomised; RR 5.00, 95% CI 0.26 to 98.00; effect P =
0.29) (Analysis 4.1).
Change in QoL
Neither short- nor long-term change in QoL data were available
to compare cholinergics against placebo.
Secondary outcomes
No short- or long-termdata on change in taste or feeling of dryness
were available for the comparison of cholinergics versus placebo.
Adverse effects
Femiano 2002b narratively reported adverse effect data, compar-
ing a cholinergic (bethanechol) against placebo. Four participants
(20%) in the bethanechol arm reported adverse events (nausea,
dizziness, blood pressure fall, cold perspiration or sporadic abdom-
inal pain). Reported data did not present the distribution of these
outcomes by participant.
Dietary supplements
Twelve studies (628 participants) provided very low-quality evi-
dence comparing dietary supplements against placebo (ALA with-
out adjunctive active ingredients (Cavalcanti 2009;Carbone 2009;
Lopez-D’alessandro 2011); ALA + vitamins (Tiobec) (Carbone
2009; Femiano 2000; Femiano 2002a; Femiano 2002b; Marino
2010); ALA + adjunctive lycopene + green tea extract (Thioderm)
(López-Jornet 2009b; Palacios-Sánchez 2015); hypericum perfo-
ratum (St John’s Wort) (Sardella 2008); ’Catuama’ herbal com-
pound (Spanemberg 2012); lycopene (Cano-Carrillo 2014)). All
studies were at either high or unclear risk of bias, apart from one
assessed at low risk of bias (Sardella 2008).
Primary outcomes
Symptom relief
Short term (≤ 3 months)
Twelve studies (628 participants) compared dietary supplements
against placebo (Cano-Carrillo 2014; Carbone 2009; Cavalcanti
2009; Femiano 2000; Femiano 2002a; Femiano 2002b; Lopez-
D’alessandro 2011; López-Jornet 2009b; Marino 2010; Palacios-
Sánchez 2015; Sardella 2008; Spanemberg 2012). There was in-
sufficient or contradictory evidence regarding the benefit of any
of the evaluated dietary supplements over placebo (Analysis 5.1;
Analysis 5.2; Analysis 5.3).
No difference in symptom relief was found betweenALA + adjunc-
tive vitamins and placebo when assessed using continuous out-
come data (two studies, 66 participants: Carbone 2009; Marino
2010; mean VAS pain score, scale 0 to 10: lower better;MD -0.49,
95% CI -1.79 to 0.81; effect P = 0.46) (not shown in Analysis
5.1). Three studies (142 participants: Femiano 2000; Femiano
2002a; Femiano 2002b) reported data for relief/no relief. There
was a short-term benefit for ALA with adjunctive vitamins (be-
spoke BMS symptomology change scale, dichotomised; RR 4.10,
95% CI 2.63 to 6.38; effect P < 0.00001). There was a substantial
amount of heterogeneity (P = 0.02; I2 = 75%) between the results
of these three studies (Analysis 5.3).
Long term (> 3 to ≤ 6 months)
Two studies (94 participants: Carbone 2009; Marino 2010) pro-
vided long-term data comparing dietary supplements against
placebo. Both studies compared ALA (either with or without ad-
junctive vitamins). Overall, there was no difference in long-term
symptom relief (mean VAS pain score, scale 0 to 10: lower bet-
ter; MD -0.89, 95% CI -2.37 to 0.59; P = 0.24). There was no
evidence of statistical heterogeneity (P = 0.83; I2 = 0%) (Analysis
5.4).
Change in QoL
One included study (50 participants: Cano-Carrillo 2014), com-
paring lycopene against placebo, provided data assessing short-
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term change inQoL.OverallQoL was assessed byOHIP-14 (Oral
Health Impact Profile 14), and anxiety and depression were also
assessed adjunctively, as surrogate markers of QoL (Analysis 5.5).
There was no difference in short-term change in QoL (mean
OHIP-14 score, scale 0 to 70: lower better; MD 0.93, 95% CI
-3.14 to 5.00; effect P = 0.65), or in depression (as a surrogate
marker of QoL: mean HAD (Hospital Anxiety and Depression)
depression score, scale 0 to 21: lower better; MD -1.87, 95% CI -
4.23 to 0.49; effect P = 0.12); however, there was short-term ben-
efit for lycopene with a mean score reduction in anxiety of -2.85
(mean HAD anxiety score, scale 0 to 21: lower better; 95% CI -
5.28 to -0.42; effect P = 0.02).
One study (43 participants: Sardella 2008), comparing hyper-
icum perforatum extract with placebo, evaluated QoL from pa-
tient self-reports and narratively indicated that both intervention
and placebo participants were better able to cope at trial comple-
tion.
No included studies assessed long-term change in QoL, or its
surrogate markers.
Secondary outcomes
No included studies assessed short- or long-term change in taste or
feeling of dryness, when comparing dietary supplements against
placebo.
Adverse effects
Three studies (138participants: Cavalcanti 2009; Femiano 2002b;
López-Jornet 2009b), comparing dietary supplements (all three
studies used ALA, with or without adjunctive active ingredi-
ents) against placebo, provided evidence that gastrointestinal com-
plaints were four times more likely to be experienced (RR 4.00,
95% CI 1.21 to 13.27; effect P = 0.02). There was no evidence of
heterogeneity (P = 0.78; I2 = 0%). The gastrointestinal effect was
sufficiently severe to cause an intervention-allocated participant
to abandon treatment in one trial (López-Jornet 2009b).
Two studies (118 participants: Cavalcanti 2009; Lopez-
D’alessandro 2011), comparing dietary supplements (ALA, with
or without adjunctive active ingredients) against placebo, indi-
cated evidence of an 11-fold increase in headache occurrence (RR
10.87, 95% CI 1.36 to 87.03; effect P = 0.02). There was no ev-
idence of heterogeneity (P = 0.82; I2 = 0%). One study (43 par-
ticipants: Sardella 2008), comparing hypericum perforatum with
placebo, failed to report adverse effect occurrence; however, the
study authors indicated a severe headache was sufficient cause for
an intervention-allocated participant to abandon treatment.
Two studies (110 participants: Cavalcanti 2009; Spanemberg
2012), comparing dietary supplements (ALA (Cavalcanti 2009);
’Catuama’ herbal compound (Spanemberg 2012)) against placebo,
showed no difference in drowsiness (RR 1.58, 95% CI 0.21 to
11.71; effect P = 0.65). There was no evidence of heterogeneity
(P = 0.64; I2 = 0%).
One study (38 participants: Cavalcanti 2009), comparing dietary
supplements (ALA without adjunctive active ingredients) against
placebo, demonstrated there was no difference in blood pressure
(RR 1.00, 95% CI 0.07 to 14.85; effect P = 1.00); however the
study authors reported increase in blood pressure was sufficient
to cause an intervention- and a placebo-allocated participant to
abandon treatment.
One study (80 participants: Lopez-D’alessandro 2011), compar-
ing dietary supplements (ALA) against placebo, indicated there
was no difference in intermittent facial skin rash (RR 8.71, 95%
CI 0.37 to 205.80; effect P = 0.18).
One study (72 participants: Spanemberg 2012), comparing di-
etary supplements (’Catuama’ herbal compound) against placebo,
showed no difference in exacerbation of symptoms (RR 1.12, 95%
CI 0.33 to 3.83; effect P = 0.86), insomnia or weight gain (both
side effects independently: RR 2.69, 95% CI 0.11 to 63.96; effect
P = 0.54).
Four studies (224 participants) comparing dietary supplements
(ALA alone and ALA with adjunctive vitamins (Tiobec) (Carbone
2009; Femiano 2000; Marino 2010) and lycopene (Cano-Carrillo
2014)) against placebo, narratively reported that no adverse effects
occurred.
Femiano 2002a (60 participants, ALA with adjunctive vitamins)
reported no “notable adverse effects”, and Femiano 2002b (40
participants, ALA with adjunctive vitamins) narratively reported
four intervention participants (20%) had experienced heartburn,
before being corrected by administration of ranitidine (150 mg).
Sardella 2008 (43 participants, hypericum perforatum extract) re-
ported that one intervention participant (5%) developed severe
headache and discontinued treatment.
Electromagnetic radiation
One study (58 participants: Spanemberg 2015) at high risk of bias,
provided very low-quality evidence comparing electromagnetic ra-
diation (infrared laser; red laser) against placebo. This study did
not assess long-term outcome data.
Primary outcomes
Symptom relief
Short term (≤ 3 months)
Spanemberg 2015 compared two types of low-level laser therapy
(infrared laser; red laser) against placebo. It demonstrated a short-
term benefit in symptom relief (mean VAS pain score, scale 0 to
100: lower better; MD -30.36, 95% CI -44.22 to -16.50; effect P
< 0.0001) (Analysis 6.1).
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Change in QoL
Short term (≤ 3 months)
There was evidence of a short-term improvement in QoL from
low-level laser therapy (58 participants: Spanemberg 2015) com-
pared with placebo (mean OHIP-14 score, scale 0 to 56: lower
better; MD -5.24, 95% CI -7.38 to -3.09; effect P < 0.00001)
(Analysis 6.2).
Secondary outcomes
Spanemberg 2015 did not assess change in taste, feeling of dryness,
or report the occurrence of adverse effects.
Physical barriers
One study (50 participants: López-Jornet 2011) at high risk of
bias, provided very low-quality evidence comparing a physical bar-
rier (tongue protector + adjunctive reinforced self-control instruc-
tion (RS-CI)) against placebo. This study did not assess long-term
outcome data.
Primary outcomes
Symptom relief
Short term (≤ 3 months)
In this single study (50 participants: López-Jornet 2011), there
was a short-term benefit for physical barriers with a mean score
reduction in symptoms of -1.10 (mean VAS pain score, scale 0 to
10: lower better; 95% CI -2.14 to -0.06; effect P = 0.04) (Analysis
7.1).
Change in QoL
Short term (≤ 3 months)
López-Jornet 2011 assessed short-term change in overall QoL by
OHIP-49, and adjunctively assessed anxiety and depression as
surrogate QoL markers. There was no difference in short-term
change in overall QoL (meanOHIP-49 score, scale 0 to 196: lower
better; MD -9.20, 95% CI -26.90 to 8.50; effect P = 0.31), or
in anxiety (mean HAD anxiety score, scale 0 to 21: lower better;
MD 0.16, 95% CI -3.19 to 3.51; effect P = 0.93) or depression
(mean HAD depression score, scale 0 to 21: lower better; MD -
0.64, 95% CI -3.98 to 2.70; effect P = 0.71) either (Analysis 7.2).
Secondary outcomes
This study did not assess change in taste or feeling of dryness.
Adverse effects
López-Jornet 2011 narratively reported that no adverse effects oc-
curred.
Psychological therapies
Primary outcomes
One study (30 participants: Bergdahl 1995a) at high risk of bias,
provided very low-quality evidence comparing a psychological
therapy (cognitive therapy (CT)) against placebo. The study pre-
sented long-term outcome data only.
Symptom relief
Long term (> 3 to ≤ 6 months)
Bergdahl 1995a demonstrated a long-term benefit for psycholog-
ical therapy with a mean score reduction in symptoms of -3.20
(mean VAS pain score, scale 1 to 7: lower better; 95% CI -4.22 to
-2.18; effect P < 0.00001) (Analysis 8.1).
Change in QoL
Neither short- nor long-term change in QoL data were available
to compare psychological therapy against placebo.
Secondary outcomes
Bergdahl 1995a did not assess change in taste, feeling of dryness,
or report the occurrence of adverse effects.
Topical treatments
Five studies (180 participants), at either high or unclear risk of
bias, provided very low-quality evidence comparing topical treat-
ments (benzydamine hydrochloride oral rinse (Sardella 1999); lac-
toperoxidase oral rinse (Biotene) (Femiano 2002b; Marino 2010);
topical urea (10%) (Alvarenga da Silva 2014); and capsaicin oral
rinse (Marino 2010; Silvestre 2012)) against placebo.
Data from Silvestre 2012 (30 participants) are not presented due
to attrition (7/30; 23%) in this cross-over study’s first phase and
their protocol requirement for participants who develop adverse
effects to be withdrawn from the trial.
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Primary outcomes
Symptom relief
Short term (≤ 3 months)
Four studies (150 participants: Alvarenga da Silva 2014; Femiano
2002b;Marino 2010; Sardella 1999) compared topical treatments
with placebo to estimate their short-term effect on symptom relief.
Pooling of data was not undertaken due to symptom data being
presented in both dichotomous and continuous form. There is
insufficient or contradictory evidence regarding the benefit of any
of the evaluated topical interventions over placebo (Analysis 9.1;
Analysis 9.2).
Long term (> 3 to ≤ 6 months)
One multi-armed study (27 participants: Marino 2010) provided
data on long-term symptom relief of topical treatments (capsaicin
oral rinse and lactoperoxidase oral rinse (Biotene)) compared with
placebo. This study, assessed at high risk of bias, demonstrated a
long-term benefit for capsaicin oral rinse (mean VAS pain score,
scale 0 to 10: lower better; MD -2.60, 95% CI -5.11 to -0.09;
effect P = 0.04)). No effect was shown for the lactoperoxidase oral
rinse (Biotene) data (MD -1.50, 95% CI -3.91 to 0.91; effect P =
0.22) (Analysis 9.3).
Change in QoL
No included studies comparing topical treatments against placebo
provided data assessing short- or long-term change in QoL.
Secondary outcomes
Change in taste
One study (38 participants: Alvarenga da Silva 2014) comparing
a topical treatment (topical urea (10%)) against placebo reported
narratively that there were no differences in short-term gustation
thresholds after treatment (Mann-Whitney: sweet P = 0.376; salty
P = 0.689; sour P = 0.689; bitter P = 0.689).
No included studies comparing topical treatments assessed long-
term change in taste.
Change in feeling of dryness
The same single study (Alvarenga da Silva 2014) reported nar-
ratively that there were no differences in short-term xerostomia
questionnaire assessment after treatment.
No included studies comparing topical treatments assessed long-
term change in feeling of dryness.
Adverse events
One study (20 participants: Sardella 1999) comparing benzy-
damine hydrochloride oral rinse against placebo, reported narra-
tively that no adverse effects occurred.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Anticonvulsants compared with placebo for treating burning mouth syndrome
Patient or population: people diagnosed with burning mouth syndrome
Settings: secondary care
Intervention: ant iconvulsants (gabapent in: +/ - alpha lipoic acid (ALA))
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Anticonvulsants
Symptom relief: short-
term (≤ 3 months)
- Bespoke geographical
burning distribut ion nu-
merical scale (0-4) (Di-
chotomised)
150 per 1000 600 per 1000
(313 to 1000)
RR 4.00
(2.09 to 7.67)
100
(1 RCT)
⊕©©©
very low1
No data were available
to est imate long-term
symptom relief
Only gabapent in (+/ -
adjunct ive ALA) was
assessed by a single
study
No data were available
to est imate the ef fect of
other ant iconvulsants
Change in quality of life
(QoL)
No included studies reported change in QoL
Change in taste No included studies reported change in taste
Change in feeling of
dryness
No included studies reported change in feeling of dryness
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Adverse effects There was evidence of an increase in drowsiness (RR 31.95, 95% CI 1.84 to
553.64) in people treated with gabapent in alone (1 RCT, 80 part icipants).
This ef fect was not found for people treated with gabapent in + adjunct ive
ALA (1 RCT, 80 part icipants), nor was there evidence of an increase in
mild headaches
100
(1 RCT)
⊕©©©
very low2
Only gabapent in (+/ -
adjunct ive ALA) was
assessed by a single
study
No data were avail-
able to est imate the
harms of other ant icon-
vulsants
* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI)
CI: conf idence interval; OIS: opt imal information size; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1Assumed placebo risk based on control est imate at short-term (≤ 3 months) follow-up: total of control part icipants
experiencing symptom relief , divided by total number of part icipants in control group mult iplied by 100; downgraded twice
due to high risk of bias across mult iple domains; downgraded once due to indirectness: concerns relat ing to applicability,
only 1 type of ant iconvulsant assessed, ef fects of other ant iconvulsants may dif fer; downgraded once due to imprecision:
OIS not met.
2Single 4-armed study (totalling 120 people), with 3 of 4 groups included in this comparison (placebo group: 60 people;
gabapent in group: 20 people; gabapent in + ALA group: 20 people), the remaining group (ALA: 20 people) and placebo group
(60 people) are included within Summary of f indings 5; downgraded twice due to high risk of bias across mult iple domains;
downgraded once due to indirectness: concerns relat ing to applicability, only 1 type of ant iconvulsant assessed, ef fects of
other ant iconvulsants may dif fer; downgraded once due to imprecision: OIS not met.
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Benzodiazepines compared with placebo for treating burning mouth syndrome
Patient or population: people diagnosed with burning mouth syndrome
Settings: secondary care
Intervention: benzodiazepines (topical/ systemic clonazepam)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Benzodiazepines
Symptom relief: short-
term (≤ 3 months)
- Mean VAS pain score
(Scale 0-10: lower bet-
ter)
4.76 1.89 lower (2.19 to 1.
59 lower)
- 111
(2 RCTs)
⊕©©©
very low1
There was evidence
of a dif ference be-
tween subgroups be-
tween the 2 subgroups:
systemic and topical
clonazepam
Short-term relief is es-
t imated f rom 2 topi-
cal clonazepam stud-
ies. Long-term symp-
tom relief (> 3 to ≤
6 months) was 1.39
lower (1.96 to 0.83
lower) than the placebo
group (1 RCT, 66 part ic-
ipants)
No evidence of short-
term symptom relief
f rom a single study as-
sessing systemic clon-
azepam (≤ 3 months)
2
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: mean VAS score in
both placebo and inter-
vent ion groups was 4.
5 (MD 0.00 lower, 95%
CI 1.86 lower to 1.86
higher) (1 RCT, 20 par-
t icipants)
No data were available
to est imate the ef fect of
other benzodiazepines
Change in quality of
life (QoL): short-term
(≤ 3 months) - Mean
depression score(Scale
0-4: lower better)
0.8 0.20 lower (0.95 lower
to 0.55 higher)
- 20
(1 RCT)
⊕©©©
very low2
Single study assessing
systemic clonazepam
No data were available
to est imate long-term
change in QoL
Change in taste: short-
term (≤ 3 months)
- Mean taste test score
(Scale 0-16: higher bet-
ter)
12.3 1.00 lower (3.11 lower
to 1.11 higher)
- 20
(1 RCT)
⊕©©©
very low3
Single study assessing
systemic clonazepam
No data were available
to est imate long-term
change in taste
Change in feeling of
dryness
No included studies reported change in feeling of dryness
Adverse effects There was no dif ference in the adverse events reported (drowsiness: 2 RCTs, 114 part icipants;
dry mouth, spasmophilia, or euphoric behaviour: 1 RCT, 48 part icipants) for people treated with
benzodiazepines
⊕©©©
very low4
Both studies used topi-
cal clonazepam
We were unable to est i-
mate the harms of sys-
temic clonazepam as
adverse events were
not reported by its study
No data were avail-
able to est imate the
harms of other benzo-
diazepines
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* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI)
CI: conf idence interval; M D: mean dif ference; OIS: opt imal information size; RCT: randomised controlled trial; RR: risk rat io; VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1Assumed placebo risk based on mean placebo group pain score at short-term (≤ 3 months) follow-up; downgraded once
due to studies being assessed at unclear risk of bias across mult iple domains; downgraded once due to inconsistency:
substant ial heterogeneity (I2 = 56%); downgraded once due to indirectness: concerns relat ing to applicability, only 1 type
of benzodiazepine (clonazepam - irrespect ive of mode of administrat ion) assessed, ef fects of other benzodiazepines may
dif fer; downgraded once due to imprecision: OIS not met.
2Assumed placebo risk based on mean placebo group depression score at short-term (≤ 3 months) follow-up; downgraded
once due to high risk of select ive report ing bias; downgraded twice due to indirectness: use of surrogate measure, and
also concerns relat ing to applicability, only 1 type of benzodiazepine (clonazepam - irrespect ive of mode of administrat ion)
assessed, ef fects of other benzodiazepines may dif fer; downgraded twice due to imprecision: OIS not met, and 95% CI
includes no ef fect.
3Assumed placebo risk based on mean placebo group taste score at short-term (≤ 3 months) follow-up; downgraded once
due to indirectness: concerns relat ing to applicability, only 1 type of benzodiazepine (clonazepam - irrespect ive of mode
of administrat ion) assessed, ef fects of other benzodiazepines may dif fer; downgraded once due to high risk of select ive
report ing bias; downgraded twice due to imprecision: OIS not met, and 95% CI includes no ef fect.
4Downgraded once due to studies being assessed at unclear risk of bias across mult iple domains; downgraded once due
to indirectness: concerns relat ing to applicability, only 1 type of benzodiazepine (clonazepam - irrespect ive of mode of
administrat ion) assessed, ef fects of other benzodiazepines may dif fer; downgraded twice due to imprecision: OIS not met,
and 95% CI includes no ef fect.
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Cholinergics compared with placebo for treating burning mouth syndrome
Patient or population: people diagnosed with burning mouth syndrome
Settings: secondary care
Intervention: cholinergics (bethanechol)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Cholinergics
Symptom relief: short-
term (≤ 3 months)
- Bespoke BMS symp-
tomology change scale
(Dichotomised)
150 per 1000 750 per 1000
(39 to 1000)
RR 5.00
(0.26 to 98.00)
40
(1 RCT)
⊕©©©
very low1
No data were available
to est imate long-term
symptom relief
Only bethanechol was
assessed by a single
study
No data were available
to est imate the ef fect
of other cholinergics
Change in quality of life
(QoL)
No included studies reported change in QoL
Change in taste No included studies reported change in taste
Change in feeling of
dryness
No included studies reported change in feeling of dryness
Adverse effects This single study narrat ively reported adverse ef fect data. 4 part icipants
(20%) in the bethanechol arm reported adverse events (nausea, dizzi-
ness, blood pressure fall, cold perspirat ion or sporadic abdominal pain)
. Reported data did not present the distribut ion of these outcomes by
40
(1 RCT)
⊕©©©
very low2
Only bethanechol was
assessed by a single
study
No data were available
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part icipant to est imate the harms
of other cholinergics
* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI)
BM S: burning mouth syndrome; CI: conf idence interval; OIS: opt imal information size; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1No placebo group part icipants experienced pain relief in the single study assessing cholinergics. Consequent ly, in order
to calculate the corresponding risk, the assumed placebo risk for cholinergics is based on the assumed placebo risk for
ant iconvulsants, as detailed in Summary of f indings 2; downgraded twice: risk of bias concerns across mult iple domains
(allocat ion, blinding, select ive report ing and absence of baseline data); downgraded once due to indirectness: concerns
relat ing to applicability, only 1 type of ant icholinergic assessed, ef fects of other cholinergics may dif fer; downgraded twice
due to imprecision: OIS not met, and 95% CI includes no ef fect.
2Downgraded twice: risk of bias concerns across mult iple domains (allocat ion, blinding, select ive report ing and absence
of baseline data); downgraded once due to indirectness: concerns relat ing to applicability, only 1 type of ant icholinergic
assessed, ef fects of other cholinergics may dif fer; downgraded twice due to imprecision: OIS not met, and narrat ive report
did not permit est imation of ef fect or 95% CI.
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Dietary supplements compared with placebo for treating burning mouth syndrome
Patient or population: people diagnosed with burning mouth syndrome
Settings: secondary care
Intervention: dietary supplements (ALA with (+ vitamins, + lycopene + green tea extract) or without adjunct ive act ive ingredients; hypericum perforatum (St John’s Wort);
’Catuama’ herbal compound; lycopene)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Dietary supplements
Symptom relief: short-
term (≤ 3 months)
There is insuf f icient or contradictory evidence regarding the benef it of any
of the evaluated dietary supplements over placebo to evaluate short-term
symptom relief
628
(12 RCTs)
⊕©©©
very low1
Intervent ions evaluated
for short-term symptom
relief included:
• ALA without
adjunct ive act ive
ingredients (3 RCTs)
• ALA with vitamins
(5 RCTs)
• ALA with lycopene
and green tea extract
(2 RCTs)
• hypericum
perforatum (St John’s
Wort) (1 RCT)
• ’Catuama’ herbal
compound (1 RCT)
• lycopene (1 RCT)
The mean VAS pain
score (scale 0-10: lower
better) for long- term
3
2
In
te
rv
e
n
tio
n
s
fo
r
tre
a
tin
g
b
u
rn
in
g
m
o
u
th
sy
n
d
ro
m
e
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
symptom relief (> 3 to
≤ 6 months) was 0.
89 lower (2.37 lower
to 0.59 higher) for peo-
ple treated with ALA
(with or without adjunc-
t ive vitamins) than the
placebo group (2 RCTs,
94 part icipants)
Change in quality of life
(QoL): short-term (≤ 3
months)
- Mean OHIP-14 score
(Scale 0-70: lower bet-
ter)
17.38 0.93 higher (3.14 lower
to 5.00 higher)
- 50
(1 RCT)
⊕©©©
very low2
Single study assessing
short-term QoL, anxiety
and depression com-
pared lycopene with
placebo
No data were available
to est imate long-term
change in QoL, or its
surrogate markers: anx-
iety or depression
No data were avail-
able to est imate the
ef fect of other dietary
supplements; however,
1 study (43 pat ients)
, comparing hypericum
perforatum extract with
placebo, evaluated QoL
f rom patient self -re-
ports and narrat ively in-
dicated that both in-
tervent ion and placebo
part icipants were bet-
ter able to cope at trial
complet ion
3
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Change in QoL - anx-
iety: short-term (≤ 3
months)
- Mean HAD anxiety
score (Scale 0-21: lower
better)
11.5 2.85 lower (5.28 to 0.
42 lower)
⊕©©©
very low3
Change in QoL - de-
pression: short-term (≤
3 months)
- Mean HAD depression
score (Scale 0-21: lower
better)
6.25 1.87 lower (4.23 lower
to 0.49 higher)
⊕©©©
very low4
Change in taste No included studies reported change in taste
Change in feeling of
dryness
No included studies reported change in feeling of dryness
Adverse effects • For people treated with ALA (with or without adjunct ive act ive ingredients), there was
evidence of an increase in headache occurrence (RR 10.87, 95% CI 1.36 to 87.03; 2 RCTs, 118
part icipants) or gastrointest inal complaints (RR 4.00, 95% CI 1.21 to 13.27; 3 RCTs, 138
part icipants). There was no dif ference in blood pressure (1 RCT, 38 part icipants) or interm it tent
facial skin rash (1 RCT, 80 part icipants)
• For people treated with ALA (with or without adjunct ive act ive ingredients) or ’Catuama’
herbal compound, there was no dif ference in drowsiness (2 RCTs, 110 part icipants)
• For people treated with ’Catuama’ herbal compound (1 RCT, 72 part icipants), there was no
dif ference in exacerbat ion of symptoms, insomnia or weight gain
• 1 RCT (60 part icipants, ALA with adjunct ive vitamins) reported no ‘‘notable adverse ef fects’’,
and another RCT (40 part icipants, ALA with adjunct ive vitamins) narrat ively reported 4 intervent ion
part icipants (20%) experienced heartburn, before correct ion by administrat ion of ranit idine (150
mg)
• Severe headache result ing f rom hypericum perforatum extract use caused 1 part icipant (5%)
to discont inue treatment (1 RCT, 43 part icipants)
• 4 RCTs (224 part icipants, ALA (with or without adjunct ive act ive ingredients) and lycopene)
narrat ively reported that no adverse ef fects occurred
⊕©©©
very low5
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* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI)
ALA: alpha lipoic acid; CI: conf idence interval; HAD: Hospital Anxiety and Depression scale; OHIP-14: Oral Health Impact Prof ile-14; OIS: opt imal information size; RCT:
randomised controlled trial; RR: risk rat io; VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1Downgraded twice due to high risk of bias across mult iple domains; downgraded twice due to inconsistency between, and
within, subgroups; 1 RCT (Carbone 2009) contributes to 2 subgroups: ALA with vitamins and ALA without adjunct ive act ive
ingredients.
2Assumed placebo risk based on mean placebo group QoL score at short-term (≤ 3 months) follow-up; downgraded once
due to high risk of bias relat ing to select ive report ing and lack of baseline data; downgraded once due to indirectness:
concerns relat ing to applicability, only 1 type of dietary supplement assessed, ef fects of other dietary supplements may dif fer;
downgraded twice due to imprecision: OIS not met, and 95% CI includes no ef fect.
3Assumed placebo risk based on mean placebo group anxiety score at short-term (≤ 3 months) follow-up; downgraded once
due to high risk of bias relat ing to select ive report ing and lack of baseline data; downgraded twice due to indirectness: use of
surrogate measure, and also concerns relat ing to applicability, only 1 type of dietary supplement assessed, ef fects of other
dietary supplements may dif fer; downgraded once due to imprecision: OIS not met.
4Assumed placebo risk based on mean placebo group depression score at short-term (≤ 3 months) follow-up; downgraded
once due to high risk of bias relat ing to select ive report ing and lack of baseline data; downgraded twice due to indirectness:
use of surrogate measure, and also concerns relat ing to applicability, only 1 type of dietary supplement assessed, ef fects of
other dietary supplements may dif fer; downgraded once due to imprecision: OIS not met.
5Downgraded twice due to high risk of bias across mult iple domains; downgraded twice due to inconsistency between, and
within, subgroups; downgraded once for imprecision: wide CIs est imated around ef fect sizes.
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Electromagnetic radiation compared with placebo for treating burning mouth syndrome
Patient or population: people diagnosed with burning mouth syndrome
Settings: secondary care
Intervention: electromagnetic radiat ion (low-level laser therapy)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Electromagnetic radia-
tion
Symptom relief:
short-term (≤ 3
months)
- Mean VAS score
(Scale 0-100: lower bet-
ter)
62.84 30.36 lower (44.22 to
16.50 lower)
- 58
(1 RCT)
⊕©©©
very low1
No data were available
to est imate long-term
symptom relief
Only low-level laser
therapy (inf rared laser
and red laser) was
assessed by a single
study
No data were avail-
able to est imate the ef -
fect of other types of
electromagnetic radia-
t ion (e.g. transcranial
magnetic st imulat ion)
Change in quality of life
(QoL):
short-term (≤ 3
months)
- Mean OHIP-14 score
(Scale 0-56: lower bet-
ter)
13.39 5.24 lower (7.38 to 3.
09 lower)
⊕©©©
very low2
Change in taste No included study reported change in taste
Change in feeling of
dryness
No included study reported change in feeling of dryness
Adverse effects No included study reported the occurrence of adverse events
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* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OHIP-14: Oral Health Impact Prof ile-14; OIS: opt imal information size; RCT: randomised controlled trial; VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1Assumed placebo risk based on mean placebo group pain score at short-term (≤ 3 months) follow-up; downgraded once due
to the single study being assessed at unclear risk of bias across mult iple domains and high risk of bias relat ing to other
bias; downgraded once due to indirectness: concerns relat ing to applicability, only 1 type of electromagnetic radiat ion
assessed, ef fects of other types of electromagnetic radiat ion may dif fer; downgraded once due to imprecision: OIS not
met.
2Assumed placebo risk based on mean placebo group QoL score at short-term (≤ 3 months) follow-up; downgraded once due
to the single study being assessed at unclear risk of bias across mult iple domains and high risk of bias relat ing to other bias;
downgraded once due to indirectness: concerns relat ing to applicability, only 1 type of electromagnetic radiat ion assessed,
ef fects of other types of electromagnetic radiat ion may dif fer; downgraded once due to imprecision: OIS not met.
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Physical barriers compared with placebo for treating burning mouth syndrome
Patient or population: people diagnosed with burning mouth syndrome
Settings: secondary care
Intervention: physical barriers (tongue protector)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Physical barriers
Symptom relief:
short-term (≤ 3
months)
- Mean VAS pain score
(Scale 0-10: lower bet-
ter)
5.6 1.10 lower (2.14 to 0.
06 lower)
- 50
(1 RCT)
⊕©©©
very low1
Single study assessing
tongue protectors
No data were available
to est imate long-term
symptom relief
Change in quality of life
(QoL): short-term (≤ 3
months)
- Mean OHIP-49 score
(Scale 0-196: lower bet-
ter)
53.72 9.20 lower (26.90 lower
to 8.50 higher)
- 50
(1 RCT)
⊕©©©
very low2
Single study assessing
tongue protectors
No data were available
to est imate long-term
change in QoL, or its
surrogate markers: anx-
iety or depression
Change in QoL - anx-
iety: short-term (≤ 3
months)
- Mean HAD anxiety
score (Scale 0-21: lower
better)
11.04 0.16 higher (3.19 lower
to 3.51 higher)
- ⊕©©©
very low3
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Change in QoL - de-
pression: short-term (≤
3 months)
- Mean HAD depression
score (Scale 0-21: lower
better)
8.92 0.64 lower (3.98 lower
to 2.70 higher)
- ⊕©©©
very low4
Change in taste No included studies reported change in taste
Change in feeling of
dryness
No included studies reported change in feeling of dryness
Adverse effects The single study narrat ively reported that no adverse events occurred f rom
the use of tongue protectors
50
(1 RCT)
⊕⊕©©
low5
* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI)
CI: conf idence interval; HAD: Hospital Anxiety and Depression scale; OHIP-49: Oral Health Impact Prof ile-49; OIS: opt imal information size; RCT: randomised controlled trial;
VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1Assumed placebo risk based on mean placebo group pain score at short-term (≤ 3 months) follow-up; downgraded twice
due to serious concerns of risk of bias, relat ing to blinding and potent ial confounding inf luence of part icipants in receipt
of anxiolyt ics; downgraded once due to imprecision: OIS not met.
2Assumed placebo risk based on mean placebo group quality of lif e score at short-term (≤ 3 months) follow-up; downgraded
twice due to serious concerns of risk of bias, relat ing to blinding and potent ial confounding inf luence of part icipants in receipt
of anxiolyt ics; downgraded twice due to imprecision: OIS not met, and 95% CI includes no ef fect.
3Assumed placebo risk based on mean placebo group anxiety score at short-term (≤ 3 months) follow-up; downgraded twice
due to serious concerns of risk of bias, relat ing to blinding and potent ial confounding inf luence of part icipants in receipt
of anxiolyt ics; downgraded twice due to imprecision: OIS not met, and 95% CI includes no ef fect; downgraded once due to
indirectness: use of surrogate measure.
4Assumed placebo risk based on mean placebo group depression score at short-term (≤ 3 months) follow-up; downgraded
twice due to serious concerns of risk of bias, relat ing to blinding and potent ial confounding inf luence of part icipants in receipt3
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of anxiolyt ics; downgraded twice due to imprecision: OIS not met, and 95% CI includes no ef fect; downgraded once due to
indirectness: use of surrogate measure.
5Downgraded twice due to serious concerns of risk of bias, relat ing to blinding and potent ial confounding inf luence of
part icipants in receipt of anxiolyt ics; downgraded once due to imprecision: OIS not met.
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Psychological therapies compared with placebo for treating burning mouth syndrome
Patient or population: people diagnosed with burning mouth syndrome
Settings: secondary care
Intervention: psychological therapies (cognit ive therapy)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Psychological thera-
pies
Symptom relief: long-
term (> 3 to≤ 6 months)
- Mean VAS pain score
(Scale 1-7: lower better)
4.6 3.20 lower (4.22 to 2.
18 lower)
- 30
(1 RCT)
⊕©©©
very low1
Single study assessing
cognit ive therapy
No data was available
to est imate short-term
symptom relief
No data was available
to est imate the ef fect
of other psychological
therapies
Change in quality of life
(QoL)
No included study reported change in QoL
Change in taste No included study reported change in taste
Change in feeling of
dryness
No included study reported change in feeling of dryness
Adverse effects No included study reported the occurrence of adverse events
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* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI)
CI: conf idence interval; OIS: opt imal information size; RCT: randomised controlled trial; VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1Assumed placebo risk based on mean placebo group pain score at long-term (> 3 to ≤ 6 months) follow-up; downgraded twice
due to serious concerns of risk of bias, relat ing to blinding and lack of baseline data; downgraded once due to indirectness:
concerns relat ing to applicability, only 1 type of psychological therapy assessed, ef fects of other psychological therapies
may dif fer; downgraded once due to imprecision: OIS not met.
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Topical treatments compared with placebo for treating burning mouth syndrome
Patient or population: people diagnosed with burning mouth syndrome
Settings: secondary care
Intervention: topical treatments (benzydamine hydrochloride oral rinse, lactoperoxidase oral rinse (Biotene), topical urea (10%), capsaicin oral rinse)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Topical treatments
Symptom relief: short-
term (≤ 3 months)
There is insuf f icient or contradictory evidence regarding the benef it of
any of the evaluated topical treatments over placebo to evaluate short-
term symptom relief
150
(4 RCTs)
⊕©©©
very low1
Intervent ions evaluated
for short-term symptom
relief included:
• benzydamine
hydrochloride oral rinse
(1 RCT)
• lactoperoxidase
oral rinse (Biotene) (2
RCTs)
• topical urea (10%)
(1 RCT)
• capsaicin oral
rinse (1 RCT)
The mean VAS pain
score (scale 0-10: lower
better) for long- term
symptom relief (> 3 to
≤ 6 months) was 2.
60 lower (5.11 to 0.09
lower) for people treated
with capsaicin oral rinse
4
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than the placebo group
(1 RCT, 18 part icipants)
No evidence of long-
term symptom relief
f rom a single study
assessing lactoperoxi-
dase oral rinse (Biotene)
: mean VAS score in
intervent ion group was
1.50 lower than people
treated with placebo (3.
91 lower to 0.91 higher)
(1 RCT, 18 part icipants)
Change in quality of life
(QoL)
No included studies reported change in QoL
Change in taste: short-
term (≤ 3 months)
- Mean Quantitat ive
Sensory Test ing (QST)
score: gustat ive thresh-
old (Scale: unknown)
A single study narrat ively reported that there was no dif ference in short-
term gustat ion thresholds
38
(1 RCT)
⊕©©©
very low2
Single study assessing
topical urea (10%)
No data were available
to est imate long-term
change in taste
No data were available
to est imate the ef fect of
other topical treatments
Change in feeling of
dryness:
short-term (≤ 3
months)
- Xerostomia quest ion-
naire (Scale 1-5: lower
better)
A single study narrat ively reported that there was no dif ference in short-
term xerostomia quest ionnaire assessment before or af ter treatment
38
(1 RCT)
⊕©©©
very low3
Single study assessing
topical urea (10%)
No data were available
to est imate long-term
change in feeling of dry-
ness
No data were available
to est imate the ef fect of
other topical treatments
4
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Adverse effects A single study narrat ively reported that no adverse events occurred
f rom the use of benzydamine hydrochloride oral rinse
20
(1 RCT)
⊕©©©
very low4
No data were available
to est imate the ef fect of
other topical treatments
* The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI)
CI: conf idence interval; OIS: opt imal information size; RCT: randomised controlled trial; VAS: visual analogue scale
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1Downgraded twice due to high risk of bias across mult iple domains; downgraded twice due to inconsistency between, and
within, subgroups; downgraded once due to imprecision: OIS not met; 1 RCT (Marino 2010) contributes to 2 subgroups:
capsaicin oral rinse and lactoperoxidase oral rinse (Biotene).
2Downgraded twice due to high risk of bias relat ing to attrit ion and select ive report ing; downgraded once due to indirectness:
concerns relat ing to applicability, only 1 type of topical therapy assessed, ef fects of other topical therapies may dif fer;
downgraded once due to imprecision: OIS not met.
3Downgraded twice due to high risk of bias relat ing to attrit ion and select ive report ing; downgraded once for indirectness:
concerns relat ing to applicability, only 1 type of topical therapy assessed, ef fects of other topical therapies may dif fer;
downgraded once due to imprecision: OIS not met.
4Downgraded once due to unclear risk of bias across mult iple domains; downgraded once due to indirectness: concerns
relat ing to applicability, only 1 type of topical therapy assessed, ef fects of other topical therapies may dif fer; downgraded
once due to imprecision: OIS not met.
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D I S C U S S I O N
Summary of main results
A total of 23 placebo-controlled randomised controlled trials
(RCTs) were included in this review, evaluating the effectiveness
of 23 different interventions for the treatment of burning mouth
syndrome (BMS) symptoms (distributed between nine interven-
tion categories: antidepressants and antipsychotics; anticonvul-
sants; benzodiazepines; cholinergics; dietary supplements; electro-
magnetic radiation; physical barriers; psychological therapies; and
topical treatments). There was a considerable amount of hetero-
geneity in the types of interventions studied, and how the inter-
ventions were delivered.
There was some evidence of a benefit in short-term symptom re-
lief for electromagnetic radiation, topical benzodiazepines, physi-
cal barriers and anticonvulsants. We found insufficient/contradic-
tory evidence regarding the short-term effectiveness of antidepres-
sants, systemic benzodiazepines, cholinergics, dietary supplements
or topical treatments. No RCT assessing psychological therapies
evaluated short-term symptom relief.
We also found some evidence of long-term symptom relief for psy-
chological therapies, capsaicin oral rinse (topical treatment) and
topical benzodiazepines. We found no evidence of a difference for
dietary supplements or lactoperoxidase oral rinse. No studies as-
sessing antidepressants, anticonvulsants, cholinergics, electromag-
netic radiation, or physical barriers evaluated long-term symptom
relief.
We found some evidence of a short-term quality of life (QoL) im-
provement for electromagnetic radiation, however findings were
inconclusive for antidepressants, benzodiazepines, dietary supple-
ments and physical barriers. No studies assessing anticonvulsants,
cholinergics, psychological therapies, or topical treatments evalu-
ated short-term change in QoL, and no RCTs from any category
assessed long-term change in QoL.
Changes in taste and feeling of dryness were assessed by included
studies in the short term only, and the findings for each were
inconclusive.
With regard to adverse events, there is very low-quality evidence
that antidepressants increase dizziness and drowsiness, and that al-
pha lipoic acid increased headache and gastrointestinal complaints.
We found insufficient/contradictory evidence regarding adverse
events for anticonvulsants or benzodiazepines. Adverse events were
poorly reported or unreported for cholinergics, electromagnetic
radiation, and psychological therapies. No adverse events occurred
from physical barriers or topical therapy use.
See Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6; Summary of
findings 7; Summary of findings 8; Summary of findings 9.
Overall completeness and applicability of
evidence
All of the study participants included in the current review were
deemed to adhere to an appropriate diagnostic classification of
BMS (Additional Table 1).
We had serious concerns regarding the applicability of the evi-
dence for seven of the nine intervention categories contained in
this review (excepting dietary supplements and physical barriers),
as studies from these seven categories assessed only one type of
each intervention and the effects of other types of these interven-
tions (antidepressants and antipsychotics; anticonvulsants; benzo-
diazepines; cholinergics; electromagnetic radiation; psychological
therapies; and topical treatments) may differ.
While we were able to assess short-term symptom relief for all
intervention categories except psychological therapies, fewer data
were available for long-term assessment. Consequently, we are cur-
rently unable to estimate long-term symptom relief resulting from
use of antidepressants, anticonvulsants, cholinergics, electromag-
netic radiation, or physical barriers.
Furthermore, we were only able to assess:
• short-term change in QoL for dietary supplements,
electromagnetic radiation, and physical barriers (no
interventions long term),
• short-term change in depression (as a surrogate measure of
QoL) for antidepressants and benzodiazepines,
• short-term change in taste for benzodiazepines and topical
treatments (no interventions long term),
• short-term change in feeling of dryness for topical
treatments alone (no interventions long term).
Nor do we have any data to assess adverse event occurrence from
electromagnetic radiation or psychological therapies.
Most studies provided baseline demographics of their included
participants. A single study (Alvarenga da Silva 2014) reported
participants’ race. In terms of the gender and age distribution pre-
sented, the majority of studies were consistent; both in compari-
son to each other and when compared to previously published epi-
demiological data (Bergdahl 1999). Several studies, however, were
inconsistent with expected male-to-female (M/F) ratios: Femiano
2002a (M/F: 18/42), Femiano 2002b (M/F: 32/48), Heckmann
2012 (M/F: 7/13), Tammiala-Salonen 1999 (M/F: 0/37). There
were no obvious reasons as to why these studies had unusual gen-
der spreads.
There is a paucity of RCTs evaluating neuropathic pain medica-
tions (Finnerup 2015; NICE 2013) in the management of BMS
- with only amitriptyline (Bogetto 1999) and very low-dosage
gabapentin (Lopez-D’alessandro 2011) being included in this re-
view. This is in spite of the growing body of evidence to sup-
port the role of neuropathic mechanisms in BMS (Jääskeläinen
2012). Moreover, only a single included RCT looked at clinical
psychology as a way of managing BMS (Bergdahl 1995a); despite
a wealth of evidence supporting the use of psychological therapies
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in chronic pain management (Sturgeon 2014).
Some of the treatments assessed within this review, or other inter-
ventions not covered by the included studies, may be effective in
the management of BMS symptoms. However, until further high-
quality evidence is forthcoming we will not be able to make any
recommendations for the treatment for BMS.
Quality of the evidence
The quality of the evidence was assessed as very low for all out-
comes (both short- and long-term) in all intervention categories
(with the exception of adverse events for physical barriers, which
were assessed as low-quality evidence).
Of the 23 studies included in this review, only one was deemed to
have a low overall risk of bias; four were found to have an unclear
risk of bias; and the remaining 18 studies were judged to be at high
overall risk of bias. ’Other bias’ was the most frequent cause of a
high risk of bias assessment of a study (n = 10; 43%), followed by
selective outcome reporting (n = 8; 35%) and blinding of partici-
pants (n = 7; 30%). Trials with open assessment of the outcome,
as described by Femiano and colleagues (Femiano 2000; Femiano
2002b) and Bogetto and colleagues (Bogetto 1999), have been
shown to overestimate the treatment effects by 35% (Jüni 1999).
Indeed, this may explain why the two open-label trials of alpha-
lipoic acid (Femiano 2000; Femiano 2002b) provided greater es-
timates of effect than the double-blinded trial of the same inter-
vention (Femiano 2002a).The most commonly occurring cause
for an ’other bias’ assessment was due to failing to present baseline
demographics for each study arm (n = 8; 35%).
We were unable to perform sensitivity analyses with regard to risk
of bias due to the fact that only one included study was assessed
to have a low overall risk of bias.
Inappropriate and misleading use of graphs and tables which did
not contain usable data was commonplace, although we sought
data directly from study authors where possible to do so. More
recently, authors have been able to publish online supplements
containing all of the relevant study data; they no longer have to
select which restricted set of data to report. In many of the studies
a high risk of reporting bias could have been avoided if additional
raw data had been made available to the review group.
Potential biases in the review process
The review authors strictly adhered to the prespecified method-
ology for conducting systematic reviews included in the Cochrane
Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (up-
datedMarch 2011) (Higgins 2011b). Two review authors screened
all abstracts independently and in duplicate, and all identified pa-
pers were then assessed and had the risk of bias assessment con-
ducted by at least two review authors.
After discussion, the review authors agreed that the placebo com-
parator arms employed by two studies were suitable for inclusion
as they were considered to be non-active placebos (Bergdahl 1995a
(psychological therapies: cognitive therapy versus motivation/oral
examination); López-Jornet 2011 (physical barriers: tongue pro-
tector + reinforced self-control instruction (RS-CI) versus RS-
CI)).
Data fromBogetto 1999 were not includedwithin the quantitative
synthesis due to excessive attrition (19/24; 79%) in the study’s
placebo arm, or from Silvestre 2012 due to attrition (7/30; 23%)
in this cross-over study’s first phase and their protocol requirement
for participants who developed adverse effects to be withdrawn
from the trial.
We decided it was inappropriate to use reported six-month data
from Grémeau-Richard 2004 and one-year data from Femiano
2002a, as both studies only presented data at these time points
from participants who had positively responded to treatment at
their earlier assessment, and consequently comprised a highly bi-
ased subset of data.
Due to one of the included cross-overRCTs containingnowashout
period (Femiano 2000), we only incorporated data from the first
phase of their study within our analyses.
We identified that two studies reported different length scales from
the same outcome assessment measure (OHIP-14 (Oral Health
Impact Profile-14): Cano-Carrillo 2014 scale 0 to 70, lower bet-
ter; Spanemberg 2015 scale 0 to 56, lower better). Despite the
inconsistency in scale length, we used the length reported for each
study rather than assuming that either one was incorrect.
Lastly, despite all studies initially assessing symptom relief by use
of a continuous outcome metric, seven studies (Femiano 2000;
Femiano 2002a; Femiano 2002b; Lopez-D’alessandro 2011;
Palacios-Sánchez 2015; Sardella 1999; Alvarenga da Silva 2014)
transformed their data to report symptom relief categorically in-
stead, which only permitted us to estimate their effect estimates
dichotomously as risk ratios. Consequently, we had to present re-
sults from continuous and dichotomous data separately; as such,
we were unable to estimate heterogeneity across the dietary sup-
plements and topical treatments categories (except where permit-
ted within subgroups), and were also unable to estimate subgroup
differences.
Agreements and disagreements with other
studies or reviews
This review largely concurs with the findings of two other system-
atic reviews of placebo-controlled RCTs:
• de Moraes 2012 (12 RCTs compared to this review’s
inclusion of 23 RCTs; includes Carbone 2009; Cavalcanti 2009;
Femiano 2002a; Femiano 2002b; Grémeau-Richard 2004;
Lopez-D’alessandro 2011; López-Jornet 2009b; Marino 2010;
Sardella 1999; Sardella 2008; Tammiala-Salonen 1999 and our
excluded study Petruzzi 2004), and
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• Kisely 2016 (24 RCTs compared to this review’s inclusion
of 23 RCTs; includes Bergdahl 1995a; Cano-Carrillo 2014;
Carbone 2009; Cavalcanti 2009; Femiano 2000; Femiano
2002a; Femiano 2002b; Grémeau-Richard 2004; Heckmann
2012; Lopez-D’alessandro 2011; López-Jornet 2009b;
López-Jornet 2011; Marino 2010; Rodríguez de
Rivera-Campillo 2010; Sardella 1999; Sardella 2008; Silvestre
2012; Spanemberg 2012; Tammiala-Salonen 1999 and five of
our excluded studies Grémeau-Richard 2010; López-Jornet
2013; Miziara 2009; Petruzzi 2004; Toida 2009).
While neither de Moraes 2012 or Kisely 2016 undertook meta-
analyses of included studies, both reviews concluded there was lim-
ited quality evidence to support the efficacy of any one treatment
over another in the treatment of primary BMS. We also highlight
agreement with their observations that few RCTs provide long-
term follow-up (longer than three months), which we endorse for
the sustained management of this chronic painful condition.
A systematic review (Cui 2016) concentrating specifically on
clonazepam (a benzodiazepine) estimated short-term relief more
conservatively than this review did (from the same three RCTs
(Grémeau-Richard 2004; Heckmann 2012; Rodríguez de Rivera-
Campillo 2010) assessed by a visual analogue scale (VAS) (0 to 10,
lower better); Cui 2016: mean difference (MD) -1.44, 95% confi-
dence interval (CI) -2.06 to -0.82 versus this review’s Analysis 3.1:
MD -1.84, 95%CI -2.14 to -1.54).However, we attribute this dif-
ference to Cui 2016’s selective use of interim data fromHeckmann
2012 (instead of the ultimately assessed outcome), standard devi-
ation errors from Grémeau-Richard 2004’s data (up to four times
larger, we assume from being incorrectly copied across), and their
decision to pool topical and systemic benzodiazepines in a single
group. Considering these differences, we maintain confidence in
our larger estimate of effectiveness despite originating from very
low-quality evidence.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently there is a dearth of high-quality research evidence to
allow the development of clear guidance for those charged with
treating burningmouth syndrome (BMS) patients. Cliniciansmay
use the results anddetailed data from this systematic review to assist
in discussions with their BMS patients, about which treatment
options to undertake in the management of their condition.
Implications for research
Further randomised controlled trials (RCTs), of longer duration
(a minimum of three months follow-up) and high methodolog-
ical quality, are required in order to establish the effective forms
of treatment for patients suffering from BMS. Future high-qual-
ity research, which further assesses the treatments included in this
review and incorporates novel BMS therapies, would very likely
result in a change in clinical practice. Furthermore, treatments es-
tablished in themanagement of other neuropathic pain conditions
and psychological therapies should be considered for clinical trials
in BMS.
Comparability of groups at baseline is of great importance, partic-
ularly with regard to intensity of symptoms, gender and psycho-
logical background. True randomisation with concealed allocation
of treatment groups should provide comparable groups, although
details of baseline characteristics should still be provided and an
estimate of comparability undertaken. Given the subjectivity of
the symptoms to be assessed, participants, healthcare providers
and outcome assessors should be blinded to the intervention.
Visual analogue scales (VAS) or validated patient-reported out-
come measures should be used for the assessment of pain inten-
sity. A decision regarding how large a treatment effect constitutes
an adequate outcome requires to be made. Most treatments for
chronic pain aim for a 50% reduction in pain scores from base-
line; however, it could be that this is too high and 30% would be
more pragmatic. Farrar et al (Farrar 2000) argue that use of consis-
tent clinically important cut-off points for pain outcomes would
not only enhance validity and comparability, but would also have
more clinical applicability. Other outcome measures looking at
improvements in quality of life, anxiety and depression are imper-
ative, as the negative impact of this condition on mood and on
daily life is potentially high. The development of a core outcome
set as described by COMET (Core Outcome Measures in Effec-
tiveness Trials Initiative; www.comet-initiative.org), may be a way
of facilitating the production of valid and homogeneous outcome
data from BMS clinical trials.
All participants included in a trial should be accounted for in the
analysis of the results, with the analysis undertaken on an inten-
tion-to-treat basis. It should be acknowledged that the conduct and
adequate funding of high-quality RCTs in this field will impact
the volume of research undertaken due to funding agencies’ lim-
ited resources. Larger studies are essential and multicentre studies
may be one way of ensuring that the study power is great enough
to yield statistically significant results.
More detailed reporting of the adverse effects of treatments are
required, as tolerability is an important factor for patients when
making treatment choices (Ioannidis 2004).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alvarenga da Silva 2014
Methods Single centre, placebo-controlled parallel RCT
Participants 38 BMS patients
Group 1 mean age 66.32 SD 12.01, Group 2 mean age 58.42 SD 13.70 years (no overall
age data provided)
Sex: 35 F:3 M (F 92%:M 8%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: topical treatments
Group 1: (n = 19) topical medication comprised of urea 10% to be applied at the oral
cavity 3-4 times per day for 3 months
Group 2: (n = 19) placebo (5% sodium carboxymethylcellulose, 0.15%methyl paraben,
and 10% glycerol in distilled water quantity sufficient to make 100 g) to be applied at
the oral cavity 3-4 times per day for 3 months
Outcomes “EDOF-HC protocol (Orofacial Pain Clinic - Hospital das Clinicas): a standardized
orofacial pain questionnaire to detail the following: 1) chief complaint, 2) general pain
characteristics (location, quality, duration, pain relief, pain triggering), 3) headache and/
or body pain complaints, and 4) patient’s medical history and comorbidities” at baseline
and 3 months
Xerostomia questionnaire at baseline and 3 months
Quantitative sensory testing (QST) at baseline and 3 months
• salivary flow and gustative and olfactory thresholds
• thermal detection thresholds for cold and warm sensations
• mechanical detection thresholds for touch, vibration, and electrical perception
• mechanical pain sensitivity, including superficial and deep pain thresholds
• electrical pain threshold at the teeth
• corneal reflex
Source of funding São Paulo State Research Foundation (FAPESP)
Notes All participants had been treated with 25-50mg of amitriptyline within the last 3months
The duration of pain was significantly longer in the study group (6.97, SD 4.93 years)
compared to 5 placebo group (2.78, SD 2.61 years)
Insufficient results data were provided not sure how well validated all the QST are and
whether there are age/gender related norms
SES: data reported on race, occupation, and marital status:
“Color: study group (n = 19) white 16, black 2, mulatto 1; control group (n = 19) white
16, black 1, mulatto 2; occupation: study group (n = 19) housekeeper 7, retired 6, do-
mestic 2, seamstress 2, biomedical 1, unemployed 1; control group (n = 19) housekeeper
9, retired 5, unemployed 2, nanny 1, secretary 1, seller 1; marital status: study group
(n = 19) married 8, widowed 6, single 4, divorced 1; control group (n = 19) married 8,
widowed 7, single 3, divorced 1”
Conflict of interests: authors reported no conflict of interests exist
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Alvarenga da Silva 2014 (Continued)
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “The subjects were randomly
divided into two groups”
Comment: insufficient information to
make a judgement
Allocation concealment (selection bias) High risk Comment: nothing stated about allocation
concealment
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotation: “double-blind clinical trial”
Comment: no further information, al-
though placebo administered as for inter-
vention
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotation: “double-blind clinical trial”
Comment: no further information, al-
though placebo administered as for inter-
vention
Incomplete outcome data (attrition bias)
All outcomes
High risk Quotation: “Among the 38 patients that
were included in this sample, 25 (65.9%)
returned for the re-evaluation (12 from the
study and 13 from the control group)”
Comment: no further detailswere provided
- inadequate data provided on dropouts
Selective reporting (reporting bias) High risk Comment: no appropriate outcome data
were reported despite being assessed - study
authors only commented on whether there
was any significant differences or not with
P values
Other bias Low risk Comment: no other sources of bias were
identified
Bergdahl 1995a
Methods Single centre, placebo-controlled parallel RCT
Participants 30 BMS patients
Sex: 24 F:6 M (F 80%:M 20%)
24/30 (80%) were women with a mean age of 56 years (range: 40-69) and 6/30 (20%)
were men with a mean age of 46 years (range: 38-57)
Inclusion/exclusion and diagnostic criteria appropriate
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Bergdahl 1995a (Continued)
Interventions Intervention category: psychological therapies
Group 1: (n = 15) “therapy group” (TG) - Phase 1: an introductory session consisting
of a motivational input and an oral examination. The patients were given time to decide
whether or not to participate in the study. Phase 2: evaluation of BMS intensity (pre-
treatment). Phase 3: cognitive therapy (CT) for 12-15 sessions; 1 hour once aweek. Phase
4: evaluation of BMS intensity and oral examination immediately after completed CT
(post-treatment). Phase 5: evaluation of BMS intensity and oral examination 6 months
after completed CT (6-month follow-up). 2 psychologists, dentist estimated outcome
Group 2: (n = 15) “attention/placebo group” (APG) - Phase 1: an introductory session
consisting of a motivational input and an oral examination. The patients were given
time to decide whether or not to participate in the study. Phase 2: evaluation of BMS
intensity (pre-treatment). Phase 3: return visits 3 times during 12-15weeks for evaluation
of BMS intensity and oral examination. Phase 4: evaluation of BMS intensity and oral
examination (post-treatment). Phase 5: evaluationof BMS intensity andoral examination
6 months later (6-month follow-up). 2 psychologists, dentist estimated outcome
Duration: 12 to 15 weeks
Outcomes VAS - graded 1-7, “graded from endurable to unendurable” pre-treatment, post-treat-
ment, 6 months post-treatment - “All the patients evaluated their burning mouth inten-
sity with the same dentist”
Global symptom reduction post-treatment and 6/12 - not prespecified
Source of funding Swedish Dental Society and the Faculty of Odontology, Umeå University, Sweden
Notes Groups comparable at baseline
SES: not reported
Conflict of interests: not reported
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “divided at random into equal
groups”
Comment: no details provided of exactly
how this was conducted
Allocation concealment (selection bias) Unclear risk Comment: no details provided on alloca-
tion concealment
Blinding (performance bias and detection
bias)
Blinding of participants
High risk Quotation: “All the patients evaluated their
burning mouth intensity with the same
dentist”
Comment: the study was unblinded to
the participants.There was no mention of
blinding - given that both arms employed
completely different treatment modalities,
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Bergdahl 1995a (Continued)
it is unlikely that it would be possible to
blind the participants or investigators
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
High risk Quotation: “All the patients evaluated their
burning mouth intensity with the same
dentist”
Comment: the study was unblinded to
the participants.There was no mention of
blinding - given that both arms employed
completely different treatment modalities,
it is unlikely that it would be possible to
blind the participants or investigators
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: it was not stated if all partici-
pants completed the study/no mention of
missing data
Selective reporting (reporting bias) Low risk Comment: the prespecified outcome mea-
sure was reported appropriately
Other bias High risk Commnent: no baseline data presented;
given lack of detail regarding randomisa-
tion process substantial inequalities at base-
line cannot be ruled out
Bogetto 1999
Methods Single centre, placebo-controlled parallel RCT
Participants 121 BMS patients
Sex: 91 F:30 M (F 75%:M 25%)
Mean age 65.4 years (SD 10.6 years)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: antidepressants and antipsychotics + benzodiazepines
Group 1: (n = 24) paroxetine 20 mg/day
Group 2: (n = 23) amitriptyline 25 mg/day
Group 3: (n = 26) clordemetildiazepam 1 mg/day
Group 4: (n = 24) amisulpride 50 mg/day
Group 5: (n = 24) placebo
Duration: 8 weeks
Outcomes Hamilton Anxiety Rating Scale (HARS) (clinician-rated)
Montgomery-Åsberg Depression Rating Scale (MADRS)
Clinical Global Impression I (CGI I) scale (clinician-rated)
Source of funding Not reported
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Bogetto 1999 (Continued)
Notes All participants were given a 2-week washout period from prior medication prior to
being randomised
SES: participants’ average number of schooling years reported (5.7 years (SD 2.3) (min
0 - max 13))
Conflict of interests: not reported
Data analysis: per-protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “...patients were subdivided in
5 groups using a random criteria...”
Comment: themethodused to generate the
randomisation is not reported in the text
Allocation concealment (selection bias) Unclear risk Comment: no details provided on alloca-
tion concealment
Blinding (performance bias and detection
bias)
Blinding of participants
High risk Quotation: “open label”
Comment: open study hence participants
not blinded
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
High risk Quotation: “open label”
Comment: open study hence assessors not
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Group1paroxetine 9/24 (37.5%)dropouts
Group 2 amitriptyline 14/23 (60.8%)
dropouts
Group 3 clordemetildiazepam 11/26 (42.
3%) dropouts
Group 4 amisulpride 1/24 (4.2%) drop-
outs
Group 5 placebo 19/24 (79.2%) dropouts
Explanation provided by study authors -
possible reasons for dropouts: “patients
with BMS tend to change medical doctor
frequently, side effects of drug tested apart
from amisulpride that is characterized by
few side effects”
Comment: insufficient details on why par-
ticipants dropped out - reason for missing
outcome data likely to be related to true
outcome
Selective reporting (reporting bias) Low risk Comment: outcomes reported in prespeci-
fied way
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Other bias High risk Commnent: no baseline data presented;
given lack of detail regarding randomisa-
tion process substantial inequalities at base-
line cannot be ruled out
Cano-Carrillo 2014
Methods Single centre, placebo-controlled parallel RCT
Participants 60 BMS patients
Sex: 48 F:12 M (F 80%:M 20%)
Mean age 63.3, SD 12.9 years
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements
Group 1: (n = 30) extra virgin olive oil (VOO) with lycopene 300 ppm: applied as a
spray to the mouth, to be swallowed afterwards: 1.5 mL 3 times a day for 12 weeks
Group 2: (n = 30) identical placebo formulation: as above - “consisted of a formulation
(water and dye) identical to that of the study product but without the active agents”
Outcomes VAS “pain”: “A visual analogue scale (VAS) was used to evaluate symptoms at the start
of treatment (Day 0) and after 12 weeks of treatment. In this way, the difference between
baseline and endpoint scores numerically expresses any symptomatic improvement (0 =
none and 10 = extreme). The subjects were asked to mark a vertical line through a 10
cm horizontal line to indicate their level of symptoms. The scores for pain were classified
into: slight (≤ 3.3), moderate (3.4-6.6), and severe (≥ 6.7)”
VAS“burning”: “A visual analogue scale (VAS)was used to evaluate symptoms at the start
of treatment (Day 0) and after 12 weeks of treatment. In this way, the difference between
baseline and endpoint scores numerically expresses any symptomatic improvement (0 =
none and 10 = extreme). The subjects were asked to mark a vertical line through a 10
cm horizontal line to indicate their level of symptoms. The scores for pain were classified
into: slight (≤ 3.3), moderate (3.4-6.6), and severe (≥ 6.7)”
General health assessment - 36-Item Short Form Health Survey (SF-36) at baseline - 12
weeks
Oral Health Impact Profile-14 (OHIP-14) at baseline - 12 weeks
The Hospital Anxiety and Depression (HAD) scale at baseline - 12 weeks
“Lipid profile blood test” at 12 weeks
“Patient-rated benefit and satisfaction” - Not stated how this was measured
Source of funding Study authors reported no funding received
Notes Outcome measures and their use were partly very confusing
SF-36 normally compared to norms for age and gender
SES: not reported
Conflict of interests: study authors reported no conflict of interests exist
Data analysis: per-protocol
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Randomization was per-
formed using the website http://random-
ization.com to assign participants to ei-
ther the intervention group or the placebo
group”
Comment: appropriate method
Allocation concealment (selection bias) Low risk Quotation: “A code for randomization was
kept in an opaque envelope in a safe envi-
ronment and was not consulted until the
end of the study”
Comment: appropriate method
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotations: “A randomized, double-blind
and placebo-controlled study design was
adopted”; “Both patients and researchers
were blind to treatment assignment (treat-
ment/placebo)”; “The placebo consisted of
a formulation (water and dye) identical to
that of the study product but without the
active agent”; “The products were coded by
an operator external to the study in identi-
cal opaque containers (without any brand
name)”
Comment: probably achieved
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotations: “In all cases, data were col-
lected by a single researcher blind to the
group to which each patient belonged”;
“Data were analysed by a third party
blinded to the allocation results”
Comment: probably achieved
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quotations: “4/30 patients in the treat-
ment group left the study; 6/30 patients in
the placebo group left the study”; “Patients
were lost from the sample due to lack of
compliance” (both groups)
Comment: dropouts not accounted for in
analysis
Selective reporting (reporting bias) High risk Not all prespecified outcomes reported in
the results (e.g. tolerability, compliance
with treatment)
All reported outcomes not specified in the
methods (e.g. patient-rated benefit and sat-
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isfaction)
Definition of outcome “evolution of pain
symptoms” unclear; numbers of partici-
pants in each of these groups are not given
Other bias High risk The baseline data provided for the arms
are incomplete, however, given appropriate
randomisation method balance/imbalance
less of a concern
Participants occasionally using anxiolytics
to induce sleep were accepted - results as
to the use of anxiolytics within the co-
hort were not given, thus it is not known
whether groups were comparable at base-
line with regards to anxiolytics. There were
also errors noted in the presented outcome
data (tables 3 and 4) - however the cor-
rected data were obtained from the study
authors after contacting them
Carbone 2009
Methods Single centre, placebo-controlled parallel RCT
Participants 66 BMS patients
Sex: 54 F:12 M (F 82%:M 18%)
Of the 52 patients who completed the trial, mean age was reported as 67.3 years (SD
11.9)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements
Group 1: (n = 22) 400 mg alpha lipoic acid (ALA) and vitamins B (1, 2, 6, 12), C,
E, and folic acid (vitamin B9) - 1 pill twice/day by mouth 30 minutes after food for
8 weeks followed by phase II which was a 2-month follow-up period without therapy
(Tiobec, produced by Laborest)
Group 2: (n = 22) 400 mg alpha lipoic acid - 1 pill twice/day by mouth 30 minutes after
food for 8 weeks followed by phase II which was a 2-month follow-up period without
therapy (produced by Laborest as standalone ALA specifically for this trial)
Group 3: (n = 22) placebo pill 1 pill twice/day 30 minutes after food (containing
dicalcium phosphate, microcrystalline cellulose, hydroxipropylmethyl cellulose, silicon
dioxide, vegetal magnesium stearate, shellac and stearic acid) for 8 weeks. Followed by
phase II which was a further 2-month follow-up period without ’therapy’
Outcomes Proportion of participants achieving a 50% improvement in BMS symptoms from
baseline to T3 and T4, measured by the VAS score. Each participant was examined by
the same examiner (blinded to treatment) at the beginning of therapy (T0), 2 weeks
(T1) and 4 weeks (T2) after the start of treatment, at the end of treatment (T3), and
after 2 months of follow-up (T4)
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Quality of pain experienced by participants was also assessed using the McGill Pain
Questionaire. Similarly, each participant was examined by the same examiner (blinded
to treatment) at the beginning of therapy (T0), at 2 weeks (T1) and at 4 weeks (T2)
after the start of treatment, at the end of treatment (T3), and after 2 months of follow-
up (T4)
Source of funding Not reported
Notes The study authors query whether all participants should have been treated with a 7-
day course of antifungal therapy to eradicate subclinical candidosis. Current clinical
practice would consider this unnecessary and irrelevant if the diagnosis is BMS. Is 8
weeks treatment sufficient time to provide a definitive answer?
SES: not reported
Conflict of interests: not reported
Data analysis: per-protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Randomization was per-
formed using computer-generated random
number tables in order to assign patients to
receive one of the three 8-week standard-
ized treatments”
Comment: satisfactory
Allocation concealment (selection bias) Unclear risk Comment: allocation concealment was not
discussed
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotations: “Double blind”; “The medi-
cation (pills) was distributed in identical
containers. During treatment, neither the
physician nor the patients knew which of
the three medications they were using”
Comment: satisfactory
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotation: “Each patient was examined by
the same examiner (blind to treatment)”
Comment: satisfactory - patient-reported
outcomes only
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quotation: “Fourteen patients did not
complete the study andwere excluded from
the efficacy sample. No side effects were
reported as being a reason for withdrawal
from the trial: 10 patients dropped out be-
cause of lack of compliance, and four pa-
tients because of lack of efficacy. No sig-
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nificant difference in the rate of dropout
was observed among the three groups (p =
0.079, v2-test)” Intention-to-treat was also
considered
Comment: reasons for dropouts were de-
scribed overall, but not for each arm. 10
participants “dropped out” due to a “lack
of compliance” - it is unclear exactly what
“lack of compliance” meant and how these
10were spread across each of the study arms
Selective reporting (reporting bias) Unclear risk Comment: full McGill Pain Questionnaire
data not provided but alluded to and par-
tially described
Quotation: “The McGill Pain Question-
naire scores showed some improvements
compared to the baseline measurements
(Friedman test), but significant differences
among the three groups were never ob-
served (Kruskall-Wallis test). In particular,
the affective, and themixed affective/evalu-
ative subscales slightly improved in Group
C (Friedman test: p = 0.004 and 0.022, re-
spectively); conversely, the evaluative sub-
scale improved in all three groups (Fried-
man test: Group A, p = 0.007; Group B, p
= 0.003; Group C, p = 0.046)”
Comment: no baseline characteristic data
were presented (only P values of statistical
tests), full McGill Pain Questionnaire data
not provided (again only P values)
Other bias Low risk Comment: no other obvious risks of bias
Cavalcanti 2009
Methods Single centre, placebo-controlled cross-over RCT
Participants 38 BMS patients
Sex: 34 F:4 M (F 89%:M 11%)
Mean age 63.1 years (range: 36-78)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements
Group 1: (n = 17) 200 mg alpha lipoic acid (ALA) capsules 3 times daily for 30 days. A
20-daywashout period followedbefore participants received placebo (cellulose starch 100
mg), administered in identical capsules 3 times daily for a further 30 days. Participants
who reported any improvement with the proposed treatment were contacted after 60
days to assess maintenance or loss of the results (follow-up)
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Group 2: (n = 14) placebo (cellulose starch 100 mg), administered in identical capsules
3 times daily for 30 days. A 20-day washout period followed before 200 mg of ALA
capsules 3 times daily for a further 30 days. Participants who reported any improvement
with the proposed treatment were contacted after 60 days to assess maintenance or loss
of the results (follow-up)
Outcomes Extent of reduction of symptoms based on VAS: rating of burning was evaluated by
measurements of the VAS, ranging from 0 (no burning) to 100 mm (maximum burning)
, before and after each cycle (i.e. before the beginning of the treatment (baseline T0) and
at follow-up visits: after completing the first cycle of 30 days (T1), at the end of washout
period of 20 days (T2) and at the end of the second cycle of 30 days (T3))
Self-reported description of improvement Global Perceived Effect (GPE). Adapted from
Femiano and colleagues and scored by the participant according to a 5-point scale, rang-
ing from: 1 =worse; 0 = no change; +1 = slight improvement; +2 = decided improvement;
+3 = no burning anymore (resolution) after each cycle
Source of funding São Paulo State Research Foundation (FAPESP)
Notes Participants taking antidepressants, possibly anxiolytics, angiotensin-converting enzyme
inhibitors and hormone replacement therapy were included in the study population -
although they appeared to be distributed evenly across the arms
SES: not reported
Conflict of interests: not reported
Data analysis: per-protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quota-
tion: “appropriate random-number gener-
ator software (available at www.graphpad.
com/quickcalcs/RandMenu.csm)”
Comment: appropriate
Allocation concealment (selection bias) Low risk Quotation: “After determining the eligibil-
ity and obtaining the consent, to guaran-
tee the blinding, the researcher sent the
patient’s study number to the pharmacist,
who then allocated patients”
Comment: participants and investigators
enrolling participants could not foresee
assignment because pharmacy-controlled
central allocation was used to conceal allo-
cation
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotations: “placebo-controlled double-
blind crossover trial”; “Patients started with
200 mg of ALA or placebo (cellulose starch
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100mg), administered in identical capsules
three times daily for 30 days”
Comment: blinding of participants andkey
study personnel ensured, and unlikely that
the blinding could have been broken. Side
effects from ALA may have led to partici-
pants being suspicious that they might be
taking the active treatment - results suggest
no significant difference in reported adverse
events between groups, hence unlikely that
adverse events introduced significant bias
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotations: “placebo-controlled double-
blind crossover trial”; “Patients started with
200 mg of ALA or placebo (cellulose starch
100mg), administered in identical capsules
three times daily for 30 days”
Comment: blinding of key study person-
nel ensured, and unlikely that the blinding
could have been broken
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 38 BMS patients commenced
the trial. 2 appear to have been lost to fol-
low-up and 5 discontinued the interven-
tions. 4 of them did not complete the pro-
posed treatment because of the symptoms
that they felt were due to treatment (these
adverse effects were listed). 4 participants
were excluded from the analysis. Propor-
tions appear similar across the 2 groups
Data from flow diagram (stating 2 par-
ticipants in each arm were excluded from
the analysis) did not match details in text
(which stated 7 patients had their data ex-
cluded from analysis)
Selective reporting (reporting bias) Low risk Comment: standard deviations not re-
ported; data by treatment cycle obtained
from study authors
Other bias Unclear risk Comment: errors in reporting within paper
(flowdiagram, and n values), although clar-
ified by authors in correspondence; data re-
ceived from study authors revealed a base-
line imbalance in relation to theVAS scores
between the 2 study arms however ran-
domisation process conducted appropri-
ately
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Femiano 2000
Methods Single centre, placebo-controlled parallel RCT
Participants 42 BMS patients
Median age 63 years (range 43 to 78)
Sex: 32 F:10 M (F 76%:M 14%)
20 had removable prostheses
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements
Group 1: (n = 21) alpha lipoic acid and vitamins B (1, 2, 6, 12), C, E, and folic acid
(vitamin B9) 600 mg/day for 20 days, followed by 200 mg/day for 10 days (Tiobec,
produced by Laborest)
Group 2: (n = 21) placebo cellulose starch 100 mg/day for 30 days
Duration: 30 days
As a second stage study, the original controls were then treated with the active regimen
for 30 days
Outcomes “All patients were reviewed at 15-day intervals”; bespoke BMS symptomology change
scale: “change in symptomatology scored asWorsening - Unchanged +/- Slight improve-
ment + Decided improvement + + Resolution + + +” - unclear as to exactly how these
data were recorded and by whom
Source of funding Not reported
Notes Unvalidated outcome measure used
Comparability of groups at baseline is unclear
SES: not reported
Conflict of interests: not reported
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “randomly divided into two
groups (Test and Control) each of 21 sub-
jects, matched for age and sex”
Comment: unclear as to how the randomi-
sation was conducted and what was meant
by “matched”
Allocation concealment (selection bias) High risk Comment: allocation concealment was not
discussed
Blinding (performance bias and detection
bias)
Blinding of participants
High risk Quotation: “open controlled clinical
study”
Comment: described as an open-label
study hence non-blinded
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Blinding (performance bias and detection
bias)
Blinding of outcome assessors
High risk Quotation: “open controlled clinical
study”
Comment: described as an open-label
study hence non-blinded - how reported
outcome was recorded (i.e. self-reported by
patient or by clinician) is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no dropouts or missing data re-
ported
Selective reporting (reporting bias) Low risk Comment: all outcomes were reported in
the prespecified format
Other bias High risk Commnent: no baseline data presented;
given lack of detail regarding randomisa-
tion process substantial inequalities at base-
line cannot be ruled out
Femiano 2002a
Methods Placebo-controlled parallel RCT (unclear where study was conducted or whether single
or multicentre)
Participants 60 BMS patients
Median age 45 years (range 22 to 68)
Sex: 42 F:18 M (F 70%:M 30%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements
Group 1: (n = 30) alpha lipoic acid and vitamins B (1, 2, 6, 12), C, E, and folic
acid (vitamin B9) in 200 mg oral pills, 3 times a day for 8 weeks (Tiobec, produced by
Laborest)
Group 2: (n = 30 ) placebo cellulose starch 100 mg/day, 3 times a day
Duration: 2 months (note: those showing improvement in symptoms at 2 months given
a further month of treatment and followed for 1 year)
Outcomes Bespoke BMS symptomology change scale - change in symptomatology scored as:
Worsening - Unchanged +- Slight improvement + Decided improvement ++ Resolution
+++
“Results at 1 year follow-up for changes in burning symptomatology in all subjects who
showed an improvement at 2 months, as shown in Table 2, using alpha lipoic acid (test)
or placebo control (starch)” - categories = No change, Slight deterioration, Significant
deterioration
Source of funding Not reported
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Notes Outcome measures were confusing and unvalidated
Comparability of groups at baseline unclear
It is unclear whether other ALA studies published by this study author around the same
time used the same participants or not
SES: not reported
Conflict of interests: not reported
Data analysis: per-protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “divided at random for two
groups of patients”
Comment: no detail provided about how
randomisation was conducted
Allocation concealment (selection bias) Unclear risk Comment: nothing stated about allocation
concealment
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotation: “using lipoic acid as test, and
cellulose starch as control, where neither
the patient nor doctor could distinguish the
substance used”
Comment: appropriate placebo control
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotation: “The patients were clinically
assessed every 15 days, and symptoma-
tology was recorded”...“neither the patient
nor doctor could distinguish the substance
used”
Comment: blinded outcome assessment,
although how reported outcomes were
recorded (i.e. self-reported by patient or by
clinician) is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: according to the results pre-
sented, no dropouts occurred
Selective reporting (reporting bias) High risk Quotation: “patients were clinically as-
sessed every 15 days, and symptomatology
was recorded”
Comment: the above was prespecified but
no data were provided in results
Quotation: “without notable adverse ef-
fects”
Comment: no prespecified method of as-
sessing adverse effects was provided and
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above comment suggests some adverse ef-
fects were reported, but no data provided
in results
Quotation: “The studywas concludedwith
a re-evaluation of the results 1 year after
commencement of the trial”
Comment: the study only analysed results
for the participants who “showed an im-
provement at 2 months”, despite the meth-
ods section suggesting “Patients that re-
ported any amelioration within 4 months
(12 of Control group and 29 of Test group)
were given further therapy for 1 month,
with a protocol identical to that used pre-
viously”. Therefore the methods and re-
sults do not correlate with each other. One
should expect that all participants should
be followed up at 1 year, not only the re-
sponders
Other bias High risk Commnent: no baseline data presented;
given lack of detail regarding randomisa-
tion process substantial inequalities at base-
line cannot be ruled out
Femiano 2002b
Methods Single centre, placebo-controlled parallel RCT
Participants 80 BMS patients
Median age 63 years (range 30 to 74)
Sex: 48 F:32 M (F 60%:M 40%)
Interventions Intervention category: dietary supplements + topical treatments + cholinergics
Group 1: (n = 20) bethanechol (urecholine) 5 mg oral dose every 8 hours betweenmeals
Group 2: (n = 20) lactoperoxidase oral solution (Biotene oral rinse) topically 5-6 times
daily
Group 3: (n = 20) alpha lipoic acid and vitamins B (1, 2, 6, 12), C, E, and folic acid
(vitamin B9) in 200 mg oral pills, 3 times a day (every 8 hours) for 60 days (Tiobec,
produced by Laborest)
Group 4: (n = 20)placebo - xylitol 3% in distilled water (no further details provided)
Study conducted over 60 days
Outcomes Bespoke BMS symptomology change scale scored as: Worsening, Unchanged, Slight
improvement, Decided improvement, Resolution - unclear as to how this was assessed
Weekly “assessments” performed - further details not provided. Unclear whether symp-
tomatology or side effects were assessed at every visit
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Source of funding Not reported
Notes 16/80 participants reported to have “used anxiolytic drugs to control the BMS” - these
were allocated equally amongst the study arms
2 participants were reported in results section to be ongoing with anxiolytics during trial
Unusually high number of male participants included within the study cohort
It is unclear whether other ALA studies published by the author around the same time
used the same participants or not
SES: not reported
Conflict of interests: not reported
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotations: “This BMS cohort was
then randomly divided into 4 groups”;
“matched for age and sex”
Comment: no detail provided about how
randomisation was conducted
Allocation concealment (selection bias) High risk Comment: no detail given regarding allo-
cation concealment
Blinding (performance bias and detection
bias)
Blinding of participants
High risk Quotation: “This open controlled study of
α-lipoic acid”
Comment: the study is described as open-
label
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
High risk Quotation: “This open controlled study of
α-lipoic acid”
Comment: the study is described as open-
label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotation: nodropouts reported.Nomiss-
ing data reported
Selective reporting (reporting bias) High risk Comment: no data provided for BMS
symptoms during trial (e.g. at week 4) only
after trial completion scores were given.
“All patients reported increased salivation”
was reported in Group 1 - but this was not
a prespecified outcome
Other bias High risk Commnent: no baseline data presented;
given lack of detail regarding randomisa-
tion process substantial inequalities at base-
line cannot be ruled out
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Grémeau-Richard 2004
Methods Multicentre (6 centres), placebo-controlled parallel RCT (open-label study continued
for 6 months following initial 14-day study - data not included in this analysis)
Participants 48 patients with “stomatodynia” (“isolated complaint of chronic pain in the oral mucosa
with normal clinical examination, with duration of pain greater than 4 months”)
Mean age 65 years SD 2.1
Sex: 44 F:4 M (F 92%:M 8%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: benzodiazepines
Group 1: (n = 24) clonazepam tablet 1 mg to be sucked without swallowing for 3
minutes, 3 times a day (after each meal) for 2 weeks
Group 2: (n = 24) placebo tablet to be sucked without swallowing for 3 minutes, 3 times
a day (after each meal) for 2 weeks
Duration: 2 weeks intervention, 6-month open follow-up
Outcomes Numerical Pain Scale (0-10): “The primary criterion used to evaluate drug efficacy was
the difference in pain intensity score observed for each subject before and after 14 days
of treatment (NS 0 - NS 2)” - mean pain intensity (0 “no pain” to 10 “maximal pain
imaginable”)
“As a secondary outcome criterion, the immediate effects of clonazepam were evaluated
by comparing, between the active treatment and control groups, the average of the
differences (NS 0 - NS 1) in pain intensity score before and 5 min after topical 5
application”
Compliance and adverse events were also recorded
Source of funding “The authors thank Laboratoire Roche for clonazepam and placebo tablets, C Cadène
and the association ’Langue de feu’ for their help, and the TeachingHospital of Clermont-
Ferrand for financial and administrative support”
Notes Groups comparable at baseline - baseline anxiety or depression status were not known
The active treatment was continued for all participants for 6 months after the initial trial
finished. It would have been interesting to note if there were any adverse events upon
withdrawal of the active treatment
SES: not reported
Conflict of interests: not reported
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Randomisation was per-
formed in blocks of eight by the hospital
pharmacy”
Comment: third party randomisation
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Allocation concealment (selection bias) Low risk Quotations: “Randomisation was per-
formed in blocks of eight by the hospital
pharmacy”; “Experimentors were blinded
to patient allocation”
Comment: appropriate method
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotations: “Experimentors were blinded
to patient allocation”; “All the tablets
looked identical”
Comment: side effects could potentially
unblind participants, however, no signifi-
cant difference in side effects reported be-
tween 2 arms. Unblinding mentioned: “Af-
ter unblinding, five patients identified as
clonazepam receivers .... ”- however, this
was after the initial trial period of 14 days
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotations: “Experimentors were blinded
to patient allocation”; “All the tablets
looked identical”
Comment: patient-reported outcomes
only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotations: “At fourteen days: Two Group
A patients discontinued intervention be-
cause of side effects. One group B patient
discontinued intervention because of side
effects”. ITT analysis performed - assump-
tion “that the three patients who did not
complete the study were not modified by
the treatment”. The pain intensity outcome
at 5 minutes only reported on active arm
“n = 22” and placebo arm “n = 23” i.e. sug-
gesting that the 3 dropouts occurred within
the first 5 minutes of the study. No ITT
analysis was provided for the 5 minute out-
come. Unclear if this was a simple error in
notation or otherwise
Comment: no real imbalance in dropouts
and number of them unlikely to influence
result
Selective reporting (reporting bias) Low risk Comment: all outcomes reported in pre-
specified way
Other bias Unclear risk Comment: baseline anxiety levels were not
assessed -hence the spread of baseline anxi-
ety between the study arms was not known.
Bearing inmind that clonazepam is an anx-
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iolytic drug which was noted to have a sys-
temic uptake within the participants, the
presence of baseline anxiety is a potential
confounder and should have been taken
into account (potential omitted variable
bias)
Heckmann 2012
Methods Single centre, placebo-controlled parallel RCT
Participants 20 BMS patients
Overall ages not presented - Group 1 (clonazepam): from text - mean 67.5 (range 49-
89) / from table - mean 65.0 SD: 12.4. Group 2 (placebo): from text - mean 65.4 (49-
78) / from table - mean 62.9 SD: 8.7
Sex: 13 F:7 M (F 65%:M 35%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: benzodiazepines
Group 1: (n = 10) clonazepam 0.5 mg capsules - 1 daily
Group 2: (n = 10) placebo capsules - 1 daily
Duration: 9 weeks
“As the intake of clonazepam can cause dependency, the medication was tapered off at
the end of study in those subjects who had received verum. They took drops (0.1 mg
clonazepam per drop) for a period of 10 days starting with five drops; this dose was
reduced by one drop every 2 days”
Outcomes Beck Depression Inventory (BDI) - 2 weeks before treatment, beginning of treatment,
3 weeks after starting treatment, at end of treatment and 2 weeks after end of treatment
Zerssen Mood Scale - 2 weeks before treatment, beginning of treatment, 3 weeks after
starting treatment, at end of treatment and 2 weeks after end of treatment
Taste test score (0-16): “Taste test. For quantitative assessment of gustatory function,
a standardized validated test based on filter papers impregnated with tastants was used.
Strips with the basic tastes sweet, sour, salty, and bitter (in four concentrations each) were
applied onto the extended tongue, which was then taken back into the closed mouth.
Before application of each taste strip, patients rinsed their mouths with water. Following
presentation of the strip, patients were asked to identify the taste from a list of four
descriptors (sweet, sour, salty, and bitter). The sum of correct identifications was used for
further statistical analysis” - performed 2 weeks before treatment and at end of treatment
and 2 weeks after end of treatment (methods fully detailed in Mueller 2003: scale 0-16
(each taste component 0-4), higher better)
Smell test score: “Smell test. The odour identification part of the Sniffin’- Sticks test
battery were used to screen for changes in olfactory function. Following presentation of
a common odour, subjects were each asked to identify it from a list of descriptors. The
sum of correct identifications was used for further analysis” - performed 2 weeks before
treatment and at end of treatment and 2 weeks after end of treatment
“Salivary flow rate. The salivary flow rate was measured using a cotton swab. It was
weighed and placed onto the patient’s tongue for 1 minute. After that, the cotton swab
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was weighed again and the resulting difference was used to calculate salivary flow rate”
- performed 2 weeks before treatment and at end of treatment and 2 weeks after end of
treatment (methods fully detailed in Navazesh 1982: weight scale, higher better. Swab
method is 1 of 4 methods (draining, spitting, suction, swab) compared to calculate
salivary flow. (Note Navazesh 1982 authors state swab method is least reliable and most
variable of the 4 options)
Numerical pain ratings scale (0-10): “Pain ratings. Patients rated the sensation of
burning pain in the mouth on a scale ranging between 0 and 10, with 0 indicating no
pain and 10 indicating maximum possible pain” - performed 2 weeks before treatment
and at end of treatment and 2 weeks after end of treatment
Source of funding Study authors reported no funding was received
Notes SES: not reported
Conflict of interests: authors reported no conflict of interests exist
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotations: “performed by an indepen-
dent individual using a specialized software
program (RANDLIST; DatInf, Tübingen,
Germany)”; “enrolment numbers were es-
tablished, and the subjects to be investi-
gated were randomized in such a way as to
form five groups made up of four partic-
ipants each (i.e., two were assigned clon-
azepam and two were assigned a placebo)”
Comment: appropriate method
Allocation concealment (selection bias) Low risk Comment: randomisation and blinding
was conducted by an independent person
Blinding (performance bias and detection
bias)
Blinding of participants
Unclear risk Quotations: “The bottles were sealed and
labelled with the study code and the enrol-
ment number”; “When the study was com-
plete, unblinding was carried out by an in-
dependent individual”
Comment: it is unclear to the review au-
thors at what point was the “study com-
plete”; was it at the end of treatment or at
the final session 5 visit? According to the
data provided, the participants were un-
blinded for the outcomes taken during the
final (session 5)
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Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Unclear risk Quotation: “When the studywas complete,
unblinding was carried out by an indepen-
dent individual”
Comment: according to above comment,
the investigators were still blinded at the
session 5 assessment point. Again there was
uncertainty about when exactly study com-
pletion occurred
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all prespecified outcomes were
reported in the prespecified way
Selective reporting (reporting bias) High risk Comment: side effects were not mentioned
as a prespecified outcome and were not ad-
equately reported in the outcomes (“The
drugs were tolerated very well by all par-
ticipants”; “does not cause major side ef-
fects”). This comment would suggest that
some side effects were noted, but not for-
mally reported. One would expect side ef-
fects from clonazepam and should be able
to expect that side effects would be more
thoroughly reported, as side effects may
have unblinded participants
Other bias Unclear risk Comment: discrepancy between baseline
ages of participants when comparing text
and table data
Lopez-D’alessandro 2011
Methods Single centre, placebo-controlled parallel RCT
Participants 120 BMS patients
Mean age 14.1 SD 57.5 years, median: 57
Sex: 94 F:26 M (F 78%:M 22%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: anticonvulsants + dietary supplements
Group 1: (n = 20) 600 mg daily alpha lipoic acid - for 2 months (Ciagen 600, produced
by Craveri). Supplement includes excipients (sodium lauryl sulfate 30.00 mg; 329.50 mg
lactose monohydrate; cornstarch 115.50 mg; croscarmellose sodium ( AC-DI-SOL) 72.
00 mg; colloidal silicon dioxide (Aerosil 200) 5.50 mg; 35.00 mg magnesium stearate;
povidone K-30 12.50 mg; methocel E15 25.08 mg; 10.05 mg lactose monohydrate; 0.
39 mg titanium dioxide; polyethylene glycol 6000 0.78 mg; yellow iron oxide 3.68 mg)
Group 2: (n = 20) 300 mg daily gabapentin (GABA)
Group 3: (n = 20) 600 mg daily alpha lipoic acid (ALA) + 300 mg daily gabapentin
(GABA)
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Group 4: (n = 60) 100 mg daily starch and cellulose placebo
Outcomes Number of sites affected - “evaluated the presence of burning through a numerical scale
especially created for this work, describing the burning from 0 to 4, where the 0 value
corresponded to the absence of burning, the 1 value to the presence of burning in a single
area of the tongue, the 2 value to two distinctive areas (tongue and gums, tongue and
lips or tongue and palate), the 3 value to three areas and the 4 value corresponded to
burning spread throughout the mouth. This specific designed scale, which considered
the geographical distribution of burning in different areas of the mouth, allowed us to
distinguish improvements or deteriorations of burning sensation in the various assess-
ments”
“Evaluation of the effects… the day before the start of treatment and thirty and sixty
days, respectively. To evaluate the changes that occurred with the taking of the different
drugs, it was established that the improvements (positive changes) involved the passage
of a certain level or numerical category of burning to a lower one, the deteriorations
(negative changes) involved an increase of a certain level of burning to a higher one and
the total resolution indicated the total absence of burning, that is to say the transition
from any higher value to zero value. In this way four categories were obtained for the
analysis of the 5 results: Category 1: with negative changes (deterioration), Category 2:
no changes; Category 3: with positive changes (improvements) and Category 4: with
total recovery”
Change in quality of life (QoL) was assessed at baseline only (consequently unable to
assess change) by use of 2 surrogate (measuring anxiety and depression) scales: - anxiety:
Hamilton Anxiety Rating Scale (HARS) - baseline only; and - anxiety/depression: Hos-
pital Anxiety and Depression (HAD) scale - baseline only
Source of funding Not reported
Notes The dosage of gabapentin given is not therapeutic as an anticonvulsant
Outcome evaluation was based on the numerical scale which was based on the number
of sites affected. Thus only 1 (not validated) outcome measure was used in the study
SES: not reported
Conflict of interests: not reported
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “The 120 patients were ran-
domly divided into 6 groups of 20 mem-
bers each”
Comment: unclear as to how the randomi-
sation was conducted
Allocation concealment (selection bias) Low risk Quotations: “The support staff of our ser-
vice made a draw with 6 balls to link the
groups with the cycles of treatment”; “allo-
cation that was always masked to both pa-
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tients and researcher”
Comment: assumption that “support staff ”
were independent to investigators - seems
unlikely that allocation concealmentwould
be compromised
Blinding (performance bias and detection
bias)
Blinding of participants
High risk Quotation: “through the use of capsules of
similar size and appearance so that just the
support staff was the one who recorded the
information until the end of the treatment
(blind)”
Comment: “similar size and appearance” -
unlikely that formulations were identical,
as weights were different and they may not
look the same. Unclear how preparations
were provided to participants and in what
packaging. Placebo only group involved 1
tablet while group 3 had 2 tablets to take
- hence unblinding group 3 that they were
on the combined treatment arm
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Comment: patient-reported outcomes
only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no dropouts were reported
Selective reporting (reporting bias) High risk Quotation: “adverse effects that appeared
were very mild”
Comment: clarification sought from con-
tact author who provided adverse effect
data. No baseline characteristics were pre-
sented for each arm of the study. Baseline
anxiety and depressionwas presented for all
participants but not for each arm.Outcome
data were not presented in the prespecified
way - graphs were presented which were
difficult to interpret as the actual data val-
ues were not presented. The study authors
combined “positive changes” with “full re-
covery” data for the active arms and “no
change” with “worsened” data with the
placebo - these outcomes should have been
presented separately as combining them is
very misleading. No useable data were pre-
sented for month 1, only month 2. Clar-
ification sought from contact author who
provided missing data from month 1
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Other bias Low risk Comment: possible selection bias caused
by exclusion criteria - “patients using more
than 3 systemically daily drugs, those ones
taking psychotropic and antihypertensives
drugs aswell as patientswith serious psychi-
atric conditions previously diagnosed were
excluded”
López-Jornet 2009b
Methods Single centre, placebo-controlled parallel RCT
Participants 60 BMS patients
Mean age 64.37 SD 11.61 years
Sex: 54 F:6 M (F 90%:M 10%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements
Group 1: (n = 23) 800 mg in oral pills per day for 8 weeks: each containing alpha
lipoic acid (0.05 mg) + adjunctive lycopene (100 mg)+ green tea extract (40%, 50
mg) (Thioderm, produced by Sesderma)
Group 2: (n = 16) placebo - cellulose tablets of the same appearance, shape, texture and
colour as the treatment for 8 weeks
Outcomes Pain intensity as recorded on a 10 cm VAS. The scores for pain were classified into: slight
(≤ 3.3), moderate (3.4-6.6) and severe (≥ 6.7). Pain scores were recorded before treat-
ment (day 0) and at 1 and 2 months (only participants completing treatment protocol
for the 2 months were included i.e. n = 39)
Source of funding Not reported
Notes SES: not reported
Conflict of interests: not reported
Data analysis: per-protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Having met the eligibility cri-
teria, participants were randomly divided
into two groups according to a list made by
simple randomization block design, gener-
ated using a randomization table. A simple
block randomization list with a block size
of four was prepared by a teammember not
involved in the recruitment and follow-up
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of the patients”
Comment: satisfactory
Allocation concealment (selection bias) Low risk Quotation: “Randomization allocation
concealment was performed by sending
the randomization numbers in sealed en-
velopes to the investigator responsible for
giving the assigned treatment after each el-
igible patient was enrolled”
Comment: satisfactory
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotations: “double blind”; “as placebo,
cellulose tablets of the same appearance
shape, texture and colour as the treatment”
[were used]
Comment: satisfactory
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotations: “double blind”; “as placebo,
cellulose tablets of the same appearance
shape, texture and colour as the treatment”
Comment: satisfactory; patient-reported
outcomes only
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: 7/30missing from intervention
group (1 due to gastrointestinal side effects,
other 6 reasons not given); 14/30 missing
from control group (authors suggest that
withdrawal may have been due to lack of
efficacy of placebo)
Proportions of dropouts different across 2
groups
Selective reporting (reporting bias) Low risk Comment: all prespecified outcomes were
reported appropriately
Other bias Low risk Comment: baseline inequalities in gender
and age are present, however randomisa-
tion appropriate
López-Jornet 2011
Methods Single centre, placebo-controlled parallel RCT
Participants 50 BMS patients
Mean age 61.18, SD 12.27 (range 37-84)
Sex: 46 F:4 M (F 92%:M 8%)
Inclusion and diagnostic criteria appropriate - exclusion of all “patients with known
neurological disorders and those previously treated, even irregularly, with antidepressants,
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anticonvulsants, other psychotropic drugs, or psychological therapy” represents exclusion
of a significant proportion of the BMS population, hence reducing applicability to all
BMS patients (i.e. possible reduced external validity)
Interventions Intervention category: physical barriers
Group 1: (n = 25) control - “Patients were informed in detail about their illness, and
were instructed not to rub their tongue against their teeth and/or dentures. A self-control
technique was used to this effect, the patients being given 10 printed habit-modifying
reminder points to be placed in visible place”
Group 2: (n = 25) tongue protector - same as group 1 with tongue protector: “The
protector consisted of a transparent, low-density polyethylene sheath covering the tongue
from 4 the tip to the posterior third. These tongue protectors were single-use devices
measuring 0.1 mm in thickness, with a standard size (67 mm in length and 66 mm
wide), and were custom manufactured by our group. Each patient received a kit with
the protectors and the reminder points for treatment”; “Instructions were provided on
their use - the protector being worn during the daytime for period of 2 months. We
recommended use of the protector 15 min/three times a day”
Duration of intervention: 2 months
Outcomes Oral symptoms VAS (0: no pain, 10: most severe pain experienced): “Patients were asked
to indicate the mean pain intensity for the 2 weeks preceding the consultation. The
difference between baseline and the endpoint scores numerically expressed symptoms
variation” - measured at baseline and 2 months
Hospital Anxiety and Depression scale (HAD) - measured at baseline and 2 months
Oral Health Impact Profile-49 (OHIP-49) - measured at baseline and 2 months
36-Item Short Form Health Survey (SF-36) - measured at baseline and 2 months
Source of funding Not reported
Notes The biological plausibility of the active treatment is not clear
SES: not reported
Conflict of interests: not reported
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “…were randomly allocated to
one of the two arms of the study. The ran-
dom allocation sequence was generated us-
ing software available online at…”
Comment: appropriate method
Allocation concealment (selection bias) Unclear risk Comment: nothing stated about allocation
concealment
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Blinding (performance bias and detection
bias)
Blinding of participants
High risk Comment: nothing stated about blinding
of participants or study personnel. The
treatment modalities differed vastly from
each other, hence unblinding participants
and the investigator
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
High risk Comment: nothing stated about blinding
of participants or study personnel. The
treatment modalities differed vastly from
each other, hence unblinding participants
and the investigator
Incomplete outcome data (attrition bias)
All outcomes
Low risk Commnent: no missing outcome data
Selective reporting (reporting bias) Low risk Comment: all prespecified outcomes were
reported in the prespecified way
Other bias Unclear risk Quotation: “Patients occasionally using
anxiolytics to induce sleep were accepted”
Comment: no data provided on baseline
use of anxiolytics between groups - prespec-
ified as inclusion criteria but not reported
upon. Important data as could induce base-
line inequality or act as confounder
Marino 2010
Methods Single centre, placebo-controlled parallel RCT
Participants 56 BMS patients
Mean age 62 years (SD 9.8)
Sex: 46 F:10 M (F 82%:M 18%)
Inclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements + topical treatments
Group 1: (n = 14) thrice daily oral rinses with capsaicin, 250 mg of red pepper emulsion
in 50 ml of water for 8 weeks followed by 8-week post-treatment observation
Group 2: (n = 14) alpha lipoic acid and vitamins B (1, 2, 6, 12), C, E, and folic acid
(vitamin B9) in 400 mg oral pills, twice a day for 60 days (Tiobec, produced by Laborest)
Group 3: (n = 14) lysozyme lactoperoxidase oral rinse (Biotene; GlaxoSmithKline
Consumer Healthcare; GlaxoSmithKline S.P.A., Verona, Italy), 5 times a day for 8 weeks
followed by 8-week post-treatment observation
Group 4: (n = 14) 0.05 g of boric acid dissolved in 100 ml of distilled water (placebo),
thrice a day for mouthwash for 8 weeks followed by 8-week post-treatment observation
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Outcomes Severity of burning mouth sensation was assessed at the beginning and at the end of both
the studies by means of a subjective VAS ranging from 0 (no burning mouth sensation)
to 10 (severe burning mouth sensation)
Source of funding Not reported
Notes Tiobec contains vitamin C, B1, 2, 6, 12, PP, folic acid, E (this is not mentioned in the
paper)
No side effects reported - unexpected given the nature of capsaicin
SES: not reported
Conflict of interests: study authors report no conflict of interests exist
Data analysis: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Patients were single-blindly
randomised by means of computer-gener-
ated random number”
Comment: probably undertaken
Allocation concealment (selection bias) High risk Quotation: “Patients were single-blindly
randomised by means of computer-gener-
ated random number tables”
Comment: study is single-blind hence al-
location was not concealed to investi-
gators. Participants and investigators en-
rolling participants appear not to have been
able to foresee assignment
Blinding (performance bias and detection
bias)
Blinding of participants
Unclear risk Comment: no blinding attempted or possi-
ble - mouthwashes (capsaicin) and Biotene
gel are being compared against a systemic
option (ALA)
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Comment: patient-reported outcomes
only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: dropouts were fully reported -
they only occurred after phase 1 (active
treatment) was completed. Although attri-
tion rate was high, missing outcome data
balanced in numbers across intervention
groups, with similar reasons for missing
data across groups
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Selective reporting (reporting bias) Low risk Comment: prespecified outcomes were re-
ported appropriately
Other bias High risk Commnent: no baseline data presented;
given lack of detail regarding randomisa-
tion process substantial inequalities at base-
line cannot be ruled out
Palacios-Sánchez 2015
Methods Single centre, parallel-arm, placebo-controlled RCT
Participants 60 BMS patients
Mean age: 62.13 years (range 36-86)
Sex: 55 F:5 M (F 92%:M 8%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements
Group 1: (n = 30) 600 mg (3 x 200 mg every 8 hours) in oral pills per day for 8 weeks:
each containing alpha lipoic acid (0.05 mg) + adjunctive lycopene (100 mg)+ green
tea extract (40%, 50 mg) (Thioderm, produced by Sesderma)
Group 2: (n = 30) placebo - similar looking cellulose tablets to group 1 intervention,
for 8 weeks (provided by ALA manufacturer)
Outcomes Symptom relief, surrogately measured by VAS (scale 0-10, but expressed dichotomously
in reporting) to measure change in symptoms, at baseline, 1 month and 2 months
Depression by Beck Depression Inventory (BDI), at baseline (unknown if recorded
latterly)
Source of funding Not reported, although all treatment (intervention and placebo) provided by Sesderma
Laboratories
Notes Adverse effects not reported despite stating a priori that their occurrence would be
recorded
Baseline mean symptom intensity presented for all participants, rather than each group
separately. May be baseline imbalance
Depression reported by 54% of participants (32/59)
Use of medication: antidepressants/anxiolytics 53%; antihypertensives 25%; thyroid
treatment 12%; other medication 43%
SES: not reported
Conflict of interests: study authors report no conflict of interests exist
Data analysis: per-protocol
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly allocated
to one of the two different sequence
groups”
Comment: no detail provided about se-
quence generation method used
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Comment: described as a “double-blind
placebo-controlled study”, but no fur-
ther detail provided. Provision of identical
placebo treatment by manufacturer would
have allowed blinding of participants and
outcome assessors, but not confirmed in
text
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Comment: described as a “double-blind
placebo-controlled study”, but no fur-
ther detail provided. Provision of identical
placebo treatment by manufacturer would
have allowed blinding of participants and
outcome assessors, but not confirmed in
text
Incomplete outcome data (attrition bias)
All outcomes
High risk 54 patients (90%) complete trial (Group 1
n = 25; Group 2 n = 29); however, rationale
for losses not reported
Selective reporting (reporting bias) High risk Comment: secondary outcomes (depres-
sion and adverse effects) not reported after
receipt of treatment:
depression reported at baseline, but un-
known if recorded latterly, as appears to
only have been used as a covariate within
the authors’ logistic regression analyses
Adverse effects not reported despite stat-
ing a priori that their occurrence would be
recorded
Other bias High risk Comment: no baseline data presented;
given lack of detail regarding randomisa-
tion process substantial inequalities at base-
line cannot be ruled out
Wide use of medication by participants,
and over half reporting depression
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Methods Single centre, placebo-controlled parallel RCT
Participants 66 BMS patients
Mean age 64.9 years (range 48-85)
Sex: 64 F:2 M (F 97%:M 3%)
Inclusion and diagnostic criteria appropriate
Baseline characteristics for each group provided in graphs and table were difficult to
interpret - no obvious differences between groups at baseline
Interventions Intervention category: benzodiazepines
Group 1: (n = 33) topical clonazepam - “Each patient was given a sealed envelope
containing 32 tablets of 0.5 mg of clonazepam. They were instructed to take a single
tablet at the first sign of discomfort in the morning. The tablet should be dissolved in the
mouth for three minutes, and then the remaining saliva should be spat out. The patient
should then note his or her sensations and the evolution of the symptoms. If there was
improvement, the procedure was to be repeated when the symptoms reappeared. Patients
were advised not to exceed four tablets a day (that is, a total dose of 2 mg of clonazepam)
”
Group 2: (n = 33) placebo - “lactose tablets, of the same shape and size as those given
to Group A. Their instructions were the same as those given to Group A”
The amount of tablets used varied between participants
Outcomes VAS from 0 to 10 (no scale descriptors provided) - baseline, 1 month, 6 months
Source of funding Not reported
Notes No email correspondence details provided - therefore, we could not contact authors to
determine VAS descriptors
SES: not reported
Conflict of interests: not reported
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “table of random numbers was
used in order to ensure the randomization
of the treatments”
Comment: appropriate method
Allocation concealment (selection bias) Unclear risk Comment: nothing stated about allocation
concealment
Blinding (performance bias and detection
bias)
Blinding of participants
Unclear risk Quotations: “double blind study”; “Each
patientwas given a sealed envelope contain-
ing 32 tablets of 0.5 mg of clonazepam”;
“Group B: 33 patients, placebo group.
They were given 32 lactose tablets, of the
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same shape and size as those given toGroup
A”
Comment: from information provided,
blinding method appears appropriate - ad-
verse effects (only reported in active arm -
“sleepiness in 5 patients of the clonazepam
group, which did not require the clinicians
to suspend the treatment”) and some par-
ticipants in active arm reported sensation
of effervescent and numbness for up to 3
hours - possible unblinding of participants
due to side effects of clonazepam
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotations: “double blind study”; “Each
patientwas given a sealed envelope contain-
ing 32 tablets of 0.5 mg of clonazepam”;
“Group B: 33 patients, placebo group.
They were given 32 lactose tablets, of the
same shape and size as those given toGroup
A”
Comment: blinded outcome assessment;
patient-reported outcomes only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no dropouts or missing data re-
ported - over a 6-month study period one
would expect some to drop out
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the prespecified way
Other bias High risk Quotations: “Three clinicians, with ex-
tensive experience in oral medicine, ex-
amined the patients”; “They were again
scheduled for visits after 1 month and 6
months, which allowed the clinicians to
monitor their evolution”; “Both groups
of patients showed improvement, which
was partially due to the psychotherapy.
The management of patients with BMS
should be focused on two aspects. On one
hand, clinicians could treat the symptoms;
on the other hand, they could use basic
psychotherapy customized to each person,
which can be carried out in our dental of-
fice. The aforementioned psychotherapy is
focused on listening to the patient, empha-
sizing affectivity, security and tranquility,
and transmitting the feeling that we know
exactly what the patient is going through
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as well as the difficulties we face in giving
him/her solutions to his/her problems.Our
personal experience has shown us that, if
we manage to calm the patient with our at-
titude, the possibility of improvement in-
creases; this is particularly true in patients
who are relatively stable from an emotional
point of view”
Comment: the above statements suggest
that there was additional treatment in the
form of psychological intervention for each
participant, undertaken by 3 different clin-
icians. No mention of standardisation of
consultations or calibration of clinicians,
hence possible confounding factor in terms
of “psychotherapy” provided in a non-stan-
dardised/uncalibrated way. Unclear if ad-
verse events were recorded by investigators
(see above) - possible unblinding of inves-
tigating clinicians, as a result of this which
could influence the consultation and “psy-
chotherapy” provided to each participant
Quotation: “None of the patients was
treated in the last month before their inclu-
sion in the study”
Comment: despite the above quotation,
the authors reportedmost participantswere
taking adjuvant medications (e.g. antide-
pressants, anxiolytics) during the study.
Therefore the former statement is mislead-
ing and inaccurate, as most would con-
sider antidepressants and anxiolytics to be
active treatments for BMS. No data were
provided on type of drugs used, any dose
changes during the study period - hence
unclear whether there were confounder in-
equalities between groups during the study
Sardella 1999
Methods Single centre, placebo-controlled parallel RCT
Participants 30 BMS patients
Mean age 69 years (range 54-85)
Sex: 26 F:4 M (F 87%:M 13%)
Inclusion/exclusion and diagnostic criteria appropriate
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Interventions Intervention category: topical treatments
Group 1: (n = 10) benzydamine hydrochloride 0.15% oral rinse, 15 ml rinse 3 times
a day for 4 weeks
Group 2: (n = 10) placebo oral rinse 3 times a day for 4 weeks
Group 3: (n = 10) no treatment
Duration: 4 weeks
Outcomes Change in severity of symptoms VAS (0 = no symptoms, 8 = a severe burning sensation)
before and after treatment scored as: “ineffective” (same dot value for the symptoms at
the 2 visits), “partially effective” (reduction in dot value of the symptoms), “effective”
(complete absence of symptoms)
Source of funding Not reported
Notes Groups comparable at baseline
Unvalidated outcome measure used
Study only double-blind for groups 1 and 2
SES: not reported
Conflict of interests: not reported
Data analysis: ITT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Each patient was assigned to
one of 3 management modalities (A, B or
C) through use of a table of random num-
bers. To avoid subgroups of different sizes,
a block randomization was used”
Comment: appropriate method
Allocation concealment (selection bias) Unclear risk Comment: nothing stated about allocation
concealment
Blinding (performance bias and detection
bias)
Blinding of participants
Unclear risk Quotation: “This study was a double-
blind, randomized, longitudinal investiga-
tion”
Comment: nothing further stated about
the blinding procedure. Group C was a
no treatment control group, thus knew
which group they have been allocated, and
were not blinded to treatment, however this
treatment arm not relevant to this review
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Unclear risk Quotation: “This study was a double-
blind”
Comment: nothing further stated about
the blinding procedure; patient-reported
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Sardella 1999 (Continued)
outcomes only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotation: “.. all patients completed the
study period”
Comment: no dropouts reported
Selective reporting (reporting bias) Low risk Comment: outcome reported in prespeci-
fied way
Other bias Unclear risk Comment: insufficient data provided on
baseline characteristics of participants.
Baseline symptom severity VAS data were
given for each individual participant. The
mean VAS scores differed between treat-
ment arms (Group A = 6.7, Group B = 6.1
and Group C = 5.7 ). It is unclear whether
there were any significant differences re-
garding the symptom severity at the base-
line
Sardella 2008
Methods Single centre, placebo-controlled parallel RCT
Participants 43 BMS patients
Mean age 64.9 SD 4.7 years
Sex: 35 F:4 M (reported per protocol) (F 90%:M 10%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements
Group 1: (n = 21) hypericum perforatum extract 300 mg capsules (hypericin 0.31%,
hyperforin 3.0%) 3 times a day for 12 weeks
Group 2: (n = 22) placebo capsules “identically appearing” 3 times a day for 12 weeks
Outcomes 10 cm VAS consisting of a horizontal line marked from 0 (no pain) to 10 (the worst
pain ever experienced) measured at first visit (t0) and at 3 follow-up visits (after 4 (t28),
8 (t56), and 12 (t84) weeks)
Number of oral mucosa sites with reported burning symptomsmeasured at first visit
(t0) and at 3 follow-up visits (after 4 (t28), 8 (t56), and 12 (t84) weeks)
Non-standardised assessment of quality of life - self-reported descriptions in response
to “simple questions (i.e. did you feel irritable/depressed/worry? or did oral burning
sensations interfere with your daily activities? or have you had difficult in concentrating
on things as reading or watching a TV movie?)”
Source of funding “This study has been supported by a grant of the University of Milan (FIRST, Fondo
Interno per la Ricerca Scientifica e Tecnologica, no 12-1-5201001-540). We also thank
Body Spring (Ancona, Italy) that kindly supplied both hypericum extract and placebo”
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Notes SES: not reported
Conflict of interests: not reported
Data analysis: per protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “random allocation sequence
was generated using online software avail-
able at http://graphpad.com/quickcalcs/
randomise1.cfm”
Comment: appropriate
Allocation concealment (selection bias) Low risk Quotation: “To guarantee allocation con-
cealment, the researchers deciding on pa-
tient eligibility did not know the sequence,
and a researcher who was not involved in
patient enrolment assigned the patients to
one of the two arms”
Comment: concealed allocation
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotations: “double-blind, placebo-con-
trolled study”; “Patients were randomized
to receive indistinguishable 300-mg cap-
sules of H. perforatum extract (hypericin
0.31%, hyperforin 3.0%; Test Group) or
placebo (Control Group)”
Comment: probably achieved
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotation: “double-blind, placebo-con-
trolled study”
Comment: patient-reported outcomes
only
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all dropouts and missing data
accounted for
Proportions similar across groups
Reasons similar across groups
Selective reporting (reporting bias) Low risk Comment: all primary outcomes were pre-
sented in the prespecified format
Other bias Low risk Comment: no other obvious risk of bias
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Methods Single centre, placebo-controlled cross-over RCT
Participants 30 BMS patients
Mean age 72.65 SD 12.10 years (range 40-90 years)
Sex: 19 F:4 M (reported per protocol) (F 83%:M 17%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: topical treatments
Group 1: (n = 30) capsaicin - 0.02% capsaicin rinse administered 3 times a day - applied
for 30 seconds in volumes of 15 ml - 1 week; “After this first week of treatment, the
patients completed a one-week washout period (no rinses, only regular dental hygiene
in the form of tooth brushing), after which they were assigned to the opposite group for
a further week of treatment”; “During this cross-over period, treatment and the scoring
of discomfort were carried out in the same way as in the first week, but administering
the opposite oral rinse”. No details of whether this was before or after meals
Group 2: (n = 30) placebo - “Placebo” rinse (unspecified preparation) - applied for 30
seconds in volumes of 15 ml - 1 week; “After this first week of treatment, the patients
completed a one-week washout period (no rinses, only regular dental hygiene in the
form of tooth brushing), after which they were assigned to the opposite group for a
further week of treatment”; “During this cross-over period, treatment and the scoring of
discomfort were carried out in the same way as in the first week, but administering the
opposite oral rinse”. No details of whether this was before or after meals
Outcomes VAS - “discomfort at different times during the study (0 cm = no discomfort, 10 cm =
unbearable or maximum discomfort)” - measured “morning before treatment in both
the capsaicin group (AM1) and in the placebo group (BM1). The VAS score was then
again recorded in the afternoon of the first day of treatment in both groups (AA1 and
BA1) and at the end of one week of treatment in both groups, in the morning (AM7
and BM7) and in the afternoon (AA7 and BA7)”
Source of funding Not reported
Notes No baseline characteristics provided for each study arm
SES: not reported
Conflict of interests: not reported
Data analysis: Per protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “The patients were randomized
to two groups”
Comment: not enough information to
make a judgement
Allocation concealment (selection bias) Unclear risk Comment: no mention of allocation con-
cealment
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Blinding (performance bias and detection
bias)
Blinding of participants
High risk Comment: likely unblinding of partici-
pants due to burning sensation of capsaicin
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
High risk Comment: likely unblinding of partici-
pants due to burning sensationof capsaicin;
patient-reported outcomes only
Incomplete outcome data (attrition bias)
All outcomes
High risk Quotation: “where indicated, those sub-
jects who developed adverse effects were re-
moved from the study”
Comment: removal of participants who
have had adverse events from the analysis
is likely to introduce significant bias
Selective reporting (reporting bias) High risk Comment: VAS scores data were not pre-
sented appropriately - graph only show-
ing capsaicin group with no raw data val-
ues (i.e. no means, standard deviations or
ranges provided). Paper suggested quanti-
tative data would be presented as median
and range - unclear why this was as the dis-
tribution of the VAS data was not stated
(i.e. no mention that it was non-normally
distributed)
Other bias Low risk Comment: given that participants had a
mean of 5 years duration of BMS, 1 week
treatment duration is very short
Spanemberg 2012
Methods Single centre, placebo-controlled parallel RCT
Participants 72 BMS patients
Mean ages - Group 1: 63.6 SD 9.61 (range 41-79); Group 2: 61.5 SD 6.76 (range 46-
73)
Sex: 53 F:7 M (reported per protocol) (F 88%:M 12%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: dietary supplements
Group 1: (n = 38) ’Catuama’ herbal compound - 310 mg capsules - Paullinia cupana
(’guarana’: 125 mg), Trichilia catigua (’catuaba’: 87.5 mg), Zingiber officinalis (’ginger
root’: 10 mg), and Ptychopetalum olacoides (’potency wood’: 87.5 mg) - 2 capsules a
day, before lunch and dinner, for 8 weeks after the first evaluation
Group 2: (n = 34) placebo capsules containing magnesium silicate, with the same colour
and shape as those taken by the group test - 2 capsules a day, before lunch and dinner,
for 8 weeks after the first evaluation
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Outcomes Visual numeric scale (VNS) consists of a ruler divided into 11 equal parts, numbered
successively from 0 (without symptoms) to 10 (maximum intensity of the symptoms).
At baseline, 4, 8, and 12 weeks after the treatment onset. The assessment at 12 weeks
was carried out 30 days after the end of treatment
Faces scale (FS): “the individual classified the intensity of their symptoms according to
the expression shown 4 in each pictured face. The expression of happiness corresponds
to 0 (without symptoms) and the expression of maximum unhappiness to 5 (maximum
intensity of the symptoms)”. At baseline, 4, 8, and 12 weeks after the treatment onset.
The assessment at 12 weeks was carried out 30 days after the end of treatment
Source of funding Not reported
Notes No data provided as to how quickly one would expect the active treatment to work and
how long it works for - presumably a prolonged benefit was expected as the study looked
at outcomes 4 weeks after cessation of treatment
SES: not reported
Conflict of interests: not reported
Data analysis: per protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “The herbal and placebo were
stored in identical vials and properly coded
to blind both researcher and patients. The
researcher chose the vial by lot and thus
were patients randomly allocated to treat-
ment groups”
Comment: appropriate method
Allocation concealment (selection bias) Low risk Comment: as above, likely that allocation
was concealed
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotation: “All patients were evaluated by
the same investigator, who had no informa-
tion about the medicine codes. The blind-
ing was maintained throughout the trial”
Comment: probably achieved
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotation: “All patients were evaluated by
the same investigator, who had no informa-
tion about the medicine codes. The blind-
ing was maintained throughout the trial”
Comment: blinded outcome assessment;
patient-reported outcomes only
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Incomplete outcome data (attrition bias)
All outcomes
High risk Quotation: “6 withdrew from the study for
reasons unrelated to the treatment” - 5 in
active, 1 in control - no reasons stated. Lost
to follow-up - 8 in active arm, 4 in control.
According to flow chart - 13 in active arm
and 5 in control arm dropped out
Comment: the paper states that 8 in ac-
tive and 4 in control arms were not evalu-
ated. Hence, there is a mismatch between
dropouts and evaluated participants which
is not explained. Higher attrition in active
arm with inadequate data provided as to
why this was
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported in
the prespecified manner
Other bias Unclear risk Quotation: “Two patients who took the
test substance reported exacerbation of the
symptoms in the first week of treatment,
but this was also observed in 4 patients in
the control group”
Comment: the text above is contradicted
by the flow chart which states 3 patients in
each arm reported exacerbation of symp-
toms
Spanemberg 2015
Methods Single centre, placebo-controlled parallel RCT
Participants 78 BMS patients
Mean age 62.8 years
Sex: 67 F:11 M (F 86%:M 14%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: electromagnetic radiation
Group 1: (n = 20) infrared weekly laser: 1 session weekly for 10 weeks (10 sessions:
Diode laser (Thera Lase, DMC Equipamentos LTDA, São Carlos, Brazil. Spot tip: 0.
028 cm²), aluminium gallium arsenide (GaAlAs), 830 nm wavelength, 100 mW output,
continuous emissions, 3.57 W/cm², 5 J energy p/point, 176 J/cm² radiant exposure,
applied 50 seconds p/point) + OHI (mucosal hydration and irritant avoidance (spicy/
citric food, alcohol, tobacco))
Group 2: (n = 20) infrared laser 3 times per week: 3 sessions weekly for 3 weeks (9
sessions: Diode laser (Thera Lase, DMC Equipamentos LTDA, São Carlos, Brazil. Spot
tip: 0.028 cm²), GaAlAs, 830 nm wavelength, 100 mW output, continuous emissions,
3.57 W/cm², 5 J energy p/point, 176 J/cm² radiant exposure, applied 50 seconds p/
point) + OHI (as above)
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Group 3: (n = 19) red laser 3 times per week: 3 sessions weekly for 3 weeks (9 sessions:
Diode laser (Thera Lase, DMC Equipamentos LTDA, São Carlos, Brazil. Spot tip: 0.
028 cm²), aluminium gallium indium phosphide (InGaAlP), 685 nm wavelength, 35
mW output, continuous emissions, 1.25 W/cm², 2 J energy p/point, 72 J/cm² radiant
exposure, applied 58 seconds p/point) + OHI (as above)
Group 4: (n = 19) placebo laser 3 times per week: 3 sessions weekly for 3 weeks (9
sessions: Diode laser (Thera Lase, DMC Equipamentos LTDA, São Carlos, Brazil. Spot
tip: 0.028 cm²), plastic-tipped with rubber interior to block radiation emission, duration
of application per point not reported) + OHI (as above)
Duration: Groups 2-4 - used in this review: 3 weeks; Group 1 - data not used within
this review due to no comparable placebo group: 10 weeks
Outcomes VAS and visual numeric scale (VNS): “Both scales were applied to check whether patients
would be consistent in their responses” at baseline, 3 weeks (end of treatment) and 11
weeks (2 months after treatment cessation) using 100 mm VAS scale (endpoints were 0
= no pain, 100 = worst pain possible) and VNS scale (endpoints were 0 = no pain, 10 =
worst pain possible)
Oral Health Impact Profile-14 (OHIP-14) (Portuguese language version) at baseline
and 3 weeks (end of treatment)
Adverse effects
Source of funding Coordenação de Aperfeiçoamento de Pessoal deNível Superior (CAPES; process number
4906-13-6), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
and Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) - all in Brazil
Notes SES: not reported
Conflict of interests: not reported
Data analysis: ITT
QoL not assessed at 11-week follow-up, only immediately after cessation of treatment
(3 weeks)
Note: While VAS (0-100 mm) and VNS (0-10) were both assessed to ensure response
consistency, VAS was used in this review’s analyses due to the greater precision in re-
ported results and reassurance from the study authors: “In both scales, the patients were
consistent in their responses, presenting Pearson correlation coefficient > 0.9”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “randomly allocated into four
groups”
Comment: not reported
Allocation concealment (selection bias) Unclear risk Comment: not reported
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotation: “the present randomized,
blind, placebo-controlled study”
Comment: although not explicitly re-
ported, it is assumed participants were
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blinded
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotation: “the present randomized,
blind, placebo-controlled study”
Comment: not reported who was blinded,
however only patient-reported outcomes
assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotation: “All the patients in the sample
(n = 78) completed the study”
Selective reporting (reporting bias) Unclear risk Comment: adverse events were not re-
ported despite being indicated to have been
assessed in the final session
Other bias High risk Comment: baseline inequality in OHIP
and VNS present between infrared and
placebo groups
Study authors did not assess OHIP-14 at
11-week follow-up, but did assess VAS and
VNS
Tammiala-Salonen 1999
Methods Single centre, placebo-controlled parallel RCT
Participants 37 BMS patients
Mean age 58.6 years (range 39 to 71)
Sex: 37 F (F 100%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: antidepressants and antipsychotics
Group 1: (n = 18) trazodone 200 mg daily
Group 2: (n = 19) placebo
Duration: 8 weeks
Outcomes VAS at 0, 2, 4 and 8 weeks using 100 mm VAS scale (endpoints were 0 = no pain, 100
= worst pain possible)
Short McGill Pain Questionnaire (MPQ) at baseline and 8 weeks - “intensity and char-
acter of the pain were further defined by the use of the Finnish version of the McGill
Pain Questionnaire”
Beck Depression Inventory (BDI)
Global assessment at 8 weeks
Source of funding Finnish Dental Society
Notes Groups differed at baseline with regard to pain intensity
Number of dropouts was higher in those who were depressed
SES: not reported
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Conflict of interests: not reported
Data analysis: per protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Randomization was per-
formed in blocks of 6 by the manufacturer
of the drug (Orion)”
Comment: third party randomisation
Allocation concealment (selection bias) Low risk Quotations: “The randomization code was
not opened during the trial”; “The exam-
iner could not guess the treatment of the
subjects”
Comment: probably achieved
Blinding (performance bias and detection
bias)
Blinding of participants
Low risk Quotations: “Identical capsules of tra-
zodone and of passive placebo were packed
in the same way”; “nothing suggested that
the blinding had not remained intact for
the patients”; “Seven subjects in the tra-
zodone group and 2 in the placebo group
failed to finish the trial because of side ef-
fects, mainly because of dizziness”
Comment: probably achieved
Blinding (performance bias and detection
bias)
Blinding of outcome assessors
Low risk Quotation: “The examiner could not guess
the treatment of the subjects”
Comment: blinded outcome assessment;
patient-reported outcomes only
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: reasons for dropouts were re-
ported appropriately. Unclear as to how
these data were handled - no mention of
numbers analysed for the outcomes
Selective reporting (reporting bias) Unclear risk Comment: prespecified outcomes were re-
ported but not completely - although VAS
measurement on speaking, eating and suf-
fering - no data provided - only mention
that there was no significant differences be-
tween the groups. McGill pain score raw
data not provided, reported to be no signif-
icant difference in standard deviations for
VAS and Beck data only shown graphically
with no raw data provided
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Other bias Low risk Comment: noother risks of biaswere noted
ALA = alpha lipoic acid; BMS = burning mouth syndrome; F = female; ITT = intention-to-treat; M = male; OHI = oral hygiene
instruction; ppm = parts per million; QoL = quality of life; RCT = randomised controlled trial; SD = standard deviation; SES =
socioeconomic status; VAS = visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bai 2010 Does not use a placebo group - electric acupuncture therapy versus oral oryzanol
Bessho 1998 Does not use a placebo group - compares Kampo medicine with diazepam
Bogetto 1997 Amisulpride versus paroxetine - conference abstract only - insufficient detail provided to confirm that
participants had burning mouth syndrome
Campisi 1997 Does not use a placebo group - compares 2 different forms of sucralfate - 20% suspension versus 1 g
chewable tablet
Ferguson 1981 Not an RCT - single-centre, double-blind CCT of 145 oophorectomised patients comparing mestranol
with placebo
Forabosco 1992 Not an RCT - the diagnosis of BMS was uncertain in this study, all subjects included in the study with
BMS symptoms received the same intervention (hormone replacement therapy)
Grechko 1996 Does not use a placebo group - compares electrical stimulation therapy with standard methods of treatment
(novocaine blockade, analgesics, etc.)
Grushka 1998 Not an RCT - all 30 subjects received clonazepam (starting dose was 0.25 mg daily, with an increase in
dose of 0.25 mg on a weekly basis if symptoms continued)
Grémeau-Richard 2010 Inappropriate design - only immediate assessment, no clinical application. “The spontaneous burning was
measured with a visual analogue scale (VAS) just before and 15 min after injection”
Hansen 1990 Not true cross-over; not all participants received both interventions. Mixed diagnosis; unable to separate
out results for BMS sufferers
Hirsch 2011 Not an RCT - pilot study reporting 3 cases of open-label application of topical sucralose
Huang 2006 Does not use a placebo group - acupoint injection of vitamin B1 and B12 versus oral oryzanol
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Huang 2009 Does not use a placebo group - acupoint injection of vitamin B1 and B12 versus oral oryzanol and vitamin
B2 complex
Hugoson 1991 Not an RCT - participants grouped according to presence of BMS symptoms or vitamin deficiency or
both. Only those with both symptoms and vitamin deficiency received therapy
Ito 2010 Not an RCT - open-label case series in 22 patients with BMS who were given varying doses of milnacipram
over a 12-week period
Kho 2010 Not an RCT - not primary BMS, some participants had anaemia, diabetes mellitus and hyposalivation
Lamey 1986 Participants initially divided according to whether they were vitamin deficient or not. The non-vitamin
deficient group were randomly allocated to various vitamin replacement regimens, although results are not
broken down according to regimen
Li 2002 Unable to locate a copy of the original article from any location worldwide after repeated search through
the British Library’s Inter-Library Loans service
Lindholm 2015 The trial included participants with various neuropathic orofacial pain conditions. Data for BMS sufferers
(n = 5; 31%) could not be separated out from other types of pain
Loldrup 1989 Participants randomly allocated to 1 of 3 groups: clomipramine, mianserin or placebo. The trial included
patients with pain of no known organic origin. Data for BMS sufferers could not be separated out from
other types of pain
Lu 2002 Does not use a placebo group - acupoint injection of vitamin B1 and B12 versus oral oryzanol and vitamin
B complex
López-Jornet 2013 Comparison between tongue protector and tongue protector plus aloe vera gel - therefore study is not
placebo-controlled, as the tongue protector is considered to be an active treatment
Ma 2006 Unable to locate a copy of the original article from any location worldwide after repeated search through
the British Library’s Inter-Library Loans service
Maina 2002 Does not use a placebo group - compares SSRIs (paroxetine 20 mg/day or sertraline 50 mg/day) with
amisulpride 50 mg/day
Miziara 2009 Inappropriate design - placebo group outcome assessed after 1 month while intervention group outcome
assessed after 3 months
Mo 2003 Unable to locate a copy of the original article from any location worldwide after repeated search through
the British Library’s Inter-Library Loans service
Palacios-Sanchez 2010 Insufficient details to permit entry to review as only conference abstract available (no inclusion/exclusion
criteria or diagnostic classifications) and possibly not a randomised study - alpha lipoic acid versus placebo
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Pellegrini 2010 Insufficient details to permit entry to review as only conference abstract available (no inclusion/exclusion
criteria or diagnostic classifications)
Peng 2001 Does not use a placebo group - compares livial (a synthetic hormone) with oryzanol and vitamin E
Petruzzi 2004 Error inMEDLINE reference.Not anRCT, sample were alternately assigned to arms. Clarification received
from lead author
Pisanty 1975 Not anRCT. Also insufficient data provided to determine whether participants had BMS or other diagnoses
causing such symptoms - estrone 10,000 U and estrone 50,000 U ointments versus placebo
Qui 2010 Does not use a placebo group - compares laser acupuncture versus acupoint injection of vitamin B1 and
B12
Romeo 2010 Not an RCT - no control group, case series - laser therapy
Toida 2009 Not primary BMS, methods state all participants were being treated for gastritis for 4 months and had oral
burning for at least a month
Vukoja 2011 Letter to the editor, insufficient details on diagnostic classification, methods or outcomes - laser therapy
versus placebo
Woda 1998 Not an RCT - all 25 subjects received clonazepam (0.5 or 1 mg) 2 or 3 times daily
Yong 2003 Does not use a placebo group - acupoint injection of vitamin B1 and B12 combined with oral oryzanolum
versus oral oryzanolum
BMS = burning mouth syndrome; CCT = controlled clinical trial; RCT = randomised controlled trial; SSRIs = selective serotonin
reuptake inhibitors.
Characteristics of studies awaiting assessment [ordered by study ID]
NCT02580734
Methods Placebo-controlled, triple-blinded cross-over RCT
Participants 20 BMS patients
Mean age: Unknown until published (eligible age range 18 to 90)
Sex: Distribution unknown until published
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: Dietary supplements
Group 1: (n = 20) Melatonin 12 mg daily (3 mg capsules taken 4 times p/day)
Group 2: (n = 20) Placebo (capsules taken 4 times p/day)
Duration: 5 months (2 months, followed by 1 month washout, and then final 2 months)
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Outcomes • Pain intensity at 2 months (assessed by VAS, verbal intensity score and numerical rating scale)
• QoL (assessed by SF-36 (36-Item Short Form Health Survey))
• QoL surrogate: Anxiety (assessed by Hamilton Anxiety Rating Scale (HAM-A))
• Adverse effects
Outcomes not of interest to this review
• Sleep (assessed by Epworth Sleepiness Scale (ESS) and sleep scale from the Medical Outcomes Study
(MOS))
• Serum melatonin levels (measured by blood sample)
Source of funding Unknown until published
Notes Study currently unpublished
Contact: Andrea Sardella (andrea.sardella@unimi.it)
Umezaki 2016
Methods Single-centre, placebo-controlled, single-blinded parallel RCT
Participants 26 BMS patients
Mean age 63.9 years (SD 9.56)
Sex: 24F:2M (F92%:M8%)
Inclusion/exclusion and diagnostic criteria appropriate
Interventions Intervention category: Electromagnetic radiation
Group 1: (n = 14) High-frequency transcranial magnetic stimulation (TMS): 10 daily sessions (1 session p/
day for 5 days, 2 days untreated and then a further 5 days of 1 session p/day) totalling 30,000 single-pulse
stimulations at 10Hz (MagVenture MagPro x100 Stimulator -MagVenture Inc., Denmark; Cool-B65 A/P figure
8 coil, positioned over left dorsolateral prefrontal cortex (DLPFC) at medial frontal 10-20 system EEG-electrode
location (F3); unconnected ECT electrodes placed under coil - Natus Neurology, Middleton, Wisconsin)
Group 2: (n = 12) Placebo: 10 daily sessions (1 session p/day for 5 days, 2 days untreated and then a further
5 days of 1 session p/day) totalling 30,000 single-pulse stimulations (MagVenture MagPro x100 Stimulator
- MagVenture Inc., Denmark; shielded Cool-B65 A/P figure 8 coil, positioned over left DLPFC at location
F3; connected ECT electrodes placed under coil to stimulate when TMS was triggered - Natus Neurology,
Middleton, Wisconsin)
Duration: 2 months
Outcomes • Pain intensity at baseline, daily during days 1-14, follow-up at day 15, 1 month and 2 months (assessed
by VAS)
• Functional impairment at baseline, days 8 and 15, 1 month and 2 months (assessed by Short Form McGill
Pain Questionnaire (SFMPQ); Brief Pain Inventory (BPI); Patient Health Questionnaire (PHQ-9); Patients’
Global Impression of Change (PGIC); Clinical Global Impression for global improvement scale (CGI-I))
• Adverse effects
Outcomes not of interest to this review
• Patients’ assumed treatment group (TMS or placebo; assessed at end of treatment)
Source of funding Not reported
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Notes No numbers (tables 1-3), means or SDs (text and figures 2-3) associated with the study’s results were available
in the published study paper. Until this information is obtained we are unable to incorporate this study within
our analyses
Quotation: “SSRIs were prescribed for around 40% of the patients, but these did not adequately relieve the BMS
pain. Although 30% of the patients had a prior history of depression, none currently met diagnostic criteria for
depression”
Comment: Unclear if SSRIs were prescribed before the trial commenced, or during the trial as a co-intervention
SES: Not reported
Conflict of interests: Not reported
Data analysis: Per-protocol (according to Figure 1). 6 participants did not complete the assigned intervention
duration due to competing commitments which allowed them to attend only 2 sessions (of 10 scheduled) each.
Group 1: 2 patients abandoned study; Group 2: 4 patients left study
BMS = burning mouth syndrome; F = female; M = male; QoL = quality of life; RCT = randomised controlled trial; SD = standard
deviation; SES = socioeconomic status; SSRIs = selective serotonin reuptake inhibitors; VAS = visual analogue scale.
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D A T A A N D A N A L Y S E S
Comparison 1. Antidepressants/antipsychotics versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief - short-term (≤3
months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Antidepressants -
Trazodone
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Anticonvulsants versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief - short-term (≤3
months)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [2.09, 7.67]
1.1 Gabapentin only 1 50 Risk Ratio (M-H, Fixed, 95% CI) 3.75 [1.36, 10.32]
1.2 Gabapentin + adjunctive
ALA
1 50 Risk Ratio (M-H, Fixed, 95% CI) 4.2 [1.80, 9.83]
Comparison 3. Benzodiazepines versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief - short-term (≤3
months)
3 131 Mean Difference (IV, Fixed, 95% CI) -1.84 [-2.14, -1.54]
1.1 Topical clonazepam 2 111 Mean Difference (IV, Fixed, 95% CI) -1.89 [-2.19, -1.59]
1.2 Systemic clonazepam 1 20 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.86, 1.86]
2 Symptom relief - long-term (>3
to ≤6 months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Topical clonazepam 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Change in QoL - Depression -
short-term (≤3 months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Systemic clonazepam 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Change in taste - short-term (≤3
months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 4. Cholinergics versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief - short-term (≤3
months)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Bethanechol 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Dietary supplements versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief - short-term (≤3
months)
6 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 ALA + adjunctive vitamins
(Tiobec)
2 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 ALA + adjunctive lycopene
+ green tea extract (Thioderm)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 ’Catuama’ herbal
compound
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Hypericum perforatum
(St John’s Wort)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Lycopene 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Symptom relief - short term (≤3
months)
2 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 ALA without adjunctive
active ingredients
2 Mean Difference (Fixed, 95% CI) -0.39 [-2.54, 1.76]
3 Symptom relief - short-term (≤3
months)
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 ALA without adjunctive
active ingredients (Ciagen)
1 80 Risk Ratio (M-H, Fixed, 95% CI) 3.67 [1.78, 7.54]
3.2 ALA + adjunctive vitamins
(Tiobec)
3 142 Risk Ratio (M-H, Fixed, 95% CI) 4.10 [2.63, 6.38]
3.3 ALA + adjunctive lycopene
+ green tea extract (Thioderm)
1 54 Risk Ratio (M-H, Fixed, 95% CI) 2.32 [1.20, 4.48]
4 Symptom relief - long-term (>3
to ≤6 months)
2 70 Mean Difference (IV, Fixed, 95% CI) -0.89 [-2.37, 0.59]
4.1 ALA without adjunctive
active ingredients
1 24 Mean Difference (IV, Fixed, 95% CI) -0.90 [-3.49, 1.69]
4.2 ALA + adjunctive vitamins
(Tiobec)
2 46 Mean Difference (IV, Fixed, 95% CI) -0.88 [-2.68, 0.91]
5 Change in QoL - short-term
(≤3 months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 OHIP-14 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Surrogate measure -
Anxiety
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.3 Surrogate measure -
Depression
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Electromagnetic radiation versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief - VAS -
short-term (≤3 months)
1 58 Mean Difference (IV, Fixed, 95% CI) -30.36 [-44.22, -16.
50]
1.1 Infrared laser 1 30 Mean Difference (IV, Fixed, 95% CI) -36.94 [-55.34, -18.
54]
1.2 Red laser 1 28 Mean Difference (IV, Fixed, 95% CI) -21.73 [-42.81, -0.
65]
2 Change in QoL - short-term
(≤3 months)
1 58 Mean Difference (IV, Fixed, 95% CI) -5.24 [-7.38, -3.09]
2.1 Infrared laser 1 30 Mean Difference (IV, Fixed, 95% CI) -6.50 [-9.36, -3.64]
2.2 Red laser 1 28 Mean Difference (IV, Fixed, 95% CI) -3.62 [-6.86, -0.38]
Comparison 7. Physical barriers versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief - short-term (≤3
months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Tongue protector 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Change in QoL - short-term
(≤3 months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 OHIP-49 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Surrogate measure -
Anxiety
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Surrogate measure -
Depression
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 8. Psychological therapies versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief - long-term (>3
to ≤6 months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 9. Topical treatments versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief - short-term (≤3
months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Capsaicin oral rinse 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Lactoperoxidase oral rinse
(Biotene)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Symptom relief - short-term (≤3
months)
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Benzydamine
hydrochloride oral rinse
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Lactoperoxidase oral rinse
(Biotene)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Topical urea (10%) 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Symptom relief - long-term (>3
to ≤6 months)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Capsaicin 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Lactoperoxidase (Biotene) 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Antidepressants/antipsychotics versus placebo, Outcome 1 Symptom relief -
short-term (≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 1 Antidepressants/antipsychotics versus placebo
Outcome: 1 Symptom relief - short-term (≤3 months)
Study or subgroup Antidepressants/antipsychotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Antidepressants - Trazodone
Tammiala-Salonen 1999 18 5.92 (2.32) 19 4.66 (2.32) 1.26 [ -0.24, 2.76 ]
-4 -2 0 2 4
Favours antidepressants Favours placebo
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Analysis 2.1. Comparison 2 Anticonvulsants versus placebo, Outcome 1 Symptom relief - short-term (≤3
months).
Review: Interventions for treating burning mouth syndrome
Comparison: 2 Anticonvulsants versus placebo
Outcome: 1 Symptom relief - short-term (≤3 months)
Study or subgroup Anticonvulsants Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Gabapentin only
Lopez-D’alessandro 2011 10/20 4/30 44.4 % 3.75 [ 1.36, 10.32 ]
Subtotal (95% CI) 20 30 44.4 % 3.75 [ 1.36, 10.32 ]
Total events: 10 (Anticonvulsants), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
2 Gabapentin + adjunctive ALA
Lopez-D’alessandro 2011 14/20 5/30 55.6 % 4.20 [ 1.80, 9.83 ]
Subtotal (95% CI) 20 30 55.6 % 4.20 [ 1.80, 9.83 ]
Total events: 14 (Anticonvulsants), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.31 (P = 0.00094)
Total (95% CI) 40 60 100.0 % 4.00 [ 2.09, 7.67 ]
Total events: 24 (Anticonvulsants), 9 (Placebo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.17 (P = 0.000030)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours anticonvulsants
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Analysis 3.1. Comparison 3 Benzodiazepines versus placebo, Outcome 1 Symptom relief - short-term (≤3
months).
Review: Interventions for treating burning mouth syndrome
Comparison: 3 Benzodiazepines versus placebo
Outcome: 1 Symptom relief - short-term (≤3 months)
Study or subgroup Benzodiazepines Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Topical clonazepam
Gr meau-Richard 2004 22 3.5 (0.7) 23 5.5 (0.4) 79.6 % -2.00 [ -2.34, -1.66 ]
Rodr guez de Rivera-Campillo 2010 33 2.848 (1.698) 33 4.24 (1.199) 17.8 % -1.39 [ -2.10, -0.68 ]
Subtotal (95% CI) 55 56 97.4 % -1.89 [ -2.19, -1.59 ]
Heterogeneity: Chi2 = 2.29, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 12.22 (P < 0.00001)
2 Systemic clonazepam
Heckmann 2012 10 4.5 (2.4) 10 4.5 (1.8) 2.6 % 0.0 [ -1.86, 1.86 ]
Subtotal (95% CI) 10 10 2.6 % 0.0 [ -1.86, 1.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 65 66 100.0 % -1.84 [ -2.14, -1.54 ]
Heterogeneity: Chi2 = 6.16, df = 2 (P = 0.05); I2 =68%
Test for overall effect: Z = 12.06 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.86, df = 1 (P = 0.05), I2 =74%
-4 -2 0 2 4
Favours benzodiazepines Favours placebo
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Analysis 3.2. Comparison 3 Benzodiazepines versus placebo, Outcome 2 Symptom relief - long-term (>3 to
≤6 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 3 Benzodiazepines versus placebo
Outcome: 2 Symptom relief - long-term (>3 to≤6 months)
Study or subgroup Benzodiazepines Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Topical clonazepam
Rodr guez de Rivera-Campillo 2010 33 3.03 (1.357) 33 4.42 (0.969) -1.39 [ -1.96, -0.83 ]
-2 -1 0 1 2
Favours benzodiazepines Favours placebo
Analysis 3.3. Comparison 3 Benzodiazepines versus placebo, Outcome 3 Change in QoL - Depression -
short-term (≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 3 Benzodiazepines versus placebo
Outcome: 3 Change in QoL - Depression - short-term (≤3 months)
Study or subgroup Benzodiazepines Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Systemic clonazepam
Heckmann 2012 10 0.6 (0.8) 10 0.8 (0.9) -0.20 [ -0.95, 0.55 ]
-2 -1 0 1 2
Favours benzodiazepines Favours placebo
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Analysis 3.4. Comparison 3 Benzodiazepines versus placebo, Outcome 4 Change in taste - short-term (≤3
months).
Review: Interventions for treating burning mouth syndrome
Comparison: 3 Benzodiazepines versus placebo
Outcome: 4 Change in taste - short-term (≤3 months)
Study or subgroup Benzodiazepines Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heckmann 2012 10 11.3 (2.5) 10 12.3 (2.3) -1.00 [ -3.11, 1.11 ]
-4 -2 0 2 4
Favours benzodiazepines Favours placebo
Analysis 4.1. Comparison 4 Cholinergics versus placebo, Outcome 1 Symptom relief - short-term (≤3
months).
Review: Interventions for treating burning mouth syndrome
Comparison: 4 Cholinergics versus placebo
Outcome: 1 Symptom relief - short-term (≤3 months)
Study or subgroup Cholinergics Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bethanechol
Femiano 2002b 2/20 0/20 5.00 [ 0.26, 98.00 ]
0.05 0.2 1 5 20
Favours placebo Favours cholinergics
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Analysis 5.1. Comparison 5 Dietary supplements versus placebo, Outcome 1 Symptom relief - short-term
(≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 5 Dietary supplements versus placebo
Outcome: 1 Symptom relief - short-term (≤3 months)
Study or subgroup Dietary supplements Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ALA + adjunctive vitamins (Tiobec)
Marino 2010 14 3.7 (2.5) 14 5.3 (2.2) -1.60 [ -3.34, 0.14 ]
Carbone 2009 18 5.94 (2.73) 20 5.05 (3.39) 0.89 [ -1.06, 2.84 ]
2 ALA + adjunctive lycopene + green tea extract (Thioderm)
L pez-Jornet 2009b 23 4 (2.7) 16 2.8 (2.5) 1.20 [ -0.45, 2.85 ]
3 ’Catuama’ herbal compound
Spanemberg 2012 30 3.33 (2.49) 30 5.73 (2.71) -2.40 [ -3.72, -1.08 ]
4 Hypericum perforatum (St John’s Wort)
Sardella 2008 19 6.15 (2.44) 20 5 (3.024) 1.15 [ -0.57, 2.87 ]
5 Lycopene
Cano-Carrillo 2014 (1) 26 4.09 (1.69) 24 4.17 (1.7) -0.08 [ -1.02, 0.86 ]
Cano-Carrillo 2014 (2) 26 6.12 (2.2) 24 5.75 (1.87) 0.37 [ -0.76, 1.50 ]
-4 -2 0 2 4
Favours dietary suppl Favours placebo
(1) VAS - burning relief
(2) VAS - pain relief
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Analysis 5.2. Comparison 5 Dietary supplements versus placebo, Outcome 2 Symptom relief - short term
(≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 5 Dietary supplements versus placebo
Outcome: 2 Symptom relief - short term (≤3 months)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 ALA without adjunctive active ingredients
Carbone 2009 -0.34 (1.123) 95.3 % -0.34 [ -2.54, 1.86 ]
Cavalcanti 2009 -1.43 (5.07) 4.7 % -1.43 [ -11.37, 8.51 ]
Subtotal (95% CI) 100.0 % -0.39 [ -2.54, 1.76 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours dietary suppl Favours placebo
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Analysis 5.3. Comparison 5 Dietary supplements versus placebo, Outcome 3 Symptom relief - short-term
(≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 5 Dietary supplements versus placebo
Outcome: 3 Symptom relief - short-term (≤3 months)
Study or subgroup Dietary supplements Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ALA without adjunctive active ingredients (Ciagen)
Lopez-D’alessandro 2011 11/20 9/60 100.0 % 3.67 [ 1.78, 7.54 ]
Subtotal (95% CI) 20 60 100.0 % 3.67 [ 1.78, 7.54 ]
Total events: 11 (Dietary supplements), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.53 (P = 0.00041)
2 ALA + adjunctive vitamins (Tiobec)
Femiano 2000 16/21 3/21 19.4 % 5.33 [ 1.82, 15.62 ]
Femiano 2002a 29/30 12/30 77.4 % 2.42 [ 1.55, 3.76 ]
Femiano 2002b 18/20 0/20 3.2 % 37.00 [ 2.38, 574.81 ]
Subtotal (95% CI) 71 71 100.0 % 4.10 [ 2.63, 6.38 ]
Total events: 63 (Dietary supplements), 15 (Placebo)
Heterogeneity: Chi2 = 8.15, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 6.24 (P < 0.00001)
3 ALA + adjunctive lycopene + green tea extract (Thioderm)
Palacios-S nchez 2015 16/25 8/29 100.0 % 2.32 [ 1.20, 4.48 ]
Subtotal (95% CI) 25 29 100.0 % 2.32 [ 1.20, 4.48 ]
Total events: 16 (Dietary supplements), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
0.002 0.1 1 10 500
Favours placebo Favours dietary suppl
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Analysis 5.4. Comparison 5 Dietary supplements versus placebo, Outcome 4 Symptom relief - long-term
(>3 to ≤6 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 5 Dietary supplements versus placebo
Outcome: 4 Symptom relief - long-term (>3 to≤6 months)
Study or subgroup Dietary supplements Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ALA without adjunctive active ingredients
Carbone 2009 14 4.5 (3.39) 10 5.4 (3.05) 32.5 % -0.90 [ -3.49, 1.69 ]
Subtotal (95% CI) 14 10 32.5 % -0.90 [ -3.49, 1.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 ALA + adjunctive vitamins (Tiobec)
Carbone 2009 18 5.11 (3.98) 10 5.4 (3.05) 31.4 % -0.29 [ -2.93, 2.35 ]
Marino 2010 9 4.1 (2.9) 9 5.5 (2.4) 36.1 % -1.40 [ -3.86, 1.06 ]
Subtotal (95% CI) 27 19 67.5 % -0.88 [ -2.68, 0.91 ]
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 41 29 100.0 % -0.89 [ -2.37, 0.59 ]
Heterogeneity: Chi2 = 0.36, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
-4 -2 0 2 4
Favours dietary suppl Favours placebo
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Analysis 5.5. Comparison 5 Dietary supplements versus placebo, Outcome 5 Change in QoL - short-term
(≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 5 Dietary supplements versus placebo
Outcome: 5 Change in QoL - short-term (≤3 months)
Study or subgroup Dietary supplements Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 OHIP-14
Cano-Carrillo 2014 26 18.31 (7.78) 24 17.38 (6.9) 0.93 [ -3.14, 5.00 ]
2 Surrogate measure - Anxiety
Cano-Carrillo 2014 (1) 26 8.65 (4.64) 24 11.5 (4.14) -2.85 [ -5.28, -0.42 ]
3 Surrogate measure - Depression
Cano-Carrillo 2014 (2) 26 4.38 (3.69) 24 6.25 (4.72) -1.87 [ -4.23, 0.49 ]
-20 -10 0 10 20
Favours dietary suppl Favours placebo
(1) Hospital anxiety scale - adjunctive surrogate marker for QoL in addition to OHIP-14
(2) Hospital depression scale - adjunctive surrogate marker for QoL in addition to OHIP-14
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Analysis 6.1. Comparison 6 Electromagnetic radiation versus placebo, Outcome 1 Symptom relief - VAS -
short-term (≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 6 Electromagnetic radiation versus placebo
Outcome: 1 Symptom relief - VAS - short-term (≤3 months)
Study or subgroup
Electromagnetic
radiation Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Infrared laser
Spanemberg 2015 20 25.9 (19.48) 10 62.84 (26.3) 56.7 % -36.94 [ -55.34, -18.54 ]
Subtotal (95% CI) 20 10 56.7 % -36.94 [ -55.34, -18.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.93 (P = 0.000083)
2 Red laser
Spanemberg 2015 19 41.11 (27.14) 9 62.84 (26.3) 43.3 % -21.73 [ -42.81, -0.65 ]
Subtotal (95% CI) 19 9 43.3 % -21.73 [ -42.81, -0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
Total (95% CI) 39 19 100.0 % -30.36 [ -44.22, -16.50 ]
Heterogeneity: Chi2 = 1.14, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 4.29 (P = 0.000018)
Test for subgroup differences: Chi2 = 1.14, df = 1 (P = 0.29), I2 =12%
-50 -25 0 25 50
Favours electromagnetic r Favours placebo
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Analysis 6.2. Comparison 6 Electromagnetic radiation versus placebo, Outcome 2 Change in QoL - short-
term (≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 6 Electromagnetic radiation versus placebo
Outcome: 2 Change in QoL - short-term (≤3 months)
Study or subgroup
Electromagnetic
radiation Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Infrared laser
Spanemberg 2015 20 6.89 (4.05) 10 13.39 (3.62) 56.2 % -6.50 [ -9.36, -3.64 ]
Subtotal (95% CI) 20 10 56.2 % -6.50 [ -9.36, -3.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.45 (P < 0.00001)
2 Red laser
Spanemberg 2015 19 9.77 (4.92) 9 13.39 (3.62) 43.8 % -3.62 [ -6.86, -0.38 ]
Subtotal (95% CI) 19 9 43.8 % -3.62 [ -6.86, -0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Total (95% CI) 39 19 100.0 % -5.24 [ -7.38, -3.09 ]
Heterogeneity: Chi2 = 1.71, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 4.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.71, df = 1 (P = 0.19), I2 =41%
-10 -5 0 5 10
Favours electromagnetic r Favours placebo
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Analysis 7.1. Comparison 7 Physical barriers versus placebo, Outcome 1 Symptom relief - short-term (≤3
months).
Review: Interventions for treating burning mouth syndrome
Comparison: 7 Physical barriers versus placebo
Outcome: 1 Symptom relief - short-term (≤3 months)
Study or subgroup Physical barriers Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Tongue protector
L pez-Jornet 2011 25 4.5 (2.2) 25 5.6 (1.5) -1.10 [ -2.14, -0.06 ]
-2 -1 0 1 2
Favours physical barrier Favours placebo
Analysis 7.2. Comparison 7 Physical barriers versus placebo, Outcome 2 Change in QoL - short-term (≤3
months).
Review: Interventions for treating burning mouth syndrome
Comparison: 7 Physical barriers versus placebo
Outcome: 2 Change in QoL - short-term (≤3 months)
Study or subgroup Physical barriers Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 OHIP-49
L pez-Jornet 2011 25 44.52 (28.17) 25 53.72 (35.3) -9.20 [ -26.90, 8.50 ]
2 Surrogate measure - Anxiety
L pez-Jornet 2011 (1) 25 11.2 (6.59) 25 11.04 (5.43) 0.16 [ -3.19, 3.51 ]
3 Surrogate measure - Depression
L pez-Jornet 2011 (2) 25 8.28 (5.93) 25 8.92 (6.13) -0.64 [ -3.98, 2.70 ]
-20 -10 0 10 20
Favours physical barrier Favours placebo
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(1) Hospital anxiety scale - adjunctive surrogate marker for QoL in addition to OHIP-49
(2) Hospital depression scale - adjunctive surrogate marker for QoL in addition to OHIP-49
Analysis 8.1. Comparison 8 Psychological therapies versus placebo, Outcome 1 Symptom relief - long-term
(>3 to ≤6 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 8 Psychological therapies versus placebo
Outcome: 1 Symptom relief - long-term (>3 to≤6 months)
Study or subgroup
Psychological
therapies Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bergdahl 1995a 15 1.4 (1.1) 15 4.6 (1.7) -3.20 [ -4.22, -2.18 ]
-4 -2 0 2 4
Favours psychological Favours placebo
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Analysis 9.1. Comparison 9 Topical treatments versus placebo, Outcome 1 Symptom relief - short-term
(≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 9 Topical treatments versus placebo
Outcome: 1 Symptom relief - short-term (≤3 months)
Study or subgroup Topical treatments Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Capsaicin oral rinse
Marino 2010 14 2.9 (2.6) 14 5.3 (2.2) -2.40 [ -4.18, -0.62 ]
2 Lactoperoxidase oral rinse (Biotene)
Marino 2010 14 3.6 (2.4) 14 5.3 (2.2) -1.70 [ -3.41, 0.01 ]
-4 -2 0 2 4
Favours topical treatment Favours placebo
Analysis 9.2. Comparison 9 Topical treatments versus placebo, Outcome 2 Symptom relief - short-term
(≤3 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 9 Topical treatments versus placebo
Outcome: 2 Symptom relief - short-term (≤3 months)
Study or subgroup Topical treatments Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Benzydamine hydrochloride oral rinse
Sardella 1999 1/10 2/10 0.50 [ 0.05, 4.67 ]
2 Lactoperoxidase oral rinse (Biotene)
Femiano 2002b 0/20 0/20 Not estimable
3 Topical urea (10%)
Alvarenga da Silva 2014 7/12 8/13 0.95 [ 0.50, 1.80 ]
0.05 0.2 1 5 20
Favours placebo Favours topical treatment
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Analysis 9.3. Comparison 9 Topical treatments versus placebo, Outcome 3 Symptom relief - long-term (>3
to ≤6 months).
Review: Interventions for treating burning mouth syndrome
Comparison: 9 Topical treatments versus placebo
Outcome: 3 Symptom relief - long-term (>3 to≤6 months)
Study or subgroup Topical treatments Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Capsaicin
Marino 2010 9 2.9 (3) 9 5.5 (2.4) -2.60 [ -5.11, -0.09 ]
2 Lactoperoxidase (Biotene)
Marino 2010 9 4 (2.8) 9 5.5 (2.4) -1.50 [ -3.91, 0.91 ]
-4 -2 0 2 4
Favours topical treatment Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies
Study ID Diagnosis description Duration of disease
Alvarenga da Silva 2014 “..patients with BMS diagnosed according to
the International Association for the Study
of Pain (IASP) guidelines. They underwent
laboratory tests and a careful examination to
exclude other causes of burning mouth. The
exclusion criteria were other facial pain syn-
dromes, other causes of abnormal salivation,
other neuropathies or primary diseases asso-
ciated with burning mouth”
Mean duration of BMS (+/- SD):
topical urea 10% (n = 19) 6.97 years (+/- 4.
93);
placebo (n = 19) 2.78 years (+/- 2.61)
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Table 1. Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies (Continued)
Bergdahl 1995a “The patientswere odontologically andmed-
ically examined and treated according to the
protocol for the management of patients
with BMS proposed by Bergdahl et al, in-
cluding complete anamnesis, general medi-
cal and odontological examination, labora-
tory investigation and an epicutaneous patch
test. [...] All the odontologically and medi-
cally diagnosed diseases were treated, but the
treatment had no influence on the burning
sensations and therefore these patients were
labelled as suffering from resistant BMS”
Not reported
Bogetto 1999 (Translated from Italian) “Inclusion criteria:
diagnosis of BMS, according to the criteria
provided by the literature [six references]”
(Translated from Italian) “The total average
duration of the disorder was 2.7 ( +/- 3.2 )
years”
Cano-Carrillo 2014 “Inclusion criteria for participating in the
study were as follows: a clinical history of
continuous symptoms of oral burning or
pain on a daily or almost daily basis, dur-
ing all or part of the day for more than 6
months, without paroxysms, and indepen-
dent of the nervous pathway; an absence of
clinical abnormalities that might account for
the symptoms; and normal blood test find-
ings (complete blood count, blood glucose,
serum, iron and transferrin levels, serum vi-
tamin B12, and folate. Patients with pain at-
tributable to other conditions (angiotensin-
converting enzyme inhibitor use, candidia-
sis, lichenoid reactions, sores, tongue atro-
phy, etc.) were excluded”
“The majority of patients had severe burning
sensation and had suffered from BMS over a
long period”
(Inclusion criteria required continuous
symptoms for longer than 6 months)
Carbone 2009 “The study was prospectively performed on
patients with previously untreated BMS re-
ferred to the Oral Medicine Section of the
University of Turin [...], approximately 90
patients reporting oral symptoms suggestive
of BMS were screened for participation [...]
Consistent with Gremeau-Richard et al
(2004), the inclusion criteria were the pres-
ence of an isolated complaint of chronic pain
in the oral mucosa with a normal clinical ex-
amination, and pain present for more than 4
months, which was continuous throughout
all or part of the day, with no paroxysms and
not following a nerve trajectory.
Not reported
(Inclusion criteria required continuous
symptoms for longer than 4 months)
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Table 1. Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies (Continued)
Candida infection was ruled out and any or-
ganic conditions that could be considered as
causative factors for similar oral symptoms
were ruled out in all subjects by laboratory
examinations (e.g. full blood cell count, and
serum levels of iron, ferritine, folate, vitamin
B12, and glucose)”
Cavalcanti 2009 “Subjects [...] who reported a history of oral
burning pain for more than 6 months and
absence of oral findings were assessed for eli-
gibility.[...] The patients underwent detailed
clinical evaluation and laboratory tests [com-
plete blood cell count; blood glucose level;
serum iron and ferritin levels; serum vitamin
B12; folic acid levels; salivary flow rate mea-
surement; exfoliative cytology; detection of
local abnormalities] to exclude possible local
and or systemic causes for oral burning”
“The mean duration of BMS was 37.43
months (range 6-132 months)”
Femiano 2000 “Only BMS patients with objective evidence
of a normal-looking oral mucosa, with ab-
sence of identifiable oral mucosal pathologi-
cal lesions, with normal salivary secretion (.
15 ml/15 min unstimulated and .1 ml min
−1 after 5% citric acid stimulation), and with
normal laboratory results [refers to earlier
quote: ”full blood count, serum ferritin, vi-
tamin B12, SGOT, SGPT, serum total IgE
(PRIST) and IgE specific for methacrylate,
corrected whole blood folate and random
blood sugars“] were included. [...] The final
patient group thus consisted of persons with
BMS and neither clinical nor laboratory ev-
idence of organic disease”
Not reported
Femiano 2002a “..patients, diagnosed with BMS from a his-
tory of constant burning discomfort in the
anterior tongue, lower lip or hard palate, for
more than two months, with no relevant
drug or medical history, were examined for
evidence of clinical oral mucosal lesions and
alterations in laboratory parameters (whole
blood folate, serum vitamin B12, serum fer-
ritin, serum glucose, thyroid hormone lev-
els) that could be responsible for the BMS.
A final study subgroup of 60 subjects with
BMS [...] was identified with no clinical or
laboratory evidence of disease”
Not reported
(Inclusion criteria required continuous
symptoms for longer than 2 months)
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Table 1. Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies (Continued)
Femiano 2002b “The study population consisted of persons
with BMS as defined elsewhere [reference in-
dicates van der Waal 1990] and with nei-
ther clinical nor laboratory evidence of or-
ganic disease. [...] the final test subjects were
BMS patients only with objective evidence
of a normal-looking oral mucosa, with ab-
sence of identifiable oral mucosal patholog-
ical lesions, with normal salivary secretion
and with normal laboratory results”
Not reported
Grémeau-Richard 2004 “..patients with stomatodynia were screened
for participation [...]. The inclusion criteria
were the presence of an isolated complaint of
chronic pain in the oral mucosa with a nor-
mal clinical examination. Pain was present
for more than 4 months, was continuous
throughout all or part of the day, with no
paroxysms and did not follow a nerve trajec-
tory. Patients presentingwith anorganic con-
dition that could be considered as a causative
factor such as diabetes or anaemia were not
included. Such local or systemic conditions
were sought with laboratory examinations
only when suspected from the clinical ap-
proach (e.g. blood cell count, serum iron fo-
late level or detection of Candida). Also, pa-
tientswith abnormal neurological conditions
and those regularly treated on a daily basis
by anti-depressants, anti-convulsants, other
psychotropic drugs or psychological therapy
were also excluded from this study. [...] Re-
liability for diagnosis of stomatodynia had
been assessed in a previous study involving
the same experimentors”
Not reported
(Inclusion criteria required continuous
symptoms for longer than 4 months)
Heckmann 2012 “Twenty-three patients suffering from BMS
were referred to the oral pain clinic of Er-
langen University Dental School. [...] Inclu-
sion was restricted to idiopathic cases. [...]
the patients received a physical examination
of their oral cavity including a test for possi-
ble pathological infections with candida”
Mean duration of disease:
clonazepam (n = 10) 2.8 years (SD 1.9);
placebo (n = 10) 3.6 years (SD 2.4)
Lopez-D’alessandro 2011 “..patients with idiopathic BMS of more
than three months duration. [...] Patients
with deficiencies of folic acid, vitamin B, car-
riers of anemias of any kind and patients with
Sjögren syndrome were also excluded”
Not reported
(Inclusion criteria required continuous
symptoms for longer than 3 months)
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Table 1. Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies (Continued)
López-Jornet 2009b “..patients attending our service with symp-
tomatology compatible with BMS were in-
vited to participate [...]. Inclusion criteria to
participate in the studywere presentationof a
clinical history of continuous symptomatol-
ogy of oral burning or pain, daily or almost
daily, during all or part of the day for more
than 6 months evolution, without parox-
ysms, and independent of the nervous path-
way; likewise, no clinical abnormality that
would justify the symptomatology. Further-
more, the patients had to present a normal
blood analysis (completed blood cell counts,
blood glucose levels, serum iron and trans-
ferrin levels, serum Vit B12 and folate) [...].
Patients with pain attributable to other en-
tities (candidiasis, lichenoid reactions, sores,
etc.) were excluded”
“The average time sufferingBMSwas 3 years,
with a minimum of 6 months and a maxi-
mum of 5 years”
López-Jornet 2011 “Inclusion criteria for participating in the
study were a clinical history of continuous
symptoms of oral burning or pain on a daily
or almost daily basis, during all or part of
the day for more than 6 months, without
paroxysms, and independent of the nervous
pathway. Likewise, the included patients pre-
sented no clinical abnormalities that could
account for the symptoms. Furthermore,
the patients had to present normal blood
test findings (complete blood count, blood
glucose, serum iron and transferrin levels,
serum vitamin B12, and folate) [...]. Pa-
tients with pain attributable to other con-
ditions (angiotensin-converting enzyme in-
hibitor use, candidiasis, lichenoid reactions,
sores, tongue atrophy, etc.) were excluded”
Not reported
(Inclusion criteria required continuous
symptoms for longer than 6 months)
Marino 2010 “..patients who referred [...] for otherwise id-
iopathic BMS [...].They all complained of a
burning, stinging or painful sensation in the
mouth in the absence of alterations in the
appearance of the oral mucosa or any local or
systemic diseases. [...] exclusion criteria were:
(i) evidence of any local disorders thatmay be
responsible for the burningmouth sensation,
such as infection by Candida species, para-
functional habits, temporomandibular joint
disorders, allergic contact stomatitis, benign
“The mean time from symptom onset to en-
rolment was 18 months”
(Inclusion criteria required continuous
symptoms for longer than 4 months)
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Table 1. Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies (Continued)
migratory glossitis and lichen planus”
“Inclusion criteria: Symptoms of diffuse
burning pain of the tongue and or oral
mucosa associated or unassociated with sub-
jective oral dryness or loss or alteration of
taste or sensation; Burning pain almost every
day; Normal-looking mucosa in the region
of burning; Absence of systemic disorders or
laboratory alterations known to be associated
with orofacial pain; Daily bilateral oral burn-
ing (or pain-like sensation); Pain is unremit-
ting for at least 4-6months [...] Exclusion cri-
teria: Presence of specific local etiologic evi-
dence for the burning (e.g. disease of the oral
mucosa, hyposalivation); Presence of specific
systemic etiologic evidence for the burning
(e.g. diabetes, anemia); Use of medications
known tobe associatedwith oral burning and
or alteration of taste or sensation”
Palacios-Sánchez 2015 “Diagnosis was made during the first screen-
ing phase. [...] patients over 18 years of age
clinically diagnosed with BMS who reported
a history of continuous oral burning pain
for more than 4 months with no clinical
signs that could justify the syndrome (Scala
2003) [...] Exclusion criteria included: pa-
tients whose burning sensation could be re-
lated to local alterations [...] All patients were
assessed for salivary flow rates, at rest and
stimulated, complete blood count and bio-
chemistry values, including ferritin, vitamin
B12 and folic acid levels. [...] According to
Lamey and Lewis’s BMS classification, 38 pa-
tients (63.3%)belonged to type I, 17patients
(28.3%) to type II, and only 5 patients (8.
3%) to type III”
“The evolution time of symptomatology var-
ied between 4 months and 20 years”
Rodríguez de Rivera-Campillo 2010 “..adults with BMS [...]. Some patients at-
tended the clinic to receive dental or medi-
cal treatment, while others were referred by
colleagues after unsuccessful treatments. All
subjects reported oral burning in the absence
of apparent oral lesions. [...]We excluded pa-
tients with disorders in the oral mucosa that
could explain the symptoms, those who were
receiving treatment for BMS [...]”
Duration of disease (all patients (n = 66)): <
6 months n = 4 (6%); 6-12 months n = 12
(18%); > 12 months n = 50 (76%)
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Table 1. Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies (Continued)
Sardella 1999 “The criterion for admission was the diag-
nosis of ”idiopathic“ or ”essential“ burning
mouth syndrome.Weuse this term to refer to
all forms of burning sensation in the mouth,
including complaints described as stinging
sensation or pain, in association with an oral
mucosa that appears clinically normal in the
absence of local or systemic diseases or alter-
ations; these include nutritional and hemato-
logic deficiencies, diabetes mellitus, the pres-
ence ofCandida albicans or candidiasis infec-
tion, xerostomia, denture design faults, para-
functional habits, contact allergy to dental
materials, oral lichen planus, and geographic
tongue
To identify the ”essential“ BMS cases, the pa-
tients’ medical and dental histories were care-
fully taken, particular attention being paid to
the characteristics of the complaint (type, lo-
calization, duration), the clinical oral inspec-
tion performed, and the laboratory evalua-
tions requested. In particular, the laboratory
data included complete blood cell counts,
blood glucose levels, serum iron and trans-
ferrin levels, and serum vitamin B12 and fo-
late levels.
Furthermore, patch testing for allergy to den-
tal material was performed, a tongue and
palate smear for the detectionofCandidawas
taken, and salivary gland flow rates, resting
and stimulated, were determined. When al-
tered parameters were detected, an appropri-
ate therapy was proposed. [...] Patients ex-
periencing symptomatic improvement after
correction of their deficiencies were excluded
from the investigations, the assumption be-
ing made that they did not have ”essential“
BMS
This clinical design led to the identification
of 30 patients with ”essential“ BMS. [...]
With reference to the classification suggested
by Lamey and Lewis,13 BMS type II was
present in 16 patients (53%), BMS type III
in 10 patients (33%), and BMS type I in the
remaining 4 patients (14%)”
“The duration of the syndrome was a matter
of months or even years, with a mean dura-
tion before the beginning of the clinical trial
of 18 months”
Sardella 2008 “Subjects referred [...] who reported a history
of oral burning pain for at least 6 months
andwho lacked oral findingswere considered
Mean duration of BMS (+/- SD):
hypericum perforatum (n = 19) 28.8months
(+/- 8.9);
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Table 1. Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies (Continued)
for this study. [...] Demographic and medi-
cal questionnaires asking for information re-
lated to the presence of current systemic dis-
eases and on-going medications were admin-
istered.
To confirm the diagnosis of essential BMS,
the patients underwent a standard set of eval-
uations to exclude local or systemic condi-
tions that could be considered causative fac-
tors for an oral burning sensation (salivary
flow rates; laboratory tests [complete blood
cell counts, blood glucose levels, serum iron
and transferrin levels, serum vitamin B12 fo-
late levels]; isolation of Candida species; de-
tection of parafunctional activities)”
placebo (n = 19) 32.4 months (+/- 9.9)
Silvestre 2012 “BMS was diagnosed according to the cur-
rent criteria, and the discomfort had been
present on a daily basis for at least 6 months
(Scala 2003). [...] excluded from the study [.
..] were those [...] patients with oral mucosal
lesions that might explain the burning sen-
sation”
“The mean duration of the disease was 5.43
± 3.23 years (range 1-14 years). Patients with
a BMS duration of 4 and 5 years represented
39.1% of the total (n = 9)”
Spanemberg 2012 “The sample comprised 72 patients of both
sexes with a diagnosis of BMS [...]. The study
included patients [...] who reported symp-
toms of burning or pain in the oral mucosa
of at least 6 months’ duration and who pre-
sented with a clinically normal mucosa. [...
] Patients who showed hyposalivation (sali-
vary flow rate at rest of 0.1 mL/min), as well
as alterations in their hemogram, serum lev-
els of glucose, iron, folic acid, and vitamin
B12, were also excluded”
“The time of development of BMS ranged
from 6 months to 20 years, with a median of
24 months”
Spanemberg 2015 “The study included patients [...] who re-
ported having had symptoms of burning or
pain in the oralmucosa for at least sixmonths
and who presented a clinically normal mu-
cosa”
“The duration of the symptoms ranged from
6 months to 30 years; 33.3% [n = 26] of the
patients had been presenting the disorder for
one to three years”
Tammiala-Salonen 1999 “..patients who were referred [...] because of
oral mucosal burning pain. [...] The patients
underwent a thorough clinical examination,
including measurement of whole salivary
flow, blood samples (blood count and lev-
els of glucose, B12 vitamins, and folate), and
diagnosis of candidiasis. The investigators
asked patients about pain intensity and du-
“Themean duration of pain in the trazodone
group was 3.0 years (6 months to
17 years) and in the placebo group it was 2.
8 years (6 months to 20 years)”
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Table 1. Diagnosis of burning mouth syndrome (BMS) and duration of disease in included studies (Continued)
ration, overall health, and medications. [...]
Criteria for inclusion were daily, or almost
daily, oral burning pain that had lasted 6
months or longer and had a moderate to se-
vere intensity”
SD = standard deviation.
Table 2. Outcome measure scales
Study ID Primary:
Symptom
relief (symptom in-
tensity/pain),
scales used
Primary:
Change in quality
of life (QoL) (anx-
iety, depression),
scales used
Secondary:
Change in taste,
scales used
Secondary:
Change in feeling
of dryness; scales
used
Additional assess-
ment scales not rel-
evant to this review
Alvarenga da Silva
2014
EDOF-HC proto-
col (Orofacial Pain
Clinic -Hospital das
Clinicas)
Outcome not as-
sessed
Quantitative Sen-
sory Testing (QST):
gustative threshold
Xerostomia
questionnaire1
Quantitative Sen-
sory Testing (QST)
: olfactory threshold
(1); thermal detec-
tion thresholds for
cold (2) and warm
(3) sensations; me-
chanical detec-
tion thresholds for
touch (4), vibration
(5), and electrical
perception (6); me-
chanical pain sen-
sitivity - superficial
(7) and deep pain
thresholds (8); elec-
trical pain thresh-
old at the teeth (9)
, corneal reflex (10),
salivary flow (11)
Bergdahl 1995a VAS2 (ranked 1-7) Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Bogetto 1999 Clinical Global Im-
pression I (CGI I)
Anxiety: Hamil-
ton Anxiety Rating
Scale (HARS)
Depression: Mont-
gomery-Åsberg De-
pression Rating
Scale (MADRS)
Outcome not as-
sessed
Outcome not as-
sessed
n/a
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Table 2. Outcome measure scales (Continued)
Cano-Carrillo
2014
VAS (0-10) General health as-
sessment: 36-Item
Short Form Health
Survey (SF-36)
Oral health im-
pact on QoL: Oral
Health Impact Pro-
file-14 (OHIP-14)
Anxiety/depres-
sion: Hospital Anx-
iety and Depression
(HAD) scale
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Carbone 2009 1. VAS (0-10)
2.
McGill Pain Ques-
tionnaire (MPQ)
Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Cavalcanti 2009 1. VAS (0-100 mm)
2. Global Perceived
Effect (GPE)
Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Femiano 2000 Bespoke burning
mouth syndrome
(BMS) symptomol-
ogy change scale
Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Femiano 2002a Bespoke burning
mouth syndrome
(BMS) symptomol-
ogy change scale
Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Femiano 2002b Bespoke burning
mouth syndrome
(BMS) symptomol-
ogy change scale
Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Grémeau-Richard
2004
Numerical Pain
Scale (0-10)
Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Heckmann 2012 Numerical pain rat-
ings scale (0-10)
Depression:
BeckDepression In-
ventory (BDI)
Taste test score (0-
16)3
Outcome not as-
sessed
1. Smell test score
2. Zerssen Mood
Scale
3. Dementia: Mini-
Mental State Exam-
ination
4. Salivary flow
score (swabmethod:
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Table 2. Outcome measure scales (Continued)
weight g/min)4
Lopez-
D’alessandro 2011
Bespoke geographi-
cal burning
distribution numer-
ical scale (0-4)
Anxiety: Hamilton
Anxiety Rat-
ing Scale (HARS) -
baseline only
Anxiety/depres-
sion: Hospital Anx-
iety and Depression
(HAD) scale - base-
line only
Outcome not as-
sessed
Outcome not as-
sessed
n/a
López-Jornet
2009b
VAS (0-10) Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
López-Jornet 2011 VAS (0-10) General health as-
sessment: 36-Item
Short Form Health
Survey (SF-36)
Oral health im-
pact on QoL: Oral
Health Impact Pro-
file-49 (OHIP-49)
Anxiety/depres-
sion: Hospital Anx-
iety and Depression
(HAD) scale
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Marino 2010 VAS (0-10) Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Palacios-Sánchez
2015
VAS (0-10) Depression: Beck
Depression Inven-
tory (BDI) - base-
line only, as covari-
ate
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Rodríguez de
Rivera-Campillo
2010
VAS (0-10) Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Sardella 1999 VAS (0-8) Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Sardella 2008 VAS (0-10) Assessed by posing
simple
questions. No stan-
dard QoL question-
naire used
Outcome not as-
sessed
Outcome not as-
sessed
n/a
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Table 2. Outcome measure scales (Continued)
Silvestre 2012 VAS (0-10) Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Spanemberg 2012 1. Visual numeric
scale (VNS) (0-10)
2. Faces scale (FS)
(0-5)
Outcome not as-
sessed
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Spanemberg 2015 1. VAS (0-100 mm)
2. Visual numeric
scale (VNS) (0-10)
Oral Health Impact
Profile-14 (OHIP-
14)
Outcome not as-
sessed
Outcome not as-
sessed
n/a
Tammiala-Salonen
1999
1. VAS (0-100 mm)
2.
McGill Pain Ques-
tionnaire (MPQ)
Depression:
BeckDepression In-
ventory (BDI)
Outcome not as-
sessed
Outcome not as-
sessed
n/a
1 No defined title. See original reference: Korn 2002.
2 VAS: visual analogue scale.
3 No defined title. See original reference: Mueller 2003.
4 No defined title. See original reference: Navazesh 1982.
Table 3. Reported adverse effects
Study ID Comparison Adverse effects reported
Alvarenga da Silva 2014 Topical treatments Comment: no adverse event data reported,
nor is there any indication that it was col-
lected by investigators
Bergdahl 1995a Psychological therapies Not reported
Bogetto 1999 Antidepressants and antipsychotics Not reported
Cano-Carrillo 2014 Dietary supplements Quote: “Nopatients experienced any adverse
effects resulting from treatment at any of the
evaluation times”
Carbone 2009 Dietary supplements Quote: “No adverse events were reported in
any of the three groups” (refers to ALA; ALA
+ vitamins; placebo)
Cavalcanti 2009 Dietary supplements Quote: “Seven patients had their data ex-
cluded from analysis, four of them did not
complete the proposed treatment because of
the symptoms that they judged as connected
to treatment and these symptoms are pre-
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Table 3. Reported adverse effects (Continued)
sented with side-effects data”
Comment: adverse events fully reported in
Table 3 in the paper. Of the 4 patients with-
drawing due to severe adverse events, 2 were
from each group (ALA and placebo)
Femiano 2000 Dietary supplements Quote: “No adverse events were recorded in
any of the groups”
Femiano 2002a Dietary supplements Quote: “..symptomatic improvements in
BMS treated with alpha-lipoic acid were seen
without notable adverse effects”
Comment: Narrative report, indicating ad-
verse events occurred, potentially missing
data. No other adverse event data reported
Femiano 2002b Cholinergics
Dietary supplements
Systemic treatments
Topical treatments
Quotes:
Bethanechol: “Four of the 20 patients com-
plained of adverse effects (nausea, dizziness,
blood pressure fall, cold perspiration or spo-
radic abdominal pain) but not severe enough
to demand the suspension of treatment”
ALA: “Four patients reported heartburn but
this was corrected by ranitidine 150 mg”
Comment: bethanechol data not usable in
analysis as distributionof 5 adverse events be-
tween 4 complainants was unclear. Adverse
events for lactoperoxidase not reported
Grémeau-Richard 2004 Benzodiazepines Quotes: “Side effects (Table 2) were not sig-
nificantly more frequent in the active treat-
ment group: they were reported by nine out
of 24 subjects in the clonazepam group and
six out of 24 in the placebo group (P > 0.05,
X2-test). Two subjects in the active treatment
group and one in the control group dropped
out from the trial because of these side ef-
fects”
Comment: adverse events fully reported in
’Table 2’ in the paper
Heckmann 2012 Benzodiazepines Not reported
Lopez-D’alessandro 2011 Anticonvulsants
Dietary supplements
Quote: “the adverse effects that appeared
were very mild”
Comment: narrative report, indicating ad-
verse events occurred; data obtained from
contact author
Gabapentin arm (n = 20): drowsiness (n = 5)
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Table 3. Reported adverse effects (Continued)
Gabapentin + ALA arm (n = 20): drowsiness
(n = 2); mild headache (n = 1)
ALA arm (n = 20): mild headache (n = 2);
intermittent facial skin rash (n = 1)
Placebo arm: no adverse effects reported
López-Jornet 2009b Dietary supplements Quotes: “All patients responded to a ques-
tionnaire on each of the visits (0, 1, and 2
months) in which they were asked about the
possible adverse effects of the medication”;
“adverse effects were minimal; only one pa-
tient [ALA group] abandoned treatment be-
cause of having gastrointestinal upset as the
side effect of the medication”
Comment: narrative report, indicating ad-
verse events occurred, potentially missing
data. No other adverse event data reported,
despite investigators repeatedly recording ad-
verse events, and the statement relates only
to the patient who withdrew from the trial
due to severe side effects
López-Jornet 2011 Physical barriers Quote: “No adverse effects were observed”
Marino 2010 Dietary supplements
Topical treatments
Quote: “All the patients successfully finished
study I [the treatment phase, distinct from
follow-up phase which 64% (36/56) com-
pleted] and no untoward effect occurred in
any of the groups”
Re: Capsaicin: “We did not observe any ad-
verse effects in our patients and the treatment
was well tolerated by the patients despite the
need for repeated applications because of its
short duration of action”
Comment: no other adverse event data re-
ported
Palacios-Sánchez 2015 Dietary supplements Quote: “All patients were assessed every 15
days [...] for the occurrence of side effects”
Comment: despite specifying assessing oc-
currence of adverse effects in the Methods
section, there is no detail reporting their oc-
currence in the results
Rodríguez de Rivera-Campillo 2010 Benzodiazepines Quotes: “All the patients were scheduled for
a visit after 1 week for the sole purpose of
detecting undesirable side effects. They were
again scheduled for visits after 1 months
and 6 months , which allowed the clinicians
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Table 3. Reported adverse effects (Continued)
to monitor their evolution”; “Some patients
reported a sensation of effervescence and
numbness of the tongue when the tablet was
dissolved. [...] The only side effect registered
was some degree of sleepiness in 5 patients in
the clonazepam group, which did not require
the clinicians to suspend the treatment”
Sardella 1999 Topical treatments Quote: “No adverse effects were noted in the
groups using the [Benzydamine] and placebo
solutions”
Sardella 2008 Dietary supplements Quotes: “During the follow-up visits [1
month, 2 months and 3 months], the pa-
tients were explicitly asked about the occur-
rence of adverse events”; “One subject in the
test group failed to finish the trial because
a severe headache that developed during the
fifth week was considered a side effect of the
therapy”
Comment: despite recording adverse effects
at 3 time points, no other adverse event data
are reported except for explaining Group A
dropout patient - not sufficient to use for
estimation of risk ratio, as other data likely
to be omitted from paper
Silvestre 2012 Topical treatments Quotes: “Patients were also questioned about
possible adverse effects or discomfort caused
by the treatments”; “Those subjects who de-
veloped adverse effects were removed from
the study”; “The study initially involved 30
patients, of which 7 abandoned the trial in
the first week of treatment [...] two com-
plained of greatly increased burning sensa-
tion when using the [capsaicin] rinse”; “in-
tense burning sensation was described by
one-third of the subjects during and for a few
minutes (maximum 20 minutes) after appli-
cation of the capsaicin rinse”
Comment: reports patients developing ad-
verse effects were removed from the study;
however, numbers for analysis estimated
from text to be 8 patients (“one-third” of
group n = 23 to estimate whole patient in-
teger) from intervention arm, in addition to
the further 2 intervention arm patients who
withdrew from the trial due to the increased
burning sensation. Data combined for anal-
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Table 3. Reported adverse effects (Continued)
ysis
Spanemberg 2012 Dietary supplements Quotes: “12 withdrew from the study. Exac-
erbation of symptoms was reported by 6 in-
dividuals: 3 in the control group and 3 in the
test group. 6withdrew from the study for rea-
sons unrelated to the treatment”; “One pa-
tient complained of somnolence and weight
gain and another of insomnia. Two patients
who took the test substance reported exac-
erbation of the symptoms in the first week
of treatment, but this was also observed in 4
patients in the control group”
Comment: adverse effects experienced by
dropout patients referred to separately under
rationale forwithdrawals.Data combined for
analysis
Spanemberg 2015 Electromagnetic radiation Not reported
Tammiala-Salonen 1999 Antidepressants and antipsychotics Quote: “Patients in the trazodone group re-
ported significantly more dizziness (P < 0.
0001) and drowsiness (P < 0.05) than pa-
tients in the placebo group (Table 1). Two
patients in the trazodone group and 8 in the
placebo group reported no side effects”
Comment: adverse events fully reported in
Table 1 in the paper; however, effect P val-
ues estimated from reported data (tabulated
in Additional Table 4) are more conservative
than the effect estimates narratively reported
in the paper
ALA = alpha lipoic acid.
Table 4. Adverse event outcomes
Antidepressants/antipsychotics versus placebo
Intervention Outcome No of studies No of patients Risk ratio (M-H,
Fixed, 95% CI)
Overall effect (P
value)
Heterogeneity (P
value; I2)
Antidepressants
(trazodone)
Dizziness 1 37 11.61 (1.66 to 81.
04)
P = 0.01 Not applicable
Drowsiness 1 37 4.75 (1.18 to 19.
07)
P = 0.03 Not applicable
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Table 4. Adverse event outcomes (Continued)
Abdominal
pains
1 37 1.32 (0.42 to 4.
15)
P = 0.64 Not applicable
Headache 1 37 1.58 (0.30 to 8.
40)
P = 0.59 Not applicable
Palpitations 1 37 1.06 (0.17 to 6.
72)
P = 0.95 Not applicable
Tremor 1 37 2.11 (0.21 to 21.
32)
P = 0.53 Not applicable
Dry mouth 1 37 3.17 (0.36 to 27.
72)
P = 0.30 Not applicable
Urinary inconti-
nence
1 37 3.16 (0.14 to 72.
84)
P = 0.47 Not applicable
Antipsychotics Adverse effect data were not available for analysis from the single included study comparing antipsychotics versus
placebo (Bogetto 1999)
Anticonvulsants versus placebo
Intervention Outcome No of studies No of patients Risk ratio (M-H,
Fixed, 95% CI)
Overall effect (P
value)
Heterogeneity (P
value; I2)
Gabapentin Drowsiness 1 80 31.95 (1.84 to
553.64)
P = 0.02 Not applicable
Gabapentin +
ALA
Drowsiness 1 80 14.52 (0.73 to
290.44)
P = 0.08 Not applicable
Mild headache 1 80 8.71 (0.37 to 205.
80)
P = 0.18 Not applicable
Benzodiazepines versus placebo
Intervention Outcome No of studies No of patients Risk ratio (M-H,
Fixed, 95% CI)
Overall effect (P
value)
Heterogeneity (P
value; I2)
Topical
clonazepam
Drowsiness 2 114 2.71 (0.84 to 8.
74)
P = 0.09 P=0.16; I2 =48%
Dry mouth 1 48 3.00 (0.13 to 70.
16)
P = 0.49 Not applicable
Spasmophilia 1 48 3.00 (0.13 to 70.
16)
P = 0.49 Not applicable
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Table 4. Adverse event outcomes (Continued)
Euphoric
behaviour
1 48 3.00 (0.13 to 70.
16)
P = 0.49 Not applicable
Cholinergics versus placebo
Bethanechol Adverse effect data presented collectively and not usable for analysis from the single included study comparing
cholinergics versus placebo (Femiano 2002b)
Dietary supplements versus placebo
Intervention Outcome No of studies No of patients Risk ratio (M-H,
Fixed, 95% CI)
Overall effect (P
value)
Heterogeneity (P
value; I2)
ALA (+/-
adjunctive ingre-
dients)
Gastrointestinal
complaints
3 138 4.00 (1.21 to 13.
27)
P = 0.02 P = 0.78; I2 = 0%
Headache 2 118 10.87 (1.36 to 87.
03)
P = 0.02 P = 0.82; I2 = 0%
Drowsiness 1 38 1.00 (0.07 to 14.
85)
P = 1.00 Not applicable
Increase in blood
pressure
1 38 1.00 (0.07 to 14.
85)
P = 1.00 Not applicable
Intermittent fa-
cial skin rash
1 80 8.71 (0.37 to 205.
80)
P = 0.18 Not applicable
’Catuama’ herbal
compound
Drowsiness 1 72 2.69 (0.11 to 63.
96)
P = 0.54 Not applicable
Weight gain 1 72 2.69 (0.11 to 63.
96)
P = 0.54 Not applicable
Insomnia 1 72 2.69 (0.11 to 63.
96)
P = 0.54 Not applicable
Exacerbation of
symptoms
1 72 1.12 (0.33 to 3.
83)
P = 0.86 Not applicable
Electromagnetic radiation versus placebo
Low-level laser
therapy
Adverse effect data were not available for analysis from the single included study comparing electromagnetic
radiation versus placebo (Spanemberg 2015)
Physical barriers versus placebo
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Table 4. Adverse event outcomes (Continued)
Tongue protec-
tor
Adverse effect data were not available for analysis from the single included study comparing physical barriers versus
placebo (López-Jornet 2011)
Psychological therapies versus placebo
Cognitive ther-
apy
Adverse effect data were not available for analysis from the single included study comparing psychological therapies
versus placebo (Bergdahl 1995a)
Topical treatments versus placebo
Benzydamine
hydrochloride
oral rinse
Adverse data only presented for benzydamine hydrochloride oral rinse against placebo; narratively reported that
no adverse effects occurred (Sardella 1999)
ALA = alpha lipoic acid; CI = confidence interval; M-H = Mantel-Haenszel.
A P P E N D I C E S
Appendix 1. Cochrane Oral Health’s Trials Register search strategy
From February 2014, searches of Cochrane Oral Health’s Trials Register for this review were undertaken using the Cochrane Register
of Studies and the search strategy below:
1 (“burning mouth”:ti,ab) AND (INREGISTER)
2 (“burning tongue”:totalling,ab) AND (INREGISTER)
3 (glossodynia:ti,ab) AND (INREGISTER)
4 (glossopyrosis:ti,ab) AND (INREGISTER)
5 ((stomatodynia or stomatopyrosis):ti,ab) AND (INREGISTER)
6 ((“oral dysaesthesia” or “oral dysesthesia”):ti,ab) AND (INREGISTER)
7 (BMS:ti,ab) AND (INREGISTER)
8 (#1 or #2 or #3 or #4 or #5 or #6 or #7) AND (INREGISTER)
Previous searches of Cochrane Oral Health’s Trials Register were undertaken using the Procite software and the search strategy below:
(“Burning mouth syndrome” OR “Burning mouth” OR “Burning tongue” OR Glossodynia OR Glossopyrosis OR Stomatodynia OR
Stomatopyrosis OR “oral dysaesthesia” OR “oral dysesthesia” OR ( #4 CONTAINS BMS) OR (#43 CONTAINS BMS))
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Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
#1 MeSH descriptor Burning Mouth Syndrome this term only
#2 (burning in All Text near/3 mouth in All Text)
#3 (burning in All Text near/3 tongue in All Text)
#4 MeSH descriptor Glossalgia this term only
#5 Glossalgia* in All Text
#6 Glossodynia* in All Text
#7 Glossopyros* in All Text
#8 Stomatodynia* in All Text
#9 Stomatopyros* in All Text
#10 “oral dysaesthesia” in All Text
#11 “oral dysesthesia” in All Text
#12 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11)
Appendix 3. MEDLINE Ovid search strategy
1. Burning Mouth Syndrome/
2. (burning adj3 mouth).mp.
3. (burning adj3 tongue).mp.
4. Glossalgia/
5. Glossalgia$.mp.
6. Glossodynia$.mp.
7. Glossopyros$.mp.
8. Stomatodynia$.mp.
9. Stomatopyros$.mp.
10. (oral adj dysaesthesia).mp.
11. (oral adj dysesthesia).mp.
12. or/1-11
This subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials (RCTs) in
MEDLINE: sensitivity-maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of theCochrane
Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) (Lefebvre 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
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Appendix 4. Embase Ovid search strategy
1. Burning Mouth Syndrome/
2. (burning adj3 mouth).mp.
3. (burning adj3 tongue).mp.
4. Glossalgia/
5. Glossalgia$.mp.
6. Glossodynia$.mp.
7. Glossopyros$.mp.
8. Stomatodynia$.mp.
9. Stomatopyros$.mp.
10. (oral adj dysaesthesia).mp.
11. (oral adj dysesthesia).mp.
12. or/1-11
This subject search was linked to Cochrane Oral Health’s filter for identifying RCTs in Embase Ovid:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocat$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
16. 14 NOT 15
Appendix 5. US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) search
strategy
“burning mouth” or “burning tongue”
Appendix 6. World Health Organization International Clinical Trials Registry Platform search
strategy
“burning mouth”
“burning tongue”
143Interventions for treating burning mouth syndrome (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
WH A T ’ S N E W
Last assessed as up-to-date: 31 December 2015.
Date Event Description
9 November 2016 New citation required but conclusions have not
changed
15 new studies added. New authors. Methods updated
31 December 2015 New search has been performed Searches updated to 31 December 2015
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 3, 2001
Date Event Description
19 August 2008 Amended Converted to new review format
15 November 2004 New search has been performed Searches updated to October 2004
15 November 2004 New citation required and conclusions have changed Substantive amendment. 2 studies previously awaiting
assessment have been excluded; a further 4 randomised
controlled trials have been included and 1 previously
included trial excluded
C O N T R I B U T I O N S O F A U T H O R S
Development and co-ordination of the update: Roddy McMillan (RM).
Running electronic searches: Anne Littlewood (Cochrane Oral Health).
Communication with authors and organisations: RM and Jo Weldon (JW).
Screening titles, abstracts and full-text papers: RM, Joanna Zakrzewska (JZ), Anne-Marie Glenny (AMG), JW.
Reviewing papers: RM, Heli Forssell (HF), JZ, John Buchanan (JB), AMG, JW.
Extracting data: RM, HF, JZ, JB, JW.
Appraising quality/risk of bias: RM, HF, JZ, JB, AMG, JW.
Inputting data: RM, JW.
Data validation: AMG.
Analysis of data: JW, AMG.
Risk of bias analysis: RM, AMG.
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Interpretation of data: JW, AMG.
Summary of findings tables: AMG, JW.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The current review has employed Cochrane’s tool for assessing risk of bias in randomised trials (Higgins 2011a). Papers identified in
previous versions were reformatted using this new template. In keeping with current best practice (Higgins 2011b), previously included
controlled clinical trials were excluded in this update (Pisanty 1975), and a GRADE ’Summary of findings’ table has been produced
for each comparison. Adverse effects were included as an outcome measure in this version of the review, despite not formally being
included as an outcome in the original protocol. After feedback, we determined the substantial effect of burning mouth syndrome upon
patients’ quality of life is of sufficient direct impact to justify upgrading quality of life from a secondary to a primary outcome. Due to
heterogeneity in study follow-up periods and outcome assessment time points, we analysed outcome data as short-term (≤ 3 months
from baseline) or long-term (> 3 to ≤ 6 months from baseline) for a manageable cut-off threshold. In accordance with Section 16.4.5
of the Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011) (Higgins 2011b), we utilised first
period data only of cross-over trials which did not incorporate a washout period.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Analgesics [therapeutic use]; Antidepressive Agents [therapeutic use]; Burning Mouth Syndrome [∗therapy]; Clinical Trials as Topic;
Cognitive Therapy; Hormone Replacement Therapy; Quality of Life; Vitamins [therapeutic use]
MeSH check words
Humans
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